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Abstract	
	The	vasculature	of	many	solid	tumours	is	highly	distinct	from	that	of	its	host	tissue,	both	structurally	and	in	terms	of	functional	protein	expression.	These	differences	offer	an	opportunity	for	specific	targeting	of	therapeutics	against	the	tumour	vasculature.	This	thesis	describes	the	investigation	of	this	tumour	vascular	profile,	in	clinical	samples	from	renal	cell	carcinoma,	colorectal	cancer	and	colorectal	liver	metastases,	as	well	as	murine	breast	tumours	resistant	to	the	anti-angiogenic	drug,	sunitinib.	This	analysis	allowed	the	identification	of	three	tumour	endothelial	markers	in	renal	and	colorectal	malignancies,	MCAM,	LAMA4	and	GRIN2D.	The	expression	of	each	of	these	markers	was	linked	with	patient	survival	with	these	malignancies,	suggesting	their	utility	for	prognostication.	MCAM	and	GRIN2D	showed	highly	tumour	specific	expression	profiles	in	multi-organ	tissue	array	analysis,	highlighting	them	as	promising	candidates	for	the	targeting	of	therapies	to	the	tumour	vasculature.	The	specific	localisation	of	monoclonal	anti-MCAM	antibodies	to	renal	tumour	vasculature	was	demonstrated,	further	supporting	this	suggestion.	Putative	vascular	markers	of	tumour	resistance	to	anti-angiogenic	therapy	were	also	identified.	Aquaporin-1	(AQP1)	was	found	to	be	up-regulated	in	cases	of	acquired	resistance,	mammalian	target	of	rapamycin	(mTOR)	in	innate	resistance	and	pleiotrophin	(PTN)	in	both,	highlighting	their	potential	as	diagnostic	candidates	for	predicting	therapy	response,	or	as	targets	to	circumvent	resistance.	The	need	for	effective	diagnostic	tests	in	this	indication,	was	demonstrated	by	the	finding	that	metastasis	is	enhanced	by	sunitinib	therapy,	in	innately	resistant	tumours.	
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General	Introduction	
												
	 2	
NB,	sections	of	this	introduction	have	been	adapted	from	excepts	of	Vascular	Targeting	
Approaches	to	Treat	Cancer,	Wragg	and	Bicknell,	2013	(1),	reproduced	with	permission.		Specific	targeting	of	therapeutics	to	the	tumour	has	long	been	a	quest	in	cancer	research.	Systematic	cytotoxics	do	not	target	cancer	cells	or	the	pro-tumourigenic	environment	selectively	and	so	lead	to	adverse	side	effects	and	provide	a	limited	anti-tumour	effect,	particularly	in	advanced	cancer.	Most	chemotherapeutics	do	not	accumulate	preferentially	in	the	tumour	site;	indeed	the	drug	dose	is	often	10-20	times	higher	in	healthy	tissue	than	in	the	tumour	(2,3).	This	poor	drug	infiltration	is	thought	to	be	due	to	irregular	tumour	vasculature	and	high	interstitial	pressure	(4,5).	Therefore	an	improved	approach	to	targeting	the	tumour	is	warranted.		
	
1.1	Targeting	the	tumour	vasculature	
	The	vasculature	is	postulated	to	be	an	ideal	candidate	for	targeted	anti-cancer	therapies.	It	is	a	key	part	of	the	tumour	microenvironment	required	for	the	delivery	of	nutrients	and	removal	of	toxic	waste	products	and	so	is	essential	for	tumour	growth	and	metastasis	(6).	The	tumour	vasculature	is	directly	accessible	to	drugs	via	the	circulation	and	composed	of	endothelial	cells	thought	to	be	genetically	stable	and	less	adaptive	than	tumour	cells,	therefore	they	are	less	likely	to	acquire	drug	resistance	(7,8).	In	addition	it	is	estimated	that	up	to	100	tumour	cells	are	fed	from	a	single	
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endothelial	cell	(3),	and	so	a	therapeutic	targeting	the	vasculature	should	achieve	a	more	potent	anti-cancer	effect	than	targeting	the	tumour	cells	directly.		The	tumour	acquires	a	vascular	network	by	the	formation	of	neovessels	(angiogenesis),	the	incorporation	of	existing	blood	vessels	(vessel	co-option),	the	splitting	of	existing	vessels	into	daughter	vessels	(intussusception)	and	even	by	mimicking	the	vasculature	by	forming	blood	vessel	like	tubes	lined	with	tumour	cells	(vascular	mimicry)	(9).	Tumour	angiogenesis	is	essential	for	the	survival	and	development	of	a	tumour	greater	than	2	mm3	in	size	(6,10,11).	However,	tumour	vascularisation	invariably	lags	behind	the	expanding	tumour	mass	(12)	resulting	in	highly	abnormal	tumour	vasculature	that	morphologically	and	functionally	differs	from	the	vasculature	of	healthy	tissues	(13).	It	is	highly	chaotic	in	nature	composed	of	tortuous,	dilated	and	elongated	vessels	with	blind	ends,	bulges,	leaky	sprouts	and	considerable	variability	in	diameter	(14)	(Figure	1.1).	The	tumour	vascular	endothelial	cells	themselves	are	highly	abnormal,	expressing	several	cell	surface	markers	barely	detectable	on	healthy	tissue	or	quiescent	vascular	endothelial	cells	(15).	The	abnormality	of	the	tumour	vasculature	is	often	associated	with	treatment	failure	due	to	poor	drug	penetrance	(4,5),	however,	it	could	offer	an	opportunity	for	targeted	anti-cancer	therapy	if	these	differences	can	be	used	to	specifically	target	therapies	against	the	tumour	vasculature.		
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Figure	1.1.	Abnormal	tumour	vasculature	in	colorectal	carcinoma.		Micro-vascular	corrosion	casts	of	human	A,	healthy	ascending	colon	and	B,	colorectal	carcinoma	(13).	Image	reproduced	with	permission.				To	this	end,	many	anti-tumour-vasculature	therapeutics	have	been	developed	over	the	last	20	years	with	a	number	reaching	the	clinic.	There	are	a	wide	variety	of	different	therapeutics,	but	they	can	be	very	broadly	divided	into	vascular	disrupting	agents	(VDAs),	which	target	and	occlude	the	existing	tumour	vasculature,	and	angiogenesis	inhibitors	(or	antiangiogenics,	AIs),	which	inhibit	neovascularisation	of	the	tumour.	Collectively	they	aim	to	devascularise	and	starve	the	tumour,	thus	achieving	tumour	regression	(6).		
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1.2	Vascular	disrupting	agents	
	It	has	long	been	known	that	the	disruption	of	the	blood	supply	to	a	tissue	causes	rapid	and	extensive	cell	death	by	ischemia	and	hemorrhagic	necrosis.	This	phenomenon	was	first	described	in	1852	in	relation	to	testicular	torsion	(16).	The	testicular	torsion	condition	is	caused	when	the	spermatic	cord,	which	carries	blood	to	the	testicles,	becomes	twisted,	reducing	blood	flow	and	causing	necrosis	in	the	affected	testicle.	It	was	not	until	1923	however,	that	the	potential	of	vascular	disruption	to	starve	a	tumour	was	realised.	In	a	seminal	paper,	William	Woglam	described	how	the	disruption	of	the	blood	supply	to	a	tumour	could	cause	regression	and	suggested	the	potential	for	novel	therapies	to	achieve	this.	He	did	however,	observe	that	the	difficulty	posed	by	this	treatment	would	be	effective	targeting,	so	that	the	vessels	of	the	tumour	are	disrupted	but	no	others	(17).	It	took	another	60	years	for	the	idea	to	be	seriously	appreciated	and	investigated.	Juliana	Denekamp	and	her	group	demonstrated	that	the	physical	obstruction	of	the	blood	supply	to	transplanted	tumours	in	mice,	using	D-shaped	metal	clamps,	caused	tumour	cell	death	directly	proportional	to	the	length	of	the	clamping	(18).	Denekamp	over	the	subsequent	years	championed	the	idea	of	tumour	vascular	disruption	as	an	anti-cancer	treatment.					As	William	Woglam	explained	many	years	ago,	the	key	to	the	use	of	vascular	targeting	therapies	is	to	achieve	maximum	tumour	endothelium	disruption	while	leaving	healthy	tissue	endothelium	unaffected.	To	this	end,	therapeutics	have	been	developed	that	take	
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advantage	of	the	many	differences	between	healthy	tissue	and	tumour	endothelium.	Such	tumour	specific	disrupting	agents	can	be	broadly	divided	into	two	types:			 1. Small	molecule	disrupting	agents	exploit	physiological	differences	between	tumour	and	healthy	tissue	vasculature	to	destroy	the	vessels.	This	class	is	primarily	made	up	of	microtubule	destabilizing	agents.		2. Ligand-based	VDAs	use	antibodies,	peptides	or	growth	factors	that	specifically	bind	to	the	tumour	vasculature	and	deliver	agents	that	destroy	the	vessels.		
	
1.2.1	Small	molecule	VDAs		
1.2.1.1	Microtubule	destabilizing	agents	Tumour	endothelium	is	immature	in	nature	and	highly	proliferative	and	thus	is	dependent	on	a	tubulin	cytoskeleton	to	maintain	cell	shape	(19,20).	Tubulin	is	also	essential	for	cell	motility,	invasion,	attachment	and	proliferation.	Mature	quiescent	vasculature,	which	supplies	most	healthy	tissues	has	a	far	more	developed	actin	cytoskeleton	and	so	is	far	less	dependent	on	the	tubulin	cytoskeleton	for	cellular	functions	(19).	Microtubule	destabilizing	agents	act	by	disrupting	the	tubulin	cytoskeleton.	This	has	the	duel	effect	of	inhibiting	spindle	formation,	leading	to	mitotic	arrest	in	tumour	cells	and	causing	tumour	vascular	collapse,	reducing	blood	flow.	Drugs	that	block	tubulin	function	therefore,	can	have	both	anti-mitotic	and	anti-vascular	effects	(21).	In	practice	the	dominant	mechanism	of	action	for	these	drugs	is	to	cause	mitotic	arrest	with	anti-vascular	activity	only	seen	at	close	to	the	maximum	tolerated	dose	(MTD)	(22).		
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1.2.1.2	Combretastatin	A-4	Disodium	Phosphate	Combretastatin	A-4	Disodium	Phosphate	(also	known	as	CA4P,	fosbretabulin,	Zybrestat)	and	formulated	by	Oxigene,	was	the	first	microtubule-destabilizing	agent	observed	to	have	anti-vascular	effects	below	the	MTD	(23).	It	is	delivered	as	a	pro-drug,	which	is	cleaved	to	its	natural	form	by	endogenous	phosphatases.	CA4P	binds	to	tubulin	disrupting	microtubule	polymerisation,	resulting	in	mitotic	arrest	and	apoptosis	of	endothelial	cells.	In	addition	it	destabilises	vascular	endothelial	cadherin	(VE-cadherin)	mediated	vascular	junctions	inhibiting	the	VE-cadherin/	β-catenin/Akt	signalling	pathway,	reducing	endothelial	cell	migration	and	capillary	formation	(23).		In	experimental	tumour	models,	CA4P	causes	extensive	vascular	damage	with	haemorrhagic	necrosis	within	one	hour	of	treatment,	coupled	with	subsequent	tumour	growth	delay	(23-26).	The	effect	of	CA4P	on	the	tumour	is	considerable	greater	than	its	effect	on	the	healthy	tissue	(27).	CA4P	is	the	subject	of	a	number	of	clinical	trials	for	advanced	anaplastic	thyroid	cancer,	non-small	cell	lung	cancer,	gynaecological	cancers	and	high-grade	glioma	(Table	1.1).	A	recent	phase	II/III	clinical	trial	for	advanced	anaplastic	thyroid	cancer	showed	considerable	survival	benefit	in	patients	treated	with	CA4P	in	combination	with	chemotherapeutics;	26%	of	patients	treated	with	CA4P	survived	one	year	compared	to	9%	treated	with	chemotherapy	alone.	The	clinical	trial	was,	however,	halted	early	due	to	lack	of	funding (28).	The	success	of	CA4P	has	led	to	the	development	of	a	number	of	derivative	drugs	including	Oxi	4503	(Oxigene),	Ombrabulin	(AVE8062)	(Aventis	Pharma),	which	are	under	investigation	in	clinical	trials	(Table	1.1).	
	
	 8	
1.2.1.3	N-Cadherin	antagonist	The	adhesive	interactions	between	endothelial	cells	are	essential	for	the	maintenance	of	functional	integrity	of	the	vasculature	(29,30).	N-Cadherin	is	a	cell	surface	protein	involved	in	mediating	these	interactions.	A	cyclic	peptide	named	ADH-1	competitively	inhibits	N-Cadherin	homotypic	binding	and	has	been	shown	to	reduce	blood	flow	and	cause	haemorrhage	necrosis	in	animal	tumour	models	(31-33).	ADH-1	has	been	investigated	in	phase	I/II	trials	as	a	monotherapy	and	phase	I	in	combination	with	chemotherapeutics	in	a	range	of	tumours	(Table	1.1).	It	was	well	tolerated	and	showed	a	modest	anti-tumour	effect	(34,35).			
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Table	1.1.	Small	molecule	VDAs	in	the	clinic.	Information	retrieved	from:	http://clinicaltrials.gov	and	http://www.cancer.gov		(accessed:	19.1.2016)		
Agent	 Company	 Type	 Clinical	trials	CA4P	(fosbretabulin,	Zybrestat)	 Oxigene	 Microtubule	destabilizing	agent	 Phase	III:	advanced	anaplastic	thyroid	cancer	(failed	to	
achieve	primary	endpoints),	ovarian	cancer	(ongoing)	Phase	II:	fallopian	tube	cancer,	peritoneal	cavity	cancer,	pancreatic	cancer,	neuroendocrine	tumours	(all	
ongoing)	Oxi4503	 Oxigene	 Microtubule	destabilizing	agent	 Phase	II:	acute	myeloid	leukaemia	(ongoing)		Phase	I:	liver	and	other	solid	tumours	(Completed	with	
positive	data)	AVE8062	(Ombrabulin)	 Sanofi-Aventis	 Microtubule	destabilizing	agent	 Phase	III:	soft	tissue	sarcoma	Phase	II:	metastatic	non-small	cell	lung	cancer,	recurrent	ovarian	cancer	(all	failed	to	
achieve	primary	endpoints)	
Discontinued	Dolastatin-10		 National	Cancer	Institute	 Microtubule	destabilizing	agent	 Phase	II:	lymphoma,	macroglobulinema,	lymphocytic	leukaemia,	colorectal	adenocarcinoma,	melanoma,	soft	tissue	sarcoma,	breast,	liver,	prostate,	pancreatic,	ovarian,	renal	and	non-small	cell	lung	cancer	(outcome	data	
unavailable)	
Not	presently	in	clinical	trials	ZD6126	 AstraZeneca/	Angiogene	pharmaceuticals	 Microtubule	destabilizing	agent	 Phase	II:	metastatic	renal	cell	carcinoma	and	colorectal	carcinoma	(failed	to	achieve	
primary	endpoints)	
Not	presently	in	clinical	trials	CYT997	 Cytopia	 Microtubule	destabilizing	agent	 Phase	II:	glioblastoma		and	myeloma	(failed	to	achieve	
primary	endpoints)	
Not	presently	in	clinical	trials	NPI	2358	(Plinabulin)	 Nereus	 Microtubule	destabilizing	agent	 Phase	III:	non-small	cell	lung	cancer	(ongoing)		BNC-105	 Bionomics	 Microtubule	destabilizing	agent	 Phase	II:	renal	cell	carcinoma	(ongoing)	and	ovarian	cancer	
(terminated)	DMXAA	(Vadimezan,	ASA404)	 Novartis	 Cytokine	inducing	agent	 Phase	II:	metastatic	prostate	cancer,	non-small	cell	lung	cancer	and	urothelial	carcinoma	
(outcome	data	unavailable)	
Not	presently	in	clinical	trials	ADH-1	(Exherin)	 Adherex	Technologies	 N-Cadherin	antagonist	 Phase	II:	melanoma	(ongoing)	Phase	I/II:	incurable	solid	tumours	(Completed	with	
positive	data)			
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1.2.1.4	Toxicity	Toxicity	is	an	important	issue	limiting	the	clinical	development	of	small	molecule	VDAs.	ZD6126	is	a	phosphate	pro-drug	of	the	tubulin-binding	agent	N-acetylcolchinol.	The	drug	disrupts	the	tubulin	cytoskeleton	of	endothelial	cells	causing	endothelial	cell	detachment.	In	vivo,	ZD6126	was	shown	to	cause	endothelial	cell	retraction,	extensive	endothelial	cell	loss	(36),	a	reduction	on	tumour	blood	flow	(37),	and	reduced	vascularisation	(38).	ZD6126	was	also	shown	to	cause	extensive	tumour	necrosis	in	a	range	of	animal	xenograft	models	(36,39,40)	and	inhibit	metastasis	from	lung	adenocarcinomas	(41).	When	ZD6126	progressed	to	clinical	trials,	however,	its	was	observed	to	have	severe	side	effects	at	the	clinically	required	dose.	Phase	II	clinical	trials	involving	ZD6126	for	the	treatment	of	metastatic	renal	cell	carcinoma	and	metastatic	colorectal	cancer	had	to	be	halted	in	2006	due	to	excessive	cardio-toxicity	(42)	and	no	subsequent	clinical	trials	have	been	arranged	(Table	1.1).		Likewise,	almost	half	of	the	small	molecule	VDAs	that	have	reached	clinical	trials	have	subsequently	had	their	development	halted,	often	due	to	insufficient	efficacy	at	dosages	with	an	acceptable	level	of	side	effects	(42).	Clinical	trials	involving	these	drugs	show	side	effects	that	are	consistent	with	anti-vascular	activity	and	include	transient	hypertension,	myocardial	infarction,	and	cardiac	ischemia	(43).	This	type	of	toxicity	suggests	that	small	molecule	VDAs	are	having	an	effect	on	healthy	vasculature	as	well	as	other	non-cancerous	cell	types,	and	therefore	the	drugs	are	insufficiently	selective	for	the	tumour	endothelium.	Experimental	models	have	shown	that	antihypertensive	therapy	can	prevent	some	of	the	side	effects	of	tubulin-targeting	drugs	in	particular,	without	reducing	the	clinical	efficacy	of	the	therapy	(43).	Another	idea	that	has	been	suggested	to	improve	the	selectivity	of	this	therapy	involves	incorporating	ligands	
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specific	for	tumour	endothelium	in	order	to	better	target	these	small	molecule	vascular	disrupting	therapies	(44).			
	
1.2.2	Ligand-Directed	VDAs	Ligand	directed	VDAs	act	directly	on	the	vasculature.	Therapeutics	of	this	class	are	made	up	of	two	components	joined	by	chemical	cross-linkers	or	peptide	bonds;	a	ligand,	such	as	an	antibody,	peptide	or	growth	factor,	which	binds	specifically	to	the	tumour	vasculature	and	an	effector,	which	once	delivered	to	the	tumour	vasculature,	destroys	it.	These	effectors	are	bioactive	molecules,	which	include,	coagulation	inducing	proteins,	toxins,	cytokines,	apoptosis	inducing	agents,	cytotoxic	agents,	and	radioisotopes.		Burrows	and	Thorpe	(45)	were	the	first	to	demonstrate	that	ligand-directed	approaches	for	disrupting	the	vasculature	of	tumours	could	be	effective.	They	set	up	subcutaneous	neuroblastoma	tumours	in	nude	mice.	The	tumours	were	engineered	to	express	interferon	gamma,	which	induced	the	vasculature	of	the	tumour	to	express	MHC	class	II.	They	targeted	the	tumour	vasculature	with	a	high	affinity	antibody	to	mouse	MHC	class	II,	coupled	with	the	toxin,	ricin.	This	approach	destroyed	the	tumour	vasculature,	causing	rapid	tumour	shrinkage,	whilst	leaving	the	vasculature	of	the	healthy	tissue	unaffected	(45)	(Figure	1.2).		A	key	requirement	for	success	using	this	treatment	strategy	is	the	discovery	of	appropriate	targets	on	the	tumour	vasculature	for	ligands	to	bind	to	and	deliver	their	effector	component.	Vessels	infiltrating	and	supplying	a	tumour	are	exposed	to	unusual	physiological	conditions	including;	hypoglycaemia,	severe	hypoxia,	oxidative	stress,	
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excessive	growth	factor	receptor	activation,	infiltration	of	inflammatory	cells	and	cytokine	activation,	as	well	as	reduced	blood	perfusion	and	shear	stress	(46).	These	factors	lead	to	distinct	cancer	vessel	gene	expression	profiles	that	can	be	exploited	by	ligand-targeted	therapies.	A	number	of	cell	surface	molecules	have	been	found	to	be	up-regulated	on	the	tumour	vasculature	when	compared	to	healthy	tissue	vasculature	and	the	discovery	of	additional	cell	surface	targets	is	a	continuing	quest	in	this	field.		
	
	
	
Figure	1.2.	Ligand	directed	VDA	induced	tumour	necrosis.	Gross	appearance	of	subcutaneous	neuroblastoma	tumours	treated	with	an	anti-MHC	class	II	immunotoxin.	At	day	0	the	tumours	are	pink/purple	(highly	vascular).	Two	days	after	treatment	the	tumour	is	blackened	(indicating	massive	intra-tumoural	haemorrhage).	At	day	7	the	tumour	has	collapsed	into	a	scab-like	plug	and	by	day	10	there	is	no	visible	living	tumour	(45).	Image	used	with	permission.	
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1.2.3	The	search	for	new	tumour	endothelial	markers	The	search	for	new,	more	specific	or	more	selectively	expressed	tumour	endothelial	markers	(TEMs)	is	on-going.	The	aim	is	to	find	markers	that	allow	drugs	to	be	efficiently	targeted	to	the	tumour	endothelium	with	appropriate	specificity	so	that	the	effector	dosage	at	the	tumour	is	sufficient	to	cause	vascular	destruction,	while	ensuring	the	effector	dosage	in	the	healthy	tissue	vascular	bed	is	below	threshold	levels	for	a	destructive	response.	To	this	end	several	techniques	have	and	are	being	used	to	identify	differentially	expressed	genes	on	tumour	endothelium.		
	
1.2.3.1	Immunohistochemical	analysis	Historically,	the	first	markers	of	tumour	endothelium	were	discovered	through	extensive	immunohistochemical	profiling	with	monoclonal	antibodies.	The	discovery	of	the	tumour	specific	fibronectin	extra-domain	B	(EDB)	was	achieved	through	the	observation	that	antibodies	specific	to	EDB-containing	fibronectin	stain	blood	vessels	in	many	cancer	types	but	not	most	healthy	tissues	(47-53).		
1.2.3.2	In	silico	analysis		
In	silico	techniques	have	also	been	used	to	predict	tumour	endothelial	markers,	which	can	then	be	further	validated	(54,55).	One	group	developed	a	subtractive	algorithm	to	screen	publically	available	sequence	tag	expression	data	as	a	method	to	identify	novel	endothelial	specific	genes	(56).	The	expression	of	these	genes	was	then	screened	by	in	
situ	hybridisation,	which	identified	ROBO4	and	EndoPDI	as	markers	of	active	angiogenesis	and	tumour	endothelium	(57,58).	Herbert	et	al.,	2008	(59),	used	publically	available	cDNA	libraries,	which	were	split	into	two	pools,	one	containing	
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gene	expression	profile	information	from	non-endothelial	cell	isolates,	cell	lines	and	bulk	tissues	and	the	other,	endothelial	cell	isolates.	Gene	expression	from	the	non-endothelial	pool	was	subtracted	from	the	endothelial	pool,	thus	generating	a	list	of	genes	with	endothelial-restricted	expression.	This	list	is	employed	in	chapter	5	to	aid	with	selection	of	tumour	endothelial	markers.	A	second	step	to	the	analysis	was	then	performed,	subtracting	healthy	bulk	tissue	gene	expression	from	tumour	bulk	tissue.	Genes	displaying	both	tumour	and	endothelial	restricted	expression	profiles	were	then	taken	forward	as	putative	tumour	endothelial	markers.	This	approach	identified	27	genes	as	being	tumour	endothelial	markers	(TEMs)	in	multiple	malignancies	(59),	including	known	TEMs	such	as	Robo4	and	novel	targets	such	as	ECSCR.		
1.2.3.3	In	vivo	phage	display	analysis	
In	vivo	phage	display	analysis	has	been	used	to	identify	endothelial	targets.	Vast	numbers	of	phage,	each	expressing	a	different	protein,	are	injected	into	animals	(60)	or	terminally	ill	patients	(61).	After	a	period	of	time,	tumour	and	healthy	tissues	are	removed,	the	endothelium	recovered	and	phage	specifically	localised	to	the	tumour	endothelium	are	isolated	and	analysed.	This	method	was	used	to	identify	an	amino-peptidase	as	a	target	on	breast	tumour	vasculature	(62).	Similarly,	phage	display	analysis	has	been	used	on	laser	micro-dissected	tissue	sections	(63),	and	on	tumour-associated	endothelial	cells	in	culture	(64).	
	
1.2.3.4	In	vivo	protein	labelling	and	isolation	A	number	of	groups	have	used	direct	vascular	labelling	techniques	to	identify	differentially	expressed	cell	surface	TEMs.	One	group	perfused	tumour-bearing	rodents	
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with	silica	beads,	which	stripped	the	membrane	proteins	from	the	surface	of	the	tumour	endothelium.	From	subsequent	proteomic	analysis	of	beads	perfusing	tumour	and	healthy	tissues,	a	number	of	cell	surface	proteins	were	found	to	be	enriched	on	tumour	endothelium	(65).	Other	groups	chemically	labelled	vascular	proteins	with	biotin	(66).	The	biotinylated	cell	surface	proteins	on	tumour	vasculature,	were	purified	on	a	streptavidin	column	and	subjected	to	proteomic	analysis,	to	quantify	expression	differences	between	hundreds	of	cell	surface	proteins	that	were	identified.	A	similar	approach	has	also	been	used	ex	vivo	to	analyse	surgically	resected	cancerous	human	kidney	and	colon	(67).		
1.2.3.5	Expression	profiling	of	cultured	ECs		Researchers	have	challenged	cultured	endothelium	with	various	facets	of	the	tumour	microenvironment,	such	as	inflammatory	or	immune	cytokines	(68),	matrix	induced	vascular	tubulogenesis	(69)	or	reduced	shear	stress	(70),	with	the	aim	of	inducing	an	expression	profile	akin	to	that	found	in	the	tumour.	By	then	conducting	microarray	or	RTqPCR	based	expression	analysis	on	these	samples,	tumour	endothelial	markers	can	be	identified.	
	
1.2.3.6	Genetic	approaches	in	animal	models	Some	groups	have	used	genetically	modified	animals,	where	haematopoiesis	and	vasculogenesis	is	disrupted,	to	investigate	embryonic	blood	vessel	development.	By	genetically	profiling	these	mutants,	the	processes	by	which	embryonic	tissue,	to	which	tumours	show	considerable	similarity,	acquire	their	vasculature	and	how	this	can	been	disrupted,	was	elucidated	(71-73).		
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1.2.3.7	Isolation	of	tumour	associated	ECs	from	tumour	resections.	Other	researchers	have	extracted	endothelial	RNA	from	clinical	samples	of	various	tumours	together	with	paired	healthy	host	tissue	and	conducted	Serial	Analysis	of	Gene	Expression	(SAGE)	(74-76)	or	microarray	analysis	(15,77-80)	to	identify	differentially	expressed	genes	between	the	endothelium	derived	from	the	host	healthy	tissue	and	the	tumour.	These	approaches	have	led	to	the	discovery	of	several	tumour	endothelial	markers	(TEMs).		
1.2.4.	Ligand	directed	drugs	under	investigation	and	in	the	clinic	A	number	of	the	targets	identified	by	these	analyses	have	subsequently	been	validated	for	vascular	targeting	(Table	1.2)	and	when	coupled	to	bioactive	effector	molecules	(Table	1.3)	have	shown	promise	in	tumour	models	and	clinical	trials	(Table	1.4).	EndoTAG-1	(Medigene)	is	composed	of	the	cytostatic	drug	paclitaxel	combined	with	cationic	lipids.	The	positively	charged	lipids	allow	EndoTAG-1	to	bind	to	newly	developed,	negatively	charged	endothelial	cells	that	make	up	the	tumour	vasculature	and	selectively	deliver	paclitaxel	to	this	site.	EndoTAG-1	has	been	successful	in	two	proof-of-concept	clinical	trials.	In	a	phase	II	clinical	trial	for	pancreatic	cancer	EndoTAG-1	in	combination	with	gemcitabine	significantly	increased	survival	rates	compared	to	gemcitabine	therapy	alone	(81).	A	phase	II	clinical	trial	involving	EndoTAG-1	for	the	treatment	of	triple	negative	breast	cancer	also	showed	promising	results	(82).	A	phase	III	clinical	trial	for	this	indication	is	planned	(Medigene	press	statement:	http://www.medigene.com/products-pipeline/development-projects/endotag-1)	(accessed:	7.8.2015).	
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Another	ligand-directed	vascular	targeting	therapy	to	progress	to	clinical	trials	is	L19-IL-2.	This	molecule	is	an	immunoconjugate	consisting	of	a	human	single	chain	Fv	antibody	fragment,	directed	against	fibronectin	ED-B	(known	to	be	up-regulated	in	proliferating	tumour	vasculature)	and	a	recombinant	form	of	the	cytokine	IL-2	(known	to	locally	induce	a	T	cell	cytotoxic	immune	response).	L19-IL-2	has	shown	promising	results	in	mouse	models	of	cancer	(83,84)	and	has	progressed	to	human	trials,	showing	clinical	activity	against	advanced	solid	tumours,	including	renal	cell	carcinoma	and	metastatic	melanoma	(85,86).	Phase	II	clinical	trials	for	the	treatment	of	advanced	pancreatic	cancer	and	metastatic	melanoma	are	on-going.	
	
	
Table	1.2.	Tumour	vascular	specific	targets.	
Class	 Examples	 Reference	Angiogenesis	/	Vascular	remodelling	 Fibronectin	ED-A	and	ED-B	domains		 (83,87-89)		 Endoglin	 (90)		 Extra	domains	of	Tenascin-C	 (91)		 Prostate-specific	membrane	antigen		 (92)		 Robo	4	 (57)		 TEM7	 (75)		 TEM8	/	anthrax	toxin	receptor	 (75)		 CD44-related	antigen	(TES-23)	 (93)		 MMP2	 (94)		 MMP9	 (94)		 STEAP1	 (80)	Cell	adhesion	 Integrins	(αvβ3)	 (95)		 VCAM-1		 (96)		 E-selectin	 (97)		 CLEC14A		 (98,99)		 TEM1	/	Endosialin	 (75,100)	Thrombosis	 Phosphatidylserine	phospholipids	 (101)		 Tissue	factor	 (102)	Inflammatory	modulation	 Annexin	A1	 (65)	
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Table	1.3.	Effector	molecules	used	in	vascular	targeting.	
Class	 Examples	 Reference	Coagulation-inducing	proteins	 Tissue	factor	 (87,92,96,103)	Toxins	 Ricin	 (45)		 Diphtheria	toxin		 (104,105)	Cytotoxic	agents	 Doxorubicin	 (106)		 Paclitaxel	 (107)	Cytokines	 Interleukin-2	 (83)		 Interleukin-12	 (88)		 Tumour	necrosis	factor-α	 (108)	Apoptosis-induction	 RAF-1	gene	 (109)		 Mitochondrial-membrane	disrupting	peptide	 (110)	Radioisotopes	 Iodine-131	 (111)		 Actinium-225	 (112)		 Bismuth-213	 (39)	
	
	
	
Table	1.4.	Ligand	directed	VDAs	in	the	clinic.		Information	retrieved	from:	http://clinicaltrials.gov	and	http://www.cancer.gov		(accessed:	7.8.2015).		
Agent	 Company	 Target	 Description	 Clinical	trials	EndoTAG-1	 Medigene	 Negatively	charged	EC	membrane	 Cationic	lipid	directed-	cytotoxic	 Phase	II:	advanced	pancreatic	cancer,	triple	negative	breast	cancer,	liver	tumours	L19-Il2	 Philogen	 ED-B	of	fibronectin	 Antibody	fragment	directed	Il-2	 Phase	II:	Metastatic	melanoma,	advanced	pancreatic	cancer	Phase	I/II:	Advanced	renal	cancer.	131I-L19	 Philogen	 ED-B	of	fibronectin	 Antibody	fragment	directed	radioisotope	 Phase	II:	Brain	metastasis	Phase	I:	Non	small	cell	lung	cancer	111In-J591	 Weill	Medical	College	of	Cornell	University	 Prostate-specific	membrane	antigen	 Antibody	directed	radioisotope	 Phase	II:	Prostate	cancer	NGR-hTNF	 MolMed	 CD13,	integrin	 Peptide	directed	TNF	 Phase	III:	pleural	mesothelioma	Phase	II:	Soft	tissue	sarcoma,	non	small	cell	lung	cancer,	ovarian	cancer,	colorectal	cancer,	hepatocellular	carcinoma		
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1.3	Project	aims	1:	Tumour	vascular	targets			One	of	the	primary	aims	of	the	project	detailed	in	this	thesis	was	to	profile	the	tumour	vasculature,	with	the	aim	of	identifying	and	validating	novel	tumour	specific	ligands	that	can	be	incorporated	into	the	pipeline	of	drug	development,	detailed	previously	in	this	section.	Work	to	achieve	this,	involving	magnetic	bead	isolation	of	tumour	and	healthy	tissue	derived	endothelium,	microarray	transcriptomic	analysis	and	validation	of	gene	and	protein	expression	in	tumour	and	healthy	tissue,	is	detailed	in	chapters	3,	4	and	5.	
	
	
1.4	Tumour	angiogenesis	
	Tumours	generally	arise	from	a	single	cell	in	which	several	genetic	events	have	occurred,	allowing	the	cell	to	escape	the	normal	growth	control	mechanisms	in	operation	in	the	tissue.	Initially	the	cancer	cell	can	proliferate	and	develop	into	a	tumour	while	receiving	sufficient	oxygen	and	nutrients	by	diffusion	from	the	surrounding	healthy	tissue	vasculature.	However,	as	the	mass	increases	the	tumour	rapidly	reaches	a	point	whereby	the	cancer	cells	furthest	from	a	blood	vessel	do	not	receive	sufficient	oxygen	and	nutrients	to	survive.	Further	expansion	of	the	tumour	is	restricted	and	the	tumour	remains	localised	and	dormant	(6)	(Figure	1.3A).		
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To	develop	further	and	metastasise	the	tumour	must	develop	its	own	blood	supply.	The	vascularisation	of	a	tumour,	known	as	angiogenesis,	is	a	complex	and	multistep	process,	driven	primarily	by	a	combination	of	tumour-associated	hypoxia	and	cellular	transformation	(113,114).	Oncogene	activation	in	tumour	cells	can	result	in	the	secretion	of	a	number	of	pro-angiogenic	growth	factors	including	platelet	derived	growth	factor	(PDGF),	vascular	endothelial	growth	factor	(VEGF)	and	basic	fibroblast	growth	factor	(bFGF)	(114).	These	factors	recruit	endothelial	cells	and	promote	their	proliferation	and	migration	to	the	source	of	the	angiogenic	signals,	where	they	create	blood	vessels	(115)	(Figure	1.3).	It	is	not	only	cancerous	cells	that	promote	angiogenesis	in	the	tumour.	When	stimulated	by	PDGF	from	the	tumour	cells,	stromal	cells	and	pericytes	are	known	to	produce	growth	factors	that	support	angiogenesis	(116).	In	addition	tumour	associated	hypoxic	conditions	can	lead	to	the	activation	of	the	transcription	factor	hypoxia	inducible	factor-1a	(HIF-1α)	(117)	in	multiple	cell	types,	including	tumour-associated	macrophages,	leading	to	the	expression	of	multiple	angiogenic	factors	such	as	VEGF	and	PDGF	(118).	Besides	this,	in	the	tumour	environment,	both	pro	and	anti-angiogenic	factors	have	been	found	to	emanate	from	endothelial	cells,	blood	and	even	the	extracellular	matrix	(113).			
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Figure	1.3.	Tumour	angiogenesis.	A,	the	tumour	is	initially	small	and	avascular,	not	exceeding	2	mm3	in	size.	B,	pro-angiogenic	molecules	emanating	from	the	tumour	initiates	sprouting	angiogenesis	from	a	nearby	capillary.	C,	The	new	tumour	vasculature	supplies	nutrients	and	oxygen,	facilitating	further	growth	and	metastasis.	Tumours	additionally	vascularise	via	vessels	co-option	and	other	mechanisms.	Adapted	from	(119).	Reproduced	with	permission.	
	
	
1.5	Angiogenesis	inhibitors	
	Folkman	was	the	first	to	champion	the	idea	of	using	therapeutics	to	inhibit	tumour	angiogenesis	and	thus	maintain	the	tumour	in	a	dormant,	avascular	state	(6,120).	The	majority	of	successful	antiangiogenic	therapies	have	been	those	developed	to	target	and	block	VEGF	pro-angiogenic	signalling	pathways	in	the	tumour.	These	therapeutics	are	broadly	split	into	three	types,	blocking	antibodies,	soluble	decoy	receptors	and	small	molecule	inhibitors.	
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1.5.1	Blocking	antibodies		
1.5.1.1	Anti-VEGF	antibodies:	Bevacizumab	Bevacizumab	(Genentech),	marketed	as	Avastin,	is	a	humanised	monoclonal	antibody	that	is	designed	to	bind	to	VEGF,	blocking	its	association	with	VEGF	receptors	on	endothelial	cells	and	thus	blocking	angiogenesis	(121,122).		In	the	clinic,	with	the	exception	of	metastatic	renal	cell	carcinoma	(123),	no	single	agent	efficacy	has	been	shown	with	the	use	of	bevacizumab	in	cancer.	It	has	however	been	found	to	improve	therapeutic	efficacy	of	chemotherapeutics	when	used	in	combination,	in	colorectal	(124),	breast	(125),	and	non-small	cell	lung	cancer	(NSCLC;	(126)).	This	finding	at	first	glance	could	appear	counterintuitive,	as	a	therapeutic	that	devascularises	the	tumour	would	presumably	inhibit	the	delivery	of	chemotherapeutics,	reducing	their	efficacy.	In	2001,	however,	Rakesh	Jain	proposed	the	now	popular	“vascular	normalisation	theory”	as	explanation	for	this	phenonomon.	He	proposed	that	bevacizumab	(and	perhaps	other	antiangiogenic	therapies),	by	reducing	aberrant	and	excessive	VEGF	signalling	in	the	tumour,	causes	the	structural	and	functional	normalisation	of	the	tumour	vasculature,	reducing	interstitial	fluid	pressure	and	improving	drug	penetration,	thereby	enhancing	the	efficacy	of	chemotherapeutic	agents	(127).	This	theory	has	gained	widespread	acceptance,	largely	based	on	preclinical	data	(reviewed	in	(128,129)),	however	despite	some	examples	of	structural	normalisation	and	vascular	maturation	in	the	clinic	(130),	to	date	there	is	little	evidence	of	improved	drug	infiltration	upon	treatment	with	bevacizumab.	Demonstration	of	reduced	perfusion	of	the	chemotherapy,	docetaxel,	in	NSCLC	after	treatment	with	bevacizumab	(131),	has	thrown	this	theory	further	into	controversy.	It	
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is	likely	therefore	that	there	are	other	mechanisms,	additional	to	vascular	normalisation,	mediating	bevacizumab-chemotherapy	drug	synergy.		In	2004	bevacizumab,	in	combination	with	irinotecan,	fluorouracil	and	leucovorin,	showed	efficacy	against	metastatic	colorectal	carcinoma	in	a	phase	III	trial	(124).	Patients	treated	with	bevacizumab	benefited	from	a	4.7-month	increase	in	overall	survival	and	the	result	caused	the	U.S	Food	and	Drug	Administration	(FDA)	to	approve	the	use	of	bevacizumab	for	the	treatment	of	colorectal	cancer.	Similar	results	against	other	cancers	meant	that	bevacizumab	was	approved	for	the	treatment	of	non-small	cell	lung	cancer	in	2006,	renal	cancer	in	2007,	breast	cancer	in	2008	and	glioblastoma	multiforme	in	2009	(Table	1.5).	However,	its	indication	in	breast	cancer	was	subsequently	revoked	by	the	FDA	in	2011	because	of	clinical	trial	data	showing	that	bevacizumab	nether	prolonged	overall	survival	nor	slowed	disease	progression	sufficiently	to	outweigh	its	risk	of	side	effects,	which	include	hypertension,	proteinuria,	bleeding,	thrombotic	events	and	in	very	rare	cases	pulmonary	embolisms	(132).	
	
1.5.1.2	Anti-VEGFR-2	Antibodies:	DC101,	Ramucirumab	and	CDP-791	A	number	of	monoclonal	antibodies	raised	against	the	extracellular	domain	of	VEGFR-2	have	been	designed	to	block	the	binding	of	VEGF	to	its	receptor	and	thus	inhibit	angiogenesis.	DC101	was	the	first	drug	of	this	type	to	show	antiangiogenic	effectiveness	(133).	The	rat	anti-mouse	monoclonal	antibody	(ImClone)	has	been	shown	to	be	a	potent	antagonist	to	VEGF	binding,	VEGFR-2	signalling	and	endothelial	cell	proliferation	in	in	vitro	models	(133).	In	animal	models	DC101	has	been	shown	to	have	potent	antiangiogenic,	antitumour	and	anti-metastatic	activity	(133-135).	
	 24	
Studies	using	DC101	led	to	the	development	of	ramucirumab	(IMC-1121b)	(ImClone),	a	fully	human	anti-VEGFR2	monoclonal	antibody	and	CDP-791	(Celltech,	UCB),	a	PEGylated,	humanised	anti-VEGFR-2	F(ab’)2	fragment.	Ramucirumab	has	recently	been	FDA	approved	for	use	in	gastric	or	gastro-esophageal	junction	adenocarcinoma	and	metastatic	non-small	cell	lung	cancer,	in	combination	with	paclitaxel	and	docetaxel	respectively,	following	successful	phase	III	clinical	trials	(136-138).	Ramucirumab	is	additionally	currently	in	phase	II	and	II	clinical	trials	for	the	treatment	of	a	range	cancers	including	breast	cancer,	hepatocellular	carcinoma,	and	metastatic	colorectal	carcinoma	(Table	1.5).	CDP-791	has	reached	phase	II	clinical	trials	against	non-small	cell	lung	cancer	in	combination	with	carboplatin	and	paclitaxel,	however,	its	development	is	currently	on	hold,	as	progression-free	survival	was	not	improved	by	CDP-791	treatment	in	this	study	(UCB	press	statement:	01.04.2008:	http://www.bionity.com/en/news/80262/ucb-phase-ii-results-for-cdp791-in-non-small-cell-lung-cancer-support-further-clinical-development.html.	Accessed:	07.08.2015).	
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Table	1.5.	Antiangiogenic	blocking	antibodies	in	the	clinic.	Information	retrieved	from:	http://clinicaltrials.gov	and	http://www.cancer.gov		(accessed:	07.08.2015).		
			
1.5.2			Soluble	decoy	receptors	Aflibercept,	also	known	as	ziv-aflibercept	or	ZALTRAP	(Sanofi-aventis	and	Regeneron)	is	a	fusion	protein	incorporating	the	second	binding	domain	of	the	VEGFR-1	receptor	and	the	third	domain	of	the	VEGFR-2	receptor	(139).	It	binds	VEGF	with	high	affinity	(Kd~1pM)	(140)	and	so	acts	as	a	potent	competitive	inhibitor	of	VEGF-R	binding.	Aflibercept	has	been	shown	to	be	a	potent	angiogenesis	inhibitor	(140),	and	is	highly	effective	against	neovascularisation	related	macular	degeneration	(141).	Aflibercept	is	the	subject	of	clinical	trials	against	a	number	of	cancers.	A	phase	III	clinical	trial	involving	aflibercept	in	combination	with	docetaxel	and	dexamethasone	for	the	treatment	of	non-small-cell	lung	cancer	reported	that	aflibercept	improved	progression	
Antibody	 Company	 Antibody	type	 Target	 Indications/	clinical	trials	Bevacizumab	(Avastin)	 Genentech	 Humanised	IgG1	 VEGF-A	 FDA	approved	for:	first	and	second	line	metastatic	colorectal	carcinoma,	first-line	advanced	non-squamous	non-small	cell	lung	cancer,	metastatic	renal	cell	cancer,	recurrent	glioblastoma	multiforme.	Phase	III:	ovarian	cancer	(ongoing)	
FDA	approval	revoked	for	metastatic	
breast	cancer	Ramucirumab	(IMC-1121b)	 ImClone	Systems	 Fully	human	IgG1	 VEGFR-2	 FDA	approved	for:	second-line	advanced	gastric	or	gastro-esophageal	junction	adenocarcinoma	and	metastatic	non-small	cell	lung	cancer.	Phase	III:	breast	cancer,	hepatocellular	carcinoma,	metastatic	colorectal	carcinoma.	Phase	II:	stomach,	renal,	bladder,	prostate,	ovarian	cancers	and	melanoma	(all	ongoing)	CDP-791	 Celltech	 Pegylated	humanised	DiFab	 VEGFR-2	 Phase	II:	non-squamous	non-small-cell	lung	cancer	(failed	to	achieve	primary	
endpoints)	IMC-18F1	 ImClone	Systems	 Fully	human	IgG1	 VEGFR-1	 Phase	II:	breast	(ongoing),	colorectal	and	renal	cancers	(outcome	data	
unavailable)	
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free	survival	but	not	overall	survival	relative	to	placebo	(142).	However,	a	phase	III	trial	involving	aflibercept	in	combination	with	Irinotecan,	5-Fluorouracil,	and	Leucovorin	for	the	treatment	of	metastatic	colorectal	cancer	reported	that	aflibercept	improved	overall	survival	relative	to	placebo	(143).	Because	of	this	trial,	in	2012	FDA	approval	was	given	for	this	drug	to	be	used	against	metastatic	colorectal	cancer.	A	subsequent	phase	III	clinical	trial,	involving	aflibercept	for	the	treatment	of	metastatic	colorectal	cancer,	also	showed	statistically	significant	improvements	in	overall	survival,	progression	free	survival	and	overall	tumour	response	rate,	relative	to	placebo	(144).	This	trial	provides	further	support	for	the	use	of	aflibercept	against	metastatic	colorectal	cancer.		
	
	
1.5.3			Small	molecule	inhibitors	The	small	molecule	inhibitors	are	an	alternative	form	of	antiangiogenic	therapy.	Rather	than	blocking	the	binding	of	VEGF	to	its	receptor,	they	block	angiogenesis	by	inhibiting	downstream	signalling	from	the	activated	proangiogenic	receptors	in	the	endothelial	cells.	Drugs	of	this	class	are	receptor	tyrosine	kinase	inhibitors.	They	bind	to	and	inhibit	the	kinase	activity	of	certain	receptor	tyrosine	kinases	(RTKs)	such	as	the	VEGFRs.	VEGFRs	are	not	the	only	receptor	tyrosine	kinases	involved	in	cancer,	or	normal	cellular	functions	however.	Unlike	targeted	anti-VEGF	signalling	therapies	discussed	previously,	this	therapeutic	class	additionally	blocks	other	pathways	involved	in	angiogenesis	and	tumourgenesis	and	thus	has	antitumour,	as	well	as	anti-angiogenic	activity	(145)	(Table	1.6).	Additionally	small	molecule	inhibitors	are	orally	available	
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and	therefore	cheaper	to	manufacture	and	administer	to	patients	than	many	anti-VEGF	signalling	therapies.		Five	antiangiogenic	small	molecule	inhibitors	have	received	FDA	approval	for	use	against	various	malignancies.	Sorafenib	(Bayer	and	Onyx	pharmaceuticals),	sunitinib,	axitinib	(both	Pfizer)	pazopanib	(GlaxoSmithKline)	and	vandetanib	(Astrazeneca)	are	collectively	approved	for	the	treatment	of	renal	cell	carcinoma,	gastrointestinal	stromal	tumours,	pancreatic	tumours,	hepatocellular	carcinoma,	soft	tissue	sarcoma	and	medullary	thyroid	cancer.	These	drugs	and	those	of	their	class	are	also	undergoing	many	clinical	trials	in	other	tumour	types	(Table	1.6).		
	Unlike	bevacizumab,	RTKIs	predominantly	display	a	direct	antiangiogenic	effect,	with	a	number	of	the	drugs	of	this	class	showing	significant	single	agent	activity	in	the	form	of	tumour	growth	inhibition	and	devascularisation,	in	both	clinical	and	preclinical	settings	(145).	Indeed	sorafenib,	sunitinib,	pazopanib	and	axitinib	are	licensed	as	monotherapies,	suggesting	that	these	drugs	may	mediate	their	anti-cancer	effect	in	quite	a	distinct	manner	to	bevacizumab.	Some	newer	antiangiogenic	RTKIs	(cediranib	and	tivozanib)	have	shown	aspects	of	vascular	normalisation	(the	widely	accepted	method	of	action	of	bevacizumab)	(146,147).	However	like	bevacizumanb,	no	compelling	evidence	of	improved	perfusion	of	the	tumour	has	been	demonstrated	for	this	type	of	therapy	in	the	clinic.	This	could	be	due	to	dosing,	however.	Low	dose	(20mg/ml)	sunitinib	was	shown	to	improve	the	tumour	distribution	of	temozolomide	in	a	preclinical	model	of	glioma,	when	compared	to	controls.		High	dose	sunitinib	(60mg/ml)	on	the	other	hand,	reduced	perfusion	of	the	drug	(148).	Despite	the	lack	of	
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obvious	mechanistic	synergy	in	humans,	several	clinical	trials	are	underway	to	investigate	the	effectiveness	of	antiangiogenic	RTKis	in	combination	with	tumour	cell	directed	therapy	(e.g.	chemotherapy	and	radiotherapy).	
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Table	1.6.	Antiangiogenic	small	molecule	inhibitors	in	the	clinic.	Information	retrieved	from:	http://clinicaltrials.gov	and	http://www.cancer.gov		(accessed:	07.08.2015).		
Inhibitor	 Alternative	
names	
Company	 Activity	 Indications/clinical	trials	Sunitinib	 Sutent,	SU11248	 Pfizer	 VEGFR-2,	PDGFRα	&	
β,	c-kit,	Flt3,	RET	
FDA	approved	for:	first	and	second	line	treatment	for	metastatic	renal	cell	carcinoma,	gastrointestinal	stromal	tumours.	progressive,	unresectable,	neuroendocrine	pancreatic	tumours	Phase	III:	breast	(failed	to	achieve	
primary	endpoints	repeatedly,	but	
trials	ongoing),	colorectal	and	lung	cancer	(ongoing)	Sorafenib	 Nexavar,	BAY	43-9006	 Bayer	HealthCare	Pharmaceuticals	and	Onyx	Pharmaceuticals	 VEGFR2	&	3,	Raf,	PDGFRβ,	Flt3	and	c-kit	
FDA	approved	for:	unresectable	hepatocellular	carcinoma,	advanced	renal	cell	carcinoma	Phase	III:	non-small	cell	lung	carcinoma	and	melanoma	(failed	to	achieve	
primary	endpoints	in	both)	Pazopanib	 Armala,	GW786034	 GlaxoSmithKline	plc	 VEGFR1-3,	PDGFRα	&	
β,	c-kit	 FDA	approved	for:	renal	cell	carcinoma,	soft	tissue	sarcoma	Phase	II:	non-small	cell	lung	carcinoma	
(failed	to	achieve	primary	
endpoints),	ovarian	cancer	(ongoing)	Phase	I:	colorectal	cancer	Axitinib	 AG-013736	Inlyta	 Pfizer	 VEGFR1-3,	PDGFRβ,	c-kit	 FDA	approved	for:	second	line	treatment	for	renal	cell	carcinoma	Phase	III:	pancreatic	cancer	(failed	to	
achieve	primary	endpoints)	Phase	II:	lung,	gastrointestinal,	thyroid	and	breast	cancer	(ongoing)	Vandetanib	 Zactima,	ZD6474	 Astrazeneca	 VEGFR1-3,	PDGFRβ,	EGFR,	RET	 FDA	approved	for:	medullary	thyroid	cancer	Phase	III:	non	small	cell	lung	carcinoma	
(ongoing)	Cediranib	 Recentin,	AZD2171	 Astrazeneca	 VEGFR1-3,	PDGFRα	&	b,	c-kit	 Phase	III:	recurrent	ovarian,	fallopian	tube,	primary	peritoneal	cancer,	glioblastoma,	colorectal	cancer	(all	
ongoing),	non	small	cell	lung	carcinoma	
(failed	to	achieve	primary	endpoints)		Vatalanib	 PTK787,	ZK222584	Caprelsa	 Novartis	 VEGFR1-3,	PDGFRα	&	b,	c-kit	 Phase	III:	Colorectal	carcinoma	(failed	to	achieve	primary	endpoints)	Phase	II:	Metastatic	neuroendocrine	tumours,	Brain	and	central	nervous	system	tumours,	sarcoma	(outcome	
data	unavailable)	Brivanib	alaninate			 BMs-582664			 Bristol-Myers	Squibb			 VEGFR1–3,	FGFR1-3			 Phase	III:	colorectal	cancer,	hepatocellular	carcinoma	(ongoing)	Phase	II:	multiple	tumour	types	
(ongoing)	Nintedanib		 Vargatef	BIBF	1120	 Boehringer	ingelheim			 VEGFR1–3,	PDGFRα	&	β,	FGFR1–3,	Flt3,	Src,	Fyn,	Lck			
Phase	III:	Non	small	cell	lung	cancer	(NSCLC),	Ovarian	cancer	(ongoing)		Phase	II:	Breast	cancer,	prostate	cancer,	acute	myeloid	leukaemia,	glioblastoma,	hepatocellular	carcinoma,	colorectal	cancer,	high	grade	glioma	(all	ongoing)	Tivozanib	 KRN951,	AV-951	 AVEO	Pharmaceuticals,	Inc.	 VEGFR-2,	PDGFR-β,	c-Kit	 Phase	III:	renal	cell	carcinoma	(completed	with	positive	results	but	insufficient	for	FDA	approval)		
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1.6	Antiangiogenic	therapy	resistance	
	Antiangiogenic	therapies	have	had	great	success	in	treating	a	number	of	solid	tumours	as	demonstrated	by	FDA	approval	for	their	use	against	nine	different	malignancies.	They	are	primarily	used	in	advanced	or	metastatic	settings	and	rarely	provide	long-term	survival	benefits.	Long-term	PFS	on	antiangiogenic	drugs	is	prevented	by	the	almost	inevitable	acquisition	of	resistance	to	the	treatment.	Additionally	tumours	often	return	with	a	more	aggressive,	invasive	and	metastatic	phenotype.	Because	of	this,	the	survival	benefits	provided	by	antiangiogenic	treatments	in	the	clinic	are	often	measured	in	months,	rather	than	years	(149-151).		There	is	a	considerable	need	for	research	into	why	certain	tumours	are	unresponsive	to	antiangiogenic	treatments	and	why	initially	sensitive	tumours	frequently	then	progress	after	a	short	period	of	stasis	or	shrinkage	(152-154)	(Figure	1.4).	The	current	hypothesis	is	that	tumours	adapt	to	therapeutic	blockade	of	angiogenesis	by	acquiring	new	mechanisms	to	functionally	evade	it	(149,152,155).	Current	experimental	evidence	suggests	five	distinct	adaptive	mechanisms	employed	by	the	tumour	and	surrounding	tissue,	to	evade	inhibition.	
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Figure	1.4.	Modes	of	anti-angiogenic	therapy	resistance.	Tumours	respond	to	antiangiogenic	therapy	in	two	distinct	ways.	Either	the	tumour	initially	responds,	via	devascularisation	and	tumour	shrinkage,	with	increased	apoptosis	and	necrosis.	After	a	time	however,	the	tumour	reestablishes	its	vascular	network	and	ceases	to	respond	to	anti-angiogenic	blockade,	becoming	adaptively	resistant.	Alternatively	the	tumour	never	responds	to	anti-angiogenic	at	all	and	is	considered	intrinsically	resistant.	Adapted	from	(149),	reproduced	with	permission.		
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1.6.1	Evasive	resistance	by	up	regulation	of	alternative	pro-angiogenic	signalling	
pathways	within	the	tumour	An	elegant	example	of	adaptation	to	evade	the	actions	of	anti-angiogenic	agents	was	observed	in	a	preclinical	trial	of	the	monoclonal	VEGFR	blocking	antibody	(DC101)	in	murine	pancreatic	neuroendocrine	cancer	(Rip1-Tag2)	(156).	The	antibody	initially	elicited	a	response	in	the	form	of	tumour	stasis	and	reduced	vascularity.	However,	this	responsiveness	was	short	lived,	after	10-14	days	the	tumour	regrew	and	dense	vasculature	was	restored.	This	response	suggested	a	reinitiation	of	tumour	angiogenesis	bypassing	the	monoclonal	VEGFR	blockade.	The	investigators	found	that	the	relapsing	tumours	had	heightened	expression	levels	of	a	number	of	angiogenic	factors,	including	several	members	of	the	fibroblast	growth	factor	family,	ephrin	A1	and	A2	as	well	as	angiopoietin-1	(156).	To	confirm	that	these	expression	changes	were	responsible	for	cancer	relapse,	tumours	were	first	treated	with	the	monoclonal	antibody,	but	after	the	10-14	day	responsive	phase	had	elapsed,	a	second	line	treatment	consisting	of	an	FGFR-FC	fusion	protein,	shown	to	suppress	signalling	through	the	FGF	ligands,	was	used	to	treat	the	tumour.	The	investigators	found	that	tumour	growth	was	slowed	and	revascularisation	attenuated	relative	to	untreated	controls.	This	result	indicated	that	FGF	signalling	played	a	part	in	the	tumour	relapse	(156)	and	that	dual	targeting	of	the	VEGF/FGF	pathways	could	slow	the	onset	of	resistance.	Preclinical	evaluation	of	brivanib	alaninate,	a	dual	inhibitor	of	VEGFR	and	FGFR,	showed	it	to	be	effective	both	as	a	first	line	therapy	and	as	a	second	line	therapy	against	tumours	that	had	relapsed	on	sorafenib	or	DC101	treatment	(157).	In	the	BRISK-PS	phase	III	clinical	trial	however,	brivanib	alaninate	treatment	failed	to	
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improve	survival	over	placebo,	in	patients	with	hepatocellular	carcinoma	that	had	relapsed	under	sorafenib	treatment	(158).	Another	study	showed	that	the	angiogenic	capability	of	tumours	deficient	in	a	key	inducer	of	VEGF	expression,	hypoxia-inducible	factor	1a	(HIF1a),	could	be	saved	by	inducing	the	expression	of	the	pro-angiogenic	cytokine	interleukin-8	(IL-8)	(159).	This	suggests	that	over-expression	of	IL-8	could	be	one	of	the	mechanisms	used	by	tumours	to	evade	VEGF	signalling	blockade.	In	agreement	with	this,	a	study	showed	that	tumours	in	which	growth	was	initially	halted	by	ectopic	expression	of	the	angiogenesis	inhibitors;	thrombospondin,	tumstatin	and	endostatin,	quickly	bypassed	growth	inhibition	by	up-regulating	a	number	of	pro-angiogenic	factors	such	as,	PDGF,	FGF	and	VEGF	(160).	
	
1.6.2	Recruitment	of	pro-angiogenic	cells	Cells	under	hypoxic	stress	caused	by	anti-angiogenic	therapy	induced	vessel	regression	have	been	shown	to	recruit	various	bone	marrow	derived	cells	(BMDCs)	that	elicit	a	pro-angiogenic	response,	fuelling	the	tumour	(161,162).	These	pro-angiogenic	BMDCs	consist	of	vascular	progenitors	and	vascular	modulatory	cells,	either	differentiating	into	new	endothelial	cells	and	pericytes,	or	expressing	various	cytokines	and	growth	factors	that	promote	vascular	development	(161,162).		
	
1.6.3	Rapid	vascular	remodelling	by	recruitment	of	pericytes	Several	groups	have	observed	that	although	there	is	a	substantial	reduction	in	vascularity	in	tumours	treated	with	VEGF	signalling	inhibitors,	a	small	population	of	functional	vessels	remain,	which	are	morphologically	distinctive	from	untreated	
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tumour	vasculature.	These	vessels	are	far	thinner,	less	dilated	and	far	more	densely	covered	in	pericytes	(163,164).	These	observations	suggest	that	endothelial	cells	recruit	pericytes	to	protect	against	VEGF	signalling	blockade-induced	death.	In	support	of	this	suggestion,	it	has	been	observed	that	vessels	with	low	pericyte	coverage	are	more	sensitive	to	VEGF	inhibition	(163,165).	
	
1.6.4	Increased	local	invasion	and	vessel	co-option,	mitigating	the	need	for	
neovascularisation	It	has	been	widely	observed	that	some	angiogenically	inhibited	tumours	become	more	invasive	than	they	were	before	treatment	(150,151).	This	increased	invasive	phenotype	was	first	observed	in	orthotropic	mouse	models	of	glioblastoma	multiforme	(GBM),	in	which	angiogenesis	was	thwarted	either	by	deletion	of	a	number	of	angiogenic	factors,	VEGF,	HIF1α,	matrix	metalloproteinase	9	(MMP9)	or	by	treatment	with	the	VEGF	inhibitor	semaxanib.	In	these	models	the	tumours	were	found	to	adapt	to	angiogenic	inhibition	by	becoming	more	invasive,	extensively	infiltrating	into	the	brain	(166-168).	It	was	suggested	that	the	glioblastoma	cells	managed	to	maintain	vascular	sufficiency,	and	so	continue	to	grow,	by	co-opting	healthy	tissue	vessels,	migrating	along	these	vessels	and	thus	dispersing	throughout	the	brain.	This	response	was	also	observed	in	clinical	trials	of	bevacizumab	therapy	in	GBM	(169,170).	Vessel	co-option	has	been	observed	in	a	range	of	tumours	as	an	alternative	method	of	tumour	vascularisation,	independent	of	angiogenesis	(171).	It	is	most	reported	in	tumours	of	highly	vascular	tissues,	such	as	the	brain,	liver	and	lungs,	with	10-30%	of	lung	tumours	using	this	method	to	maintain	vascular	sufficiency	(172).	Vessel	co-option	is	therefore	of	great	interest	as	a	potential	method	by	which	tumours	can	
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become	resistant	to	antiangiogenic	therapy	(172).	Certainly	the	tumour	stromal	architecture,	including	the	utilisation	of	co-opted	vessels,	has	been	reported	to	be	predictive	of	intrinsic	resistance	to	antiangiogenic	therapy	(173).			
1.6.5	Increased	distant	metastasis	Besides	increased	local	invasion,	potentially	mediated	by	a	switch	towards	vessel	co-option,	there	is	extensive	preclinical	data	suggesting	that	metastatic	seeding	of	tumour	cells	is	enhanced	by	antiangiogenic	therapy	usage	(150,151).	This	effect	is	not	universal	however,	being	dependent	on	tumour	type	and	cell	line	(174),	the	class	of	therapy	used	(TKI	vs.	monoclonal	anti-VEGF	antibody)	(175)	and	drug	dosage	(174,176).	Additionally	there	is	little	substantive	evidence	suggesting	this	effect	is	recapitulated	in	the	clinical	setting	(177).	Nevertheless	the	potential	for	antiangiogenic	therapies	to	enhance	metastasis	is	still	an	area	of	great	concern	and	research,	due	to	the	potential	for	a	patient’s	condition	to	be	worsened	by	this	type	of	therapy	in	certain	settings.	
	
1.6.6	Selection	of	resistant	endothelium	There	is	increasing	interest	in	the	role	endothelial	cells	play	in	mediating	antiangiogenic	resistance.	Isolated	endothelium	from	hepatocellular	carcinoma	were	found	to	behave	quite	differently	from	healthy	liver	endothelium	in	culture.	They	exhibited	an	increased	rate	of	migration	and	proliferation,	were	far	less	dependent	on	growth	factors	for	their	survival	as	well	as	being	more	resistant	to	antiangiogenic	and	other	chemotherapeutic	treatments	(178).	This	result	suggests	that	the	tumour	endothelium	is	quite	adaptive	and	that	the	environment	within	the	tumour	could	
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induce	permanent	epigenetic	changes,	which	reduce	endothelial	responsiveness	to	anti-angiogenic	therapies.	
	
1.6.7	Tumour	cell	metabolic	change	Over	the	last	decade	increasing	evidence	points	to	the	role	of	hypoxia	induced	metabolic	changes	in	the	acquisition	of	resistance.	Many	studies	report	an	increase	in	tumour	hypoxia	induced	by	antiangiogenic	therapy	(reviewed	in	(179)),	in	line	with	the	expected	mode	of	operation	of	most	anti-angiogenic	therapies	(namely	devascularisation).		This	increased	hypoxia	has	been	reported	to	result	in	the	activation	of	a	number	of	gene	transcription	programs,	including	HIF1	and	HIF2,	the	unfolded	protein	response	(UPR)	(180)	and	ATF4	(181),	making	fundamental	changes	to	energy	metabolism	in	the	tumour.	HIF	induced	changes	to	genes	regulating	glycolysis	and	oxidative	phosphorylation	were	found	to	be	responsible	for	bevacizumab	resistance	in	glioblastoma	(182).	Increase	tumour	cell	autophagy	has	also	been	reported	as	a	response	to	antiangiogenic	blockade	(183).	A	recent	study	charting	metabolic	changes	in	a	range	of	tumour	xenographs,	occurring	after	removal	of	sorafenib	and	sunitinib	treatment,	revealed	a	rapid	shift	from	glycolysis	to	lipid	metabolism,	concurrent	with	a	drastic	increase	in	metastatic	tumour	spread	(184).		In	summary,	antiagiogenic	blockade	appears	to	induce	drastic	changes	in	tumour	cell	metabolism,	potentially	via	a	normal	physiological	response	to	hypoxia,	which	at	least	in	part	leads	to	a	loss	of	tumour	cell	sensitivity	to	antiangiogenic	therapy.				
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1.6.8	Innate	insensitivity	to	antiangiogenic	therapy	A	significant	minority	of	patients	enrolled	in	clinical	trials,	where	the	efficacy	of	antiangiogenic	drugs	was	tested,	are	documented	to	fail	to	respond	at	all	to	treatment	(Figure	1.4).	There	is	no	discernable	beneficial	effects	from	treatment,	no	tumour	shrinkage	or	stasis	and	no	improvement	in	quality	of	life	or	survival	(154).	It	is	possible	that	the	tumours	of	these	patients	adapted	to	anti-angiogenic	treatment	before	any	benefit	could	be	observed,	but	a	more	plausible	explanation	is	that	these	tumours	have	intrinsic	resistance	to	anti-angiogenic	therapy	(149).	The	mechanism	of	resistance	could	be	quite	similar	to	that	of	tumours	that	gain	resistance,	however,	the	necessary	changes	have	been	driven	by	pressures	from	the	intrinsic	tumour	microenvironment	rather	than	by	pressures	from	anti-angiogenic	treatment	(149).	VEGF	is	not	the	only	growth	factor	capable	of	mediating	angiogenesis	in	the	tumour.	Some	tumours	may	be	intrinsically	resistant	to	VEGF	targeted	antiangiogenic	therapies	because	their	vasculature	has	developed	to	be	dependent	on	a	different	angiogenic	growth	factor,	such	as	FGF	or	IL-8.			Given	the	considerable	proportion	of	people	who	don’t	respond	or	respond	very	poorly	to	antiangiogenic	therapies,	there	appears	to	be	a	need	for	predictive	biomarkers	of	response,	so	that	those	for	whom	antiangiogenic	therapy	would	be	effective	can	be	identified.	A	few	potential	biomarkers	have	been	identified	from	clinical	trials,	such	as	VEGF	polymorphisms	or	pharmacodynamics	changes	induced	by	antiangiogenic	treatment	(185),	but	further	analysis	is	warranted.	
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1.7	Project	aims	2:	Antiangiogenic	therapy	resistance		
	The	other	primary	aim	of	this	project	was	to	investigate	the	development	of	antiangiogenic	small	molecular	inhibitor	therapy	resistance	in	vivo,	with	particular	focus	on	the	molecular	mechanisms	behind	enhanced	metastatic	growth	after	treatment	relapse.	This	being	an	area	of	paticular	concern,	due	to	the	potential	for	treatment	to	worsen	the	status	of	the	patient	if	metastasis	is	enhanced.	As	discussed	however,	there	are	many	other	potential	factors	limiting	the	efficacy	of	antiangiogenic	therapy	use,	including	vessel	co-option,	the	use	of	alternative	pro-angiogenic	growth	factors	and	the	metabolic	adaption	of	cancer	cells	to	hypoxia	and	attention	will	be	paid	to	some	of	these	factors	as	well.		For	this	purpose	the	4T1	syngeneic	model	of	metastatic	breast	cancer	was	selected.	This	is	one	of	the	very	few	genuine	in	vivo	metastatic	models.	It	is	a	faithful	model	of	spontaneous	lymphatic	metastasis	from	a	primary	mammary	tumour	(186).	Chapter	6	of	this	thesis	reports	the	development	of	a	reliable	model	of	breast	cancer	growth	and	metastasis	in	which	both	primary	tumour	growth	and	metastasis	can	be	readily	traced	
in	vivo	and	ex	vivo.	Sunitinib	was	selected	as	the	drug	of	choice	for	the	investigation	of	post-treatment	relapse,	as	it	has	repeatedly	failed	to	achieve	primary	endpoint	goals	of	prolonged	progression	free	survival	and	overall	survival	in	phase	III	trials	of	metastatic	breast	cancer,	as	a	monotherapy	(187)	or	in	combination	with	chemotherapy	(188-190),	compared	with	standard-of-care,	with	only	overall	response	rate	being	improved	in	combination	with	docetaxel,	compared	with	docetaxel	alone	(189).	Consequently	
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sunitinib	has	been	broadly	dismissed	as	a	therapeutic	agent	in	breast	cancer.	Despite	this,	the	molecular	mechanisms	behind	this	treatment	failure	warrant	investigation,	as	it	can	inform	about	the	nature	of	antiagiogenic	resistance	applicable	to	other	malignancies.																					
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2.1	Materials	
	
Table	2.1.	Equipment	used	for	the	research	detailed	in	this	thesis.	
Equipment	 Product	code	 Manufacturer	Barnstead	Nanopure	diamond	water	purifier	(for	deionised	water)	 D11901	 Thermo	Scientific,	Walmington,	UK	Magnetic	particle	concentrator	 123-21D	 Invitrogen,	Paisley,	UK	Nanodrop	 1000	 Thermo	Scientific,	Walmington,	UK	Agilent	Bioannalyser	 2100	 Agilent,	Stockport,	UK	High	Resolution	Microarray	Scanner		 G2565CA		 Agilent,	Stockport,	UK	Rotor-gene		 RG-3000	 Qiagen,	Manchester,	UK		Light	and	fluorescent	microscope	 DM6000	 Leica,	Milton	Keynes,	UK	60°C	Baking	oven	 HIS25	 Grant	Boekel	Scientific,	Feasterville,	USA	Gyro-Rocker	 SSL3	 Stuart,	Stone,	UK	Roller-mixer	 SRT6D	 Stuart,	Stone,	UK	Block	heater	 SBH200D	 Stuart,	Stone,	UK	AccuSPIN	17R	Micro	centrifuge	 13-100-676	 Fisher	Scientific,	Loughborough,	UK	Mikro	22R	Refrigerated	centrifuge	 C1110	 DJB	Labcare,	Newport	Pagnell,	UK	Heraeus	Labofuge	400R	microplate	centrifuge		 75008371	 Thermo	Scientific,	Walmington,	UK	Category	2	tissue	culture	hood	 Holten	Lamin	air	 Thermo	Scientific,	Walmington,	UK	Cell	culture	incubator	CO2	incubator	 INCUsafe	 Sanyo,	Osaka.	Japan	Haemocytometer	 0630010	 Marienfeld,	Lauda-Königshofen,	Germany	Acumen	high	content	screening	machine	 eX3	 TTP	labtech,	Melbourn,	UK	IVIS	Spectrum	Preclinical	In	Vivo	Imaging	System	 IVISSPE	 PerkinElmer,	Waltham,	USA		
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Table	2.2.	Chemicals	and	drugs	used	for	the	research	detailed	in	this	thesis.		
Chemicals	/	drugs	 Product	code	 Manufacturer	Sodium	azide	(NaN-3)	 S8032	 Sigma-Aldrich,	Gillingham,	UK	Glycine	 G8898	 Sigma-Aldrich,	Gillingham,	UK	Tetramethylethylenediamine	(TEMED)	 T9281	 Sigma-Aldrich,	Gillingham,	UK	Ammonium	persulphate	(APS)	 A3678	 Sigma-Aldrich,	Gillingham,	UK	Sodium	chloride	(NaCl)	 S9625	 Sigma-Aldrich,	Gillingham,	UK	IGEPAL	CA-630	 I8896	 Sigma-Aldrich,	Gillingham,	UK	Deoxycholic	acid	(DOC)	 D2510	 Sigma-Aldrich,	Gillingham,	UK	Sodium	dodecyl	sulfate	(SDS)	 A1112,0100	 AppliChem,	St	Louis,	USA	Bromophenol	blue	 B0126	 Sigma-Aldrich,	Gillingham,	UK	Glycerol	 G5516	 Sigma-Aldrich,	Gillingham,	UK	Tris(hydroxymethyl)aminomethane	(Tris)	 T1503	 Sigma-Aldrich,	Gillingham,	UK	Dithiothreitol	(DTT)	 43819	 Sigma-Aldrich,	Gillingham,	UK	Triton	X-100		 T8787	 Sigma-Aldrich,	Gillingham,	UK	Propidium	iodide		 P4170	 Sigma-Aldrich,	Gillingham,	UK	Actinomycin	D		 A9415	 Sigma-Aldrich,	Gillingham,	UK	Phosphate	buffered	saline	(PBS)		 P4417	 Sigma-Aldrich,	Gillingham,	UK	Qiazol	lysis	reagent		 79306	 Qiagen,	Manchester,	UK	Express	qPCR	Supermix	 A10312	 Invitrogen,	Paisley,	UK	Histoclear		 HS-200	 National	diagnostics,	Hessle,	UK	Ethanol	 20821-330	 VWR	chemicals,	East Grinstead, UK	Hydrogen	peroxide	 H1009	 Sigma-Aldrich,	Gillingham,	UK	Casein	solution		 SP-5020	 Vector	labs,	Orton,	UK	
Ethylenediaminetetraacetic	(EDTA)	 E5134	 Sigma-Aldrich,	Gillingham,	UK	Tween	20	 P1379	 Sigma-Aldrich,	Gillingham,	UK	Mayers	Haematoxylin	solution	 MHS32	 Sigma-Aldrich,	Gillingham,	UK	Surgipath	Eosin	Y-alcoholic	solution		 01602	 Leica,	Milton	Keynes,	UK	Formaldehyde	 252549	 Sigma-Aldrich,	Gillingham,	UK	Bisbenzimide	 B1155	 Sigma-Aldrich,	Gillingham,	UK	Acetone	 A/0520/17	 Fisher	Scientific,	Loughborough,	UK	Polybrene		 107689	 Sigma-Aldrich,	Gillingham,	UK	Puromycin	dihydrochloride		 P8833	 Sigma-Aldrich,	Gillingham,	UK	D-luciferin		 122799	 PerkinElmer,	Waltham,	USA	Dimethyl	sulfoxide	(DMSO)	 D2650	 Sigma-Aldrich,	Gillingham,	UK	Sunitinib	malate		 S1042	 Selleck	Chemicals,	Houston,	US	Acrylamide	Protogel	 A2-0072	 National	diagnostics,	Hessle,	UK	Gentamicin/amphotericin		 R-015-10	 Gibco,	Paisley,	UK	Penicillin-streptomycin		 15140-122	 Gibco,	Paisley,	UK	
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Table	2.3.	Organic	products	and	culture	media	used	for	the	research	detailed	in	this	thesis.			
Organic	products	and	culture	media	 Product	
code	
Manufacturer	Bovine	serum	albumin	(BSA)	 421501L	 VWR	chemicals,	East Grinstead, 
UK	Milk		 92964	 Marvel,	St	Albans,	UK	RNAse	free	DNAse		 79254	 Qiagen,	Manchester,	UK	RNAse	A		 19101	 Qiagen,	Manchester,	UK	Collagenase	type	V	from	Clostridium	histolyticum	 C9263	 Sigma-Aldrich,	Gillingham,	UK	Biotyinylated	lectin	from	Ulex	europaeus		 L8262	 Sigma-Aldrich,	Gillingham,	UK	Medium	199	(M199)	 M2154	 Sigma-Aldrich,	Gillingham,	UK	High	glucose	Dulbecco's	Modified	Eagle	Medium	(DMEM)	 51435C		 Sigma-Aldrich,	Gillingham,	UK	Optimem	 31985070	 Gibco,	Paisley,	UK	L-Glutamine		 25030	 Gibco,	Paisley,	UK	Heparin	sodium	salt	from	porcine	intestinal	mucosa	 H3149	 Sigma-Aldrich,	Gillingham,	UK	Collagenase	1A	from	Clostridium	histolyticum	 C9891	 Sigma-Aldrich,	Gillingham,	UK	Gelatin	from	porcine	skin		 04055	 Sigma-Aldrich,	Gillingham,	UK	Fetal	calf	serum	(FCS)	 10270	 PAA,	Cambridge,	UK	Trypsin-EDTA	 L11-003		 PAA,	Cambridge,	UK	Recombinant	human	VEGF-165	 100-20	 Peprotech,	London,	UK	Brain	extract	(prepared	as	described	in	(191))	 N/A	 N/A		
	
Table	2.4.	Kits	used	for	the	research	detailed	in	this	thesis.	
Kits	 Product	code	 Manufacturer	miRNeasy	mini	kit	 217004	 Qiagen,	Manchester,	UK	Low	Input	Quick	Amp	Labelling	Kit,	One-Color		 5190-2305	 Agilent,	Stockport,	UK	SurePrint	G3	Human	Gene	Expression	8x60K	v2	Microarray	kit		 G4851B	 Agilent,	Stockport,	UK	SurePrint	G3	Mouse	Gene	Expression	v2	8x60K	Microarray	Kit	 G4852B	 Agilent,	Stockport,	UK	High-capacity	cDNA	reverse	transcription	kit		 4368813	 Invitrogen,	Paisley,	UK	Universal	Probe	Library	set,	Human	 04683633001	 Roche,	Burgess	Hill,	UK	ImmPRESS	universal	secondary	antibody	(rabbit	and	mouse	IgG)	 MP-7500	 Vector	labs,	Orton,	UK	ImmPRESS	anti-rabbit	secondary	antibody		 MP-7401	 Vector	labs,	Orton,	UK	ImmPACT	NovaRed	peroxidase	HRP	substrate	 SK-4805	 Vector	labs,	Orton,	UK	RNAiMAX	lipofectamine	transfection	reagent	kit	 13778030	 Invitrogen,	Paisley,	UK	Lipofectamine	2000	transfection	reagent	kit	 11668027	 Invitrogen,	Paisley,	UK	ECL	prime	western	blotting	detection	reagent	kit		 45-002-401	 GE	Healthcare,	Amersham,	UK	CellTiter	96®	AQueous	One	Solution	Cell	Proliferation	Assay	(MTS)	 G3582	 Promega,	Southampton,	UK	
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Table	2.5.	Human	tissue	arrays	used	for	the	research	detailed	in	this	thesis.	
Tissue	arrays	 Product	code	 Manufacturer	Human,	common	cancers	(1)	 MA2	 Superbiochip,	Seoul,	Korea	Human,	normal	matching	tissue	of	MA2	 MAN2	 Superbiochip,	Seoul,	Korea	Human,	common	cancers	(2)	 MB4	 Superbiochip,	Seoul,	Korea	Human,	normal	matching	tissue	of	MB4	 MBN4	 Superbiochip,	Seoul,	Korea	Human,	common	cancers	(3)	 MC4	 Superbiochip,	Seoul,	Korea	Human,	normal	matching	tissue	of	MC4	 MCN4	 Superbiochip,	Seoul,	Korea	Human,	colorectal	cancer	 CD4	 Superbiochip,	Seoul,	Korea	Human,	normal	colon	and	rectum	(matching	CD4)	 CDN4	 Superbiochip,	Seoul,	Korea	Human,	colorectal	cancer-metastasis-normal	 CDA3	 Superbiochip,	Seoul,	Korea	Human,	Kidney	cancer	 CL2	 Superbiochip,	Seoul,	Korea	Kidney	clear	cell	carcinoma	 Hkid-CRC180Sur-01	 US	biomax,	Rockville,	USA	Kidney	cancer	with	matched	normal	adjacent	tissue	and	metastatic	carcinoma	 KD951a	 US	biomax,	Rockville,	USA	Kidney	disease	spectrum	(kidney	cancer	progression)	 BC07001	 US	biomax,	Rockville,	USA	Kidney	disease	spectrum	(renal	cancer	progression)	 KD807	 US	biomax,	Rockville,	USA		
	
Table	2.6.	Other	materials	used	for	the	research	detailed	in	this	thesis.	
Other	materials	 Product	code	 Manufacturer	PVDF	immobilon	transfer	membrane		 IPFL00010	 Merck-Millipore,	Darmstadt,	Germany	Amersham	Hyperfilm™	ECL		 10534205	 GE	Healthcare,	Amersham,	UK	100	µm	cell	strainer		 352360	 BD	Falcon,	Oxford,	UK	8μm	pore	well	inserts	 	 	Corning®	Costar®	6-well	plate	 CLS3516	 Sigma-Aldrich,	Gillingham,	UK	Corning®	Costar®	12	well	plate	 CLS3512	 Sigma-Aldrich,	Gillingham,	UK	Corning®	Costar®	24	well	plate	 CLS3527	 Sigma-Aldrich,	Gillingham,	UK	Scalpel	 GC686	 Swann-Morton,	Sheffield,	UK	ProLong	Gold	mounting	media	not	containing	DAPI		 P36930	 Invitrogen,	Paisley,	UK	ProLong	Gold	mounting	media	containing	DAPI		 P-36931	 Invitrogen,	Paisley,	UK	Streptavidin	coated	M-280	dynabeads		 11205D	 Invitrogen,	Paisley,	UK	Sheep	anti-rat	IgG	coated	M-280	dynabeads		 11035	 Invitrogen,	Paisley,	UK	Distyrene–plasticiser–xylene	resin		 06522	 Sigma-Aldrich,	Gillingham,	UK	
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Table	2.7.	Solution	formulations	used	for	the	research	detailed	in	this	thesis.	
Solutions:	 Constituents:	Tissue	digestion	solution	 Dulbecco's	Modified	Eagle	Medium	(DMEM),	25mg/ml	Collagenase	type	V,	7.4	μg/ml	Actinomycin	D	and	3.6	kunits	DNAse	RTqPCR	reaction	mix	 1µl	forward	primer	(10µM),	1µl	reverse	primer	(10µM),	0.25µl	of	the	appropriate	probe	from	the	Universal	Probe	Library	set,	Human,	0.25µl	deionised	water,	12.5µl	Express	qPCR	Supermix	Antigen	unmasking	solution	 0.1mM	EDTA	pH	8,	0.01%	Tween	20	in	distilled	water	Propidium	iodide	staining	solution	 0.1%	Triton	X-100,	100	ug/mL	RNAse	A	and	10	ug/mL	propidium	iodide	made	up	in	PBS	RIPA	buffer	 150	mM	NaCl,	1%	IGEPAL	CA-630,	0.5%	DOC,	0.1%	SDS	and	50	mM	Tris-HCl	pH	7.5	in	deionised	water	SDS	loading	buffer	 200	mM	Tris	HCL	pH	6.8,	8%	SDS,	0.4%	bromophenol	blue,	40%	glycerol	and	400	mM	DTT	8%	SDS-polyacrylamide	gel	 Resolving	gel:	8%	acrylamide,	0.1%	SDS,	375	mM	Tris-HCl	pH	8.8,	0.1%	APS,	0.06%	TEMED	in	deionised	water.	Stacking	gel:	4.5%	acrylamide,	0.1%	SDS,	125	mM	Tris-HCl,	pH	6.8,	0.1%	APS,	0.1%	TEMED	in	deionised	water	Running	buffer	 0.1%	SDS,	25	mM	Tris,	192	mM	Glycine	in	deionised	water	Transfer	buffer	 10	mM	Tris,	100	mM	glycine,	0.005%	SDS	in	deionised	water	PBS-Tween	 0.1%	Tween	in	PBS	Primary	endothelial	cell	growth	media	(cM199)	 Medium	199,	10%	fetal	calf	serum	(FCS),	2	mM	L-Glutamine,	100	U/ml	penicillin-streptomycin,	90	ug/ml	heparin	and	0.3%	brain	extract	Low	serum	endothelial	growth	media	(lsM199)	 Medium	199,	1%	fetal	calf	serum	(FCS),	2	mM	L-Glutamine,	100	U/ml	penicillin-streptomycin,	90	ug/ml	heparin	Cancer	cell	line	growth	media	(cDMEM)	 High	glucose	Dulbecco's	Modified	Eagle	Medium,	10%	FCS,	100	U/ml	penicillin-streptomycin	and	2	mM	L-glutamine	
	
Table	2.8.	Plasmids	used	for	the	research	detailed	in	this	thesis.	
Plasmids	 Details	MSCV-LUC	 MSCV	plasmid	(Clonetech)	containing	the	luciferase	gene,	generated	by	the	Hwang	group	(192).				
Table	2.9.	Cultured	cells	used	for	the	research	detailed	in	this	thesis.	
Cultured	cells	 Details	4T1	 Murine	breast	cancer	cell	line	of	BALB/c	origin,	distributed	by	ATCC,	Teddington,	UK	(product	code:	CRL-2539).	4T1-LUC	 4T1	cell	line	containing	the	MSCV-LUC	plasmid.		RENCA	 Murine	renal	adenocarcinoma	cell	line	of	BALB/c	origin,	gift	of	the	Reynolds	group.	HUVEC	 Human	umbilical	vein	endothelial	cells,	extracted	from	a	human	umbilical	cord	by	the	Bicknell	group.	HDMEC	 Human	dermal	micro-vascular	endothelial	cells	of	multiple	origins	distributed	by	PromoCell,	Heidelberg,	Germany	(product	code:	C-12210).	Phoenix-Ampho	 293T	derived	cell	line	containing	retroviral	packaging	constructs,	generated	by	the	Nolan	lab	(193).	
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Table	2.10.	Antibodies	used	for	the	research	detailed	in	this	thesis.	
Target	 Antibody	type	 Product	
code	
Manufacturer	 Region	of	
recognition	
Application	and	
Concentration	Human	MCAM	 Rabbit	polyclonal	 HPA008848	 Sigma-Aldrich,	Gillingham,	UK	 225-374aa	(Extracellular	region)	 1.500-1.1000	(IHC)	1.1000	(WB)	[0.3-0.6	μg/ml]	Human	LAMA4	 Rabbit	polyclonal	 HPA015693	 Sigma-Aldrich,	Gillingham,	UK	 638-777aa	 1.200	(IHC)	[0.5	μg/ml]	Human	PECAM	 Mouse	monoclonal	 JC70A	 Dako,	Cambridge,	UK	 Cell	membrane	preparation	from	the	spleen	of	a	patient	with	hairy	cell	leukaemia	
1.100	(IHC)	[2	μg/ml]	
Human	GRIN2D	 Vaccinated	rabbit	serum	 Custom-	7GB14072-686	 Eurogenetec,	Southampton,	UK	 1-78aa	(Extracellular	region)	 1.500	(IHC)	Mouse	PECAM	(1)	 Rabbit	polyclonal	 ab28364	 Abcam,	Cambridge,	UK	 C-terminus	 1.200	(IF)		Mouse	PECAM	(2)	 Rat	monoclonal	 553369	(clone:	MEC13.3)	 BD	Falcon,	Oxford,	UK	 129/Sv	mouse-derived	endothelioma	cell	line	tEnd.1	
1.200	(IF)	[75	ng/ml]		2.5	μg	per	107	beads	Mouse	MCAM	 Rat	monoclonal	 MAB7718	(clone:	733216)	 R&D,	Minneapolis,	US	 1-563aa	(Extracellular	region)	 1.200	(IF)		[5	μg/ml]	20	μg	(AL)	Mouse	AQP1		 Rabbit	polyclonal	 PA1010	 Boster	Immunoleader,	Pleasanton,	USA	 251-269aa	 1.500	(IF)	[2	μg/ml]	Mouse	IgGs	 Sheep	polyclonal	conjugated	to	ECL	peroxidase	
NA931	 GE	Healthcare,	Amersham,	UK	 Mouse	gamma	immunoglobins	heavy	and	light	chains	
1.2500	(WB)	[0.4	μg/ml]	
Rabbit	IgGs	(1)	 Donkey	polyclonal	conjugated	to	alexafluor	488	
A21206	 Invitrogen,	Paisley,	UK	 Rabbit	gamma	immunoglobins	heavy	and	light	chains	
1.500	(IF)	[4	μg/ml]	
Rabbit	IgGs	(2)	 Donkey	polyclonal	conjugated	to	ECL	peroxidase	
NA934	 GE	Healthcare,	Amersham,	UK	 Rabbit	gamma	immunoglobins	heavy	and	light	chains	
1.2500	(WB)	[0.4	μg/ml]	
Rat	IgGs	 Goat	polyclonal	conjugated	to	alexafluor	546	 A11081	 Invitrogen,	Paisley,	UK	 Rat	gamma	immunoglobins	heavy	and	light	chains	
1.500	(IF)	[4	μg/ml]	
IHC:	Immunohistochemistry;		IF:	Immunofluorescence;		WB:	Western	blot		AL:	Antibody	localisation	
	
Table	2.11.	siRNA	duplexes	used	for	the	research	detailed	in	this	thesis.	
Duplex	name	 Duplex	sequence	Scrambled	duplex	 rCrGrUrUrArArUrCrGrCrGrUrArUrArArUrArCrGrCrGrUAT	GRIN2D	duplex	1	 rGrCrArArGrCrArCrGrGrArArArGrArArGrArUrCrGrArUGG	GRIN2D	duplex	2	 rGrGrArUrUrArCrUrCrCrUrUrCrArArUrGrArGrGrArCrGGC	
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2.1.1	RTqPCR	primers		A	web-based	tool,	“Universal	Probe	Library	Assay	Design	Centre”	(Roche,	Burgess	Hill,	UK)	was	used	to	design	the	forward	and	reverse	primers.	These	primers	amplify	a	region	containing	a	sequence	where	a	probe	could	bind	and	amplify	a	product	crossing	an	exon	boundary.	Primers	were	generated	by	Eurogentec,	Southampton,	UK.		
Table	2.12.	Human	RTqPCR	primers	used	for	the	research	detailed	in	this	thesis.	
Target	name		 Primer	sequences		 Probe	number		CD11b		 Fwd:	ggcatccgcaaagtggta		 9	Rev:	ggatcttaaaggcattctttcg			CD68		 Fwd:	gtccacctcgacctgctct		 1	Rev:	cactggggcaggagaaact			EPCAM		 Fwd:	ccatgtgctggtgtgtgaa		 3	Rev:	tgtgttttagttcaatgatgatcca			PDGFRA		 Fwd:	ccacctgagtgagattgtgg		 27	Rev:	tcttcaggaagtccaggtgaa			PECAM		 Fwd:	gcaacacagtccagatagctgt		 14	Rev:	gacctcaaactgggcatcat		FLOT2		 Fwd:	gatcctcagcttcaccatcaa		 61	Rev:	tcagcatctctctgcaccac		MCAM		 Fwd:	gggtaccccattcctcaagt		 63	Rev:	cagtctgggacgactgaatg		LAMA4		 Fwd:	gaccctgaggacacagtgtttta		 22	Rev:	aggcaggtttaagctggtagg		STRA6	 Fwd:	ctctggcctgactgtgtgc		 23	Rev:	tgtccccagccaagaaatc		GRIN2D		 Fwd:	ggctcagtgaccgcaagt	 57	Rev:	gcacggtcccaaacttca	FNDC1		 Fwd:	agactgaggggaaagtgaaaga		 80	Rev:	atccaccagggcagaagtag		GPR4		 Fwd:	ttccgccatccctctacat		 44	Rev:	ccacagagccaggcagtt		RGS5		 Fwd:	cccactcatgcctggaaa		 65	Rev:	tgacaaggtcaccaactgagtc		TGM2		 Fwd:	agggtgacaagagcgagatg		 86	Rev:	tggtcatccacgactccac		KCNJ8		 Fwd:	cgctacccggagtctgag	 34	Rev:	cagcttagccacctccctct	OR51E1		 Fwd:	cagcctgccagacctctt	 69	Rev:	cagcaccaggcaggtagag	
	 48	
Table	2.13.	Mouse	RTqPCR	primers	used	for	the	research	detailed	in	this	thesis.	
Target	name		 Primer	sequences		 Probe	number		CD11b	 Fwd:	gcacctcggtatcagcatatt		 9	Rev:	cccaggtaccgaaattctcc		CD68	 Fwd:	ttctcttgcaaccgtgacc		 34	Rev:	gaggaggaccaggccaat		EPCAM	 Fwd:	ggttagcgcttccgaggta		 53	Rev:	tgttggatagtcaaggccagt		PDGFRA	 Fwd:	aacggggctagaagtcaacc		 4	Rev:	tgacatgaagccaagaacttaaac		PECAM		 Fwd:	gctggtgctctatgcaagc	 30	Rev:	atggatgctgttgatggtga	β-ACTIN	 Fwd:	ggagggggttgaggtgtt	 71	Rev:	gtgtgcacttttattggtctcaa	LEPR		 Fwd:	cctccatctaacgtaaaagcaga		 47	Rev:	tggcttttcccaagatactttc		PRLR	 Fwd:	gccttcctgctctgtctcac		 55	Rev:	cctgagccccgtgtaaaat		ESAM		 Fwd:	tgattcttcaggctggaacc		 54	Rev:	tcagtcccaggaacaaaacc				PTN		 Fwd:	tgtcactttgctctccttgg		 55	Rev:	agtgggcttcctggcttc			AQP1		 Fwd:	atcaactcagcaccccactc			 25	Rev:	caggtgggtccctcacttt			ANGPT2		 Fwd:	aagagcgtggacagcacag		 8	Rev:	gtagctgcagggtccgttc			DARC		 Fwd:	cttcaccttgggactcagtgt			 32	Rev:	gactggcagccctaagagg			ECSCR		 Fwd:	gctagacacttggcctgctc		 18	Rev:	ttgactcctcgttcctgagttt			TSPAN7	 Fwd:	ttggatgctttgctacatgc		 89	Rev:	gggacaggaacatggcatac			STC2		 Fwd:	catgccctgcgtcataaat		 18	Rev:	catttccctaattgctggaca	RET		 Fwd:	cacagcccagcaacttacg		 2	Rev:	ggccctgagaattctgctct				MMRN2		 Fwd:	agcccctcaccatgatcc		 3	Rev:	agtccccagctcaggtacac			VEGFR2		 Fwd:	accagagaccctcgttttca			 22	Rev:	catttgcttgcaggaggttt			EDN1		 Fwd:	cagcatccttgatccaaaca		 30	Rev:	gacgcagacaggctaggg		
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2.1.2	Tissue	provision	/	processing	
	
Queen	Elizabeth	Hospital,	Mindelsohn	Way,	Edgbaston,	Birmingham,	West	Midlands,	B15	2GW	
	
Queen	Elizabeth	Women’s	Hospital,	Mindelsohn	Way,	Birmingham,	West	Midlands,	B15	2TG		
University	of	Birmingham	Tissue	Bank	Service,	Human	Biomaterials	Resource	Centre,	University	of	Birmingham,	Edgbaston,	Birmingham,	West	Midlands,	B15	2TT		
	
2.1.3	Facilities	
	
Animal	care	and	housing,	Biomedical	Services	Unit	(BMSU),	University	of	Birmingham,	Edgbaston,	Birmingham,	West	Midlands,	B15	2TT		
Agilent	bioanalysis	and	microarray	slide	scanning,	Technology	Hub,	University	of	Birmingham,	Edgbaston,	Birmingham,	West	Midlands,	B15	2TT	
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2.2	Endothelial	isolation	methods	
	
2.2.1	Endothelial	cell	extraction	from	human	tissue	
	
2.2.1.1	Tissue	collection	and	ethics.	Tumour	and	distant	healthy	tissue	were	obtained	immediately	post-surgery.	Full	patient	consent	and	ethical	approval	was	granted	(Queen	Elizabeth	Hospital	Birmingham:	Colorectal	cancer	(CRC)	and	Colorectal	liver	metastasis	(CRM),	South	Birmingham	REC,	No.	2003/242.	Renal	Cell	Carcinoma	(RCC),	No.	12-090.	
	
2.2.1.2	Digestion	of	tissue	The	tissue	was	weighed,	soaked	in	tissue	digestion	solution	and	then	finely	sliced	with	a	scalpel	to	roughly	1-3	mm3	pieces.	The	tissue	was	digested	for	1.5	hours	in	a	shaking	37°C	incubator.	The	digested	tissue	was	filtered	through	a	100	µm	cell	strainer.	The	resulting	cell	suspension	was	washed	twice	by	centrifugation	for	5	minutes	at	300	×	g	and	resuspended	in	phosphate	buffered	saline	(PBS).		
2.2.1.3	Preparation	of	Ulex	lectin	coated	dynabeads	Streptavidin	coated	M-280	dynabeads	were	washed	twice:	the	beads	were	pelleted	on	a	magnetic	particle	concentrator	and	resuspended	in	PBS.	50	µg	biotyinylated	lectin	from	
Ulex	europaeus	was	added	to	the	bead	suspension	and	incubated	for	30	minutes	in	a	shaking	37oC	incubator.	
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2.2.1.4	Endothelial	cell	isolation	1.4x107	Ulex	lectin	coated	dynabeads	per	gram	of	tissue	were	added	to	the	cell	suspension	and	the	solution	mixed	on	a	rotator	at	4°C	for	30	minutes.	The	bead	rosetted	endothelial	cells	were	then	pelleted	out	of	suspension	using	a	magnetic	particle	concentrator.	The	pelleted	cells	were	washed	with	PBS	as	described	in	section	2.2.1.3.	The	pelleted	cells	were	then	resuspended	in	Qiazol	lysis	reagent	in	preparation	for	RNA	extraction.	
	
2.2.2	Endothelial	cell	isolation	from	mouse	tissue	
	
2.2.2.1	Digestion	of	tissue	As	described	in	section	2.2.1.2	
	
2.2.2.2	Preparation	of	Rat	anti-mouse	PECAM-1	antibody	coated	dynabeads	Sheep	anti-rat	IgG	coated	M-280	dynabeads	were	washed	twice:	the	beads	were	pelleted	on	a	magnetic	particle	concentrator	and	resuspended	in	PBS.	2.5	µg	rat	anti-mouse	PECAM-1	antibody	was	added	per	107	beads	and	incubated	for	overnight	at	4°C	on	a	rotator.	
	
2.2.2.3	Mouse	tumour	endothelial	cell	isolation	2	x	107	rat	anti-mouse	PECAM-1	antibody	coated	dynabeads	per	gram	of	tissue	were	added	to	the	cell	suspension	and	the	solution	mixed	on	a	rotator	at	4°C	for	30	minutes.	The	bead	rosetted	endothelial	cells	were	then	pelleted	out	of	suspension	using	a	magnetic	particle	concentrator.	The	pelleted	cells	were	washed	with	PBS	as	described	
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in	section	2.2.1.3.	The	pelleted	cells	were	then	resuspended	in	Qiazol	lysis	reagent	in	preparation	for	RNA	extraction.	
	
	
2.3	Molecular	biology	methods	
	
2.3.1	RNA	extraction	RNA	was	extracted	from	Qiazol	lysed	cells	using	the	miRNeasy	mini	kit	following	manufacturer’s	conditions.	The	protocol	used	was	taken	from	the	October	2007	“miRNeasy	minihandbook;	Purification	of	total	RNA	from	animal	cells;”	p.19-22.	RNA	concentration	was	quantified	by	use	of	the	Nanodrop	spectophotometer.		
2.3.2	RNA	integrity	validation	RNA	integrity	was	assessed	using	an	Agilent	Bioannalyser,	by	Steve	Kissane,	a	University	of	Birmingham	technician.	
	
2.3.3	RNA	labelling	RNA	was	labelled	using	the	“Low	Input	Quick	Amp	Labelling	Kit,	One-Color,”	following	the	manufacturer’s	protocol	detailed	in	the	“One-Color	Microarray-Based	Gene	Expression	Analysis,	low	input	Quick	Amp	Labelling”	handbook,	p.19-30.	
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2.3.4	Microarray	analysis	Labelled	cRNA	was	hybridised	onto	an	Agilent	SurePrint	G3	Human	Gene	Expression	8x60K	v2	Microarray	slide	following	the	manufacturer’s	protocol	detailed	in	the	“One-Color	Microarray-Based	Gene	Expression	Analysis,	low	input	Quick	Amp	Labelling”	handbook,	p.	31-41.	The	hybridised	slide	was	scanned	using	a	High	Resolution	Microarray	Scanner	and	the	features	extracted	with	Agilent	feature	extraction	software	using	the	protocol	detailed	in	the	“One-Color	Microarray-Based	Gene	Expression	Analysis,	low	input	Quick	Amp	Labelling”	handbook,	p.	42-51.	
	
2.3.5	cDNA	production	cDNA	was	generated	using	between	50-100	μg	of	template	RNA	in	a	master	mix	generated	from	the	“High-capacity	cDNA	reverse	transcription	kit”.	The	thermal	cycling	conditions	were:		
• 25°C	for	10	minutes		
• 37°C	for	120	minutes	
• 85°C	for	5	minutes	
• 4°C	indefinitely	
	
2.3.6	Quantitative	Reverse	Transcription	Polymerase	Chain	Reaction	(RT-qPCR)	The	“Roche	Exiqon	universal	probe	system”	was	used	to	perform	RT-qPCR	(see	Table	2.1.1	for	primer	sequences	and	probe	numbers).	The	RTqPCR	reaction	mix	was	combined	with	10µl	of	cDNA,	diluted	1	in	10	from	that	produced	in	section	2.3.5.		The	RT-qPCR	was	conducted	on	a	Rotor-gene	RG-3000	using	a	36	well	rotor	and	the	following	program.		
	 54	
• 92°C	for	10	minutes	
• 92°C	for	15	seconds	
• 60°C	for	45	seconds	
• 55°C	for	30	seconds	
• Ramp	up	from	55-95°C	by	1°C	per	5	seconds		RNA	samples	were	assessed	in	triplicate	and	the	expression	levels	of	the	genes	of	interest	were	determined	using	the	delta-delta	CT	method	normalised	to	flotillin-2.		
	
2.3.7	Western	blot	
	
2.3.7.1	Preparation	of	protein	extract	Cells	were	harvested	by	scraping,	lysed	with	RIPA	buffer	and	disrupted	by	being	drawn	through	a	19	gauge	needle	several	times.	The	cell	lysate	was	agitated	for	15	minutes	on	a	tube	rotator	at	4°C,	then	centrifuged	at	21910×g	for	15	minutes	and	supernatant	collected.	
	
2.3.7.2	SDS-polyacrylamide	gel	production	and	running	Protein	samples	were	mixed	with	one	part	SDS	loading	buffer	to	three	parts	sample	and	loaded	onto	an	8%	SDS-polyacrylamide	gel.	The	gel	was	immersed	in	running	buffer	and	run	at	140	V	for	90	minutes.		
	
	
	 45	Cycles	
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2.3.7.3	Protein	transfer	A	PVDF	immobilon	transfer	membrane	was	hydrated	by	emersion	in	methanol	for	30	seconds,	deionised	water	for	5	minutes	and	then	transfer	buffer.	Once	the	SDS-polyacrylamide	gel	had	run	it	was	clamped	into	a	cassette	with	the	membrane,	immersed	in	transfer	buffer	and	proteins	transferred	from	the	gel	to	the	membrane	for	2	hours	at	4°C,	using	a	maximum	current	of	400	mA	with	voltage	capped	at	30	V.		
2.3.7.4	Development	of	the	membrane	Once	the	proteins	were	transferred,	the	membrane	was	washed	twice	with	PBS-Tween	for	5	minutes.	The	membrane	was	blocked	using	10%	milk	in	PBS-Tween	for	1	hour,	then	washed	three	times	with	PBS-Tween	for	5	minutes	then	incubated	with	the	primary	antibody,	at	the	appropriate	concentration,	in	a	3%	bovine	serum	albumin	(BSA),	NaN-3,	PBS-tween	solution	overnight	at	4°C.	The	membrane	was	washed	four	times	with	PBS-Tween	for	5	minutes	then	incubated	with	a	secondary	antibody	conjugated	to	ECL	peroxidase	in	10%	milk	in	PBS-Tween	for	1	hour.	The	membrane	was	washed	four	times	with	PBS-Tween	for	5	minutes,	then	incubated	with	ECL	detection	reagent	for	1	minute.	The	membrane	was	then	used	to	develop	Amersham	Hyperfilm™	ECL.	
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2.4	Tissue	staining	methods	
	
2.4.1	Immunohistochemistry	Immunohistochemistry	was	performed	on	formalin	fixed,	paraffin	embedded	sections	by	first	deparaffinising	by	emersion	in	two	tanks	of	Histoclear	for	5	minutes	each.	Sections	were	then	placed	in	100%,	90%	and	70%	ethanol	sequentially	for	5	minutes	each.	Sections	were	then	rehydrated	with	tap	water	for	5	minutes.	A	blocking	step	for	endogenous	tissue	peroxidases	was	performed,	using	0.3%	hydrogen	peroxide,	for	15	minutes.	The	sections	were	then	washed	with	water	and	placed	in	the	antigen	unmasking	solution	and	left	at	60°C	overnight	under	constant	stirring.	The	following	morning	the	sections	in	the	unmasking	solution	were	slowly	cooled	in	a	bath	of	ice	and	water	until	at	room	temperature.	The	slides	were	then	washed	with	PBS	for	5	minutes.	A	second	blocking	step,	for	non-specific	protein	binding,	was	performed	using	20%	Casein	solution	for	10	minutes.	The	sections	were	incubated	with	the	primary	antibody	at	the	appropriate	concentration	in	PBS,	for	1	hour	at	room	temperature.	The	sections	were	washed	three	times	with	PBS-Tween	(0.1%)	for	5	minutes	each	and	then	incubated	with	the	“ImmPRESS	universal	secondary	antibody”	for	30	minutes.	The	sections	were	again	washed	3	times	with	PBS-Tween	for	5	minutes	and	then	stained	using	the	“ImmPACT	NovaRed	chromogen”	for	2	minutes.	The	sections	were	washed	with	water	for	5	minutes,	counterstained	with	haematoxylin	solution	for	1	minute,	washed	in	warm	tap	water	for	5	minutes	then	dehydrated	by	immersion	in	100%	ethanol	and	Histoclear	for	5	minutes	each.	The	sections	were	finally	mounted	in	distyrene–plasticiser–xylene	resin.	All	IHC	staining	images	were	acquired	using	a	Leica	DM6000	light	microscope.	
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Note:	For	immunohistochemistry	involving	commercial	tissue	arrays	an	additional	1	hour	bake	in	a	60°C	oven	was	performed	to	remove	an	additional	layer	of	paraffin	wax	added	for	shipping	and	storage	purposes.		
2.4.2	Immunofluorescent	staining	on	frozen	sections	Frozen	sections	were	defrosted	for	10	minutes	at	room	temperature	and	then	fixed	with	acetone	for	5	minutes.	Sections	were	rinsed	with	deionised	water	4	times	and	blocked	with	20%	Casein	for	10	minutes.	The	sections	were	incubated	with	the	primary	antibody	at	the	appropriate	concentration	for	2	hours.	The	sections	were	then	washed	three	times	with	PBS-Tween	for	5	minutes	and	incubated	with	the	appropriate	fluorescently	labelled	secondary	antibody,	at	1	in	500	dilution	in	PBS,	for	1	hour.	The	sections	were	washed	three	times	with	PBS-Tween	and	then	once	with	deionised	water	for	5	minutes	and	mounted	in	ProLong	Gold	mounting	media	containing	DAPI.	Quantification	of	fluorescence	was	conducted	using	the	ImageJ	software	package	(194).		
2.4.3	Immunofluorescent	staining	on	paraffin	embedded	sections	Sections	were	deparaffinised	by	emersion	in	two	tanks	of	Histoclear	for	5	minutes	each.	Sections	were	then	placed	in	100%,	90%	and	70%	ethanol	sequentially	for	5	minutes	each.	Sections	were	then	rehydrated	with	tap	water	for	5	minutes.	The	sections	were	placed	in	an	antigen	unmasking	solution	and	left	at	60°C	overnight	in	the	continuously	stirred	solution.	The	following	morning	the	sections	in	the	unmasking	solution	were	slowly	cooled	in	a	bath	of	ice	and	water	until	at	room	temperature.	The	slides	were	then	washed	with	PBS	for	5	minutes.	A	second	blocking	step,	for	non-specific	protein	binding,	was	performed	
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using	20%	Casein	for	10	minutes.	The	sections	were	incubated	with	the	primary	antibody	at	the	appropriate	concentration	for	2	hours.	The	sections	were	then	washed	three	times	with	PBS-Tween	for	5	minutes	and	incubated	with	the	appropriate	fluorescently	labelled	secondary	antibody,	at	1	in	500	dilution	in	PBS,	for	1	hour.	The	sections	were	washed	three	times	with	PBS-Tween	and	then	once	with	deionised	water	for	5	minutes	and	mounted	in	ProLong	Gold	mounting	media	containing	DAPI.	
	
2.4.4	Haematoxylin	and	Eosin	(H&E)	stain	on	paraffin	embedded	sections	Sections	were	deparaffinised	by	emersion	in	two	tanks	of	Histoclear	for	5	minutes	each.	Sections	were	then	placed	in	100%,	90%	and	70%	ethanol	sequentially	for	5	minutes	each.	Sections	were	then	rehydrated	with	tap	water	for	5	minutes.	Sections	were	incubated	in	Mayers	Haematoxylin	for	10	minutes,	then	washed	in	warm	tap	water	for	3	minutes.	Sections	were	then	incubated	in	Eosin	for	10	minutes.	Sections	were	then	sequentially	washed	in	tap	water,	70%	ethanol,	90%	ethanol,	100%	ethanol	then	Histoclear	before	being	mounted	in	DPX	on	a	coverslip.	
	
	
	
	
	
	
	
	
	 59	
2.5	Cell	culture	(in	vitro)	methods	
	
2.5.1	Primary	cell	and	cell	line	culture	All	cell	work	was	performed	in	a	category	2	tissue	culture	hood	using	aseptic	techniques.	Cells	were	incubated	in	their	appropriate	growth	media	at	37°C	and	5%	CO2	unless	stated	otherwise.	The	use	of	five	cell	types	is	detailed	in	this	report;	Human	umbilical	cord	vein	endothelial	cells	(HUVEC),	Human	dermal	micro-vascular	cells	(HDMEC),	4T1,	Phoenix-Ampho	and	RENCA.	HUVEC	are	freshly	isolated	primary	cells,	HDMEC	are	commercially	produced	primary	cells,	4T1	and	RENCA	are	cancer	cell	lines	and	Phoenix-Ampho	is	an	immortalised	embryonic	kidney	cell	line.	All	these	cell	types	are	adherent.		
2.5.2	Cell	resuscitation,	splitting	and	counting	Cells	were	resuscitated	from	liquid	nitrogen	storage	by	defrosting	rapidly	at	37°C,	suspending	the	cells	in	10	ml	culture	medium,	pelleting	the	cells	by	centrifugation	for	5	minutes	at	300	×	g,	resuspending	the	pellet	in	the	appropriate	growth	medium	and	plating	the	cells	onto	10	cm	plates.			Culture	media	was	changed	every	2-3	days	by	aspirating	off	the	old	media	from	the	plates	and	replacing	it	with	fresh	media	warmed	to	37oC		Cell	plates	were	split,	when	confluent,	by	aspirating	off	the	media	from	the	plates,	washing	the	plate	with	PBS,	deadhering	the	cells	from	the	plate	with	3	ml	trypsin-EDTA	(0.1%)	and	incubating	the	plate	for	2	minutes	at	37°C.	6	ml	culture	media	was	added	to	
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the	suspended	cells	to	neutralise	the	trypsin,	the	cells	were	plated	onto	10	cm	plates	and	the	volume	of	the	suspension	in	each	plate	was	made	up	to	10	ml	with	the	addition	of	culture	media.	
	Where	necessary	the	cellular	concentration	of	a	cell	suspension	was	determined	by	use	of	a	haemocytometer.	
	
2.5.3	Human	umbilical	cord	vein	endothelial	cell	(HUVEC)	isolation	Cords	were	collected	from	the	delivery	suite	in	the	Queen	Elizabeth	Women’s	Hospital,	Birmingham,	anonymised	by	the	University	of	Birmingham	HBRC	and	delivered	to	the	tissue	culture	laboratory.	The	exterior	of	the	cords	were	cleaned	with	70%	ethanol,	examined	for	holes	and	dissected	around	these	holes	or	into	roughly	6-inch	sections.	Cannula	were	inserted	into	the	vein	at	either	end	of	the	cord	section	and	secured	with	cable	ties.	Using	the	cannulae	as	an	entrance	and	exit,	the	cord	vein	was	washed	through	with	PBS	in	a	pulsatile	manner	until	the	effluent	ran	clear.	The	valve	on	the	exit	cannula	was	closed,	the	cord	filled	with	1	mg/ml	collagenase	1A	in	M199,	the	valve	on	the	entrance	cannula	was	then	closed.	The	cord	was	incubated	for	15-20	minutes	at	37°C	and	5%	CO2,	then	the	collagenase	digestion	solution	was	flushed	out	of	the	cord	using	PBS	then	air	and	the	solution	continually	collected.	The	solution	was	span	down	at	300	×	g	for	6	minutes.	The	cell	pellet	was	then	resuspended	in	HUVEC	early	growth	media	(complete	M199	plus	0.2%	gentamicin/amphotericin)	and	applied	to	gelatine-coated	flasks.	
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2.5.4	siRNA	knockdown	and	HUVEC	functional	assays	
	
2.5.4.1	siRNA	transfection	HUVEC	were	plated	on	gelatin	coated	plates	at	a	density	of	175000	cells	per	well	in	a	6	well	plate	and	incubated	overnight	at	37°C	and	5%	CO2.	A	duplex	mix	of	50	nM	siRNA	was	generated	in	optimem	and	incubated	for	10	minutes	with	0.3%	RNAiMAX	lipofectamine.	The	plated	cells	were	washed	twice	with	PBS	and	then	the	siRNA	duplex	mix	was	added	to	the	cells	and	incubated	at	37°C	and	5%	CO2	for	4	hours.	The	duplex	mix	was	then	replaced	with	cM199	(except	without	antibiotics)	and	incubated	in	standard	growth	conditions	overnight.	These	cells	were	then	used	for	functional	assays	or	harvested	to	confirm	knockdown	of	target	genes.	
	
2.5.4.2	Scratch	wound	assay	HUVEC	were	plated	at	a	density	of	300,000	cells	per	well	in	a	6-well	plate.	The	cells	were	then	allowed	to	grow	to	confluence.	6	scratches	were	made	in	the	cell	monolayer,	3	from	top	to	bottom	and	3	left	to	right,	making	9	intersections	which	were	then	incubated	at	37°C	and	5%	CO2	and	imaged	regularly	for	analysis	of	scratch	wound	closure.			
2.5.4.3	Transfilter	assay	Both	sides	of	an	8	μm	pore	well	inserts	were	gelatin	coated	in	a	24	well	plate.	HUVEC	were	harvested	and	suspended	in	optimem	for	15	minutes.	The	cells	were	then	added	into	the	top	of	the	well	inserts	at	a	density	of	30,000	cells	per	well.	The	top	portion	of	
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the	well	was	then	filled	with	low	serum	medium	199.	Complete	M199	was	added	to	the	bottom	of	the	well	in	sufficient	quantities	to	bath	the	underside	of	the	well	insert.	This	set	up	was	then	incubated	for	16	hours	at	37°C	and	5%	CO2.		After	this	period	cell	growth	medium	was	removed	from	the	wells	and	inserts,	the	inserts	were	washed	with	PBS	and	cells	on	both	sides	of	the	insert	were	fixed	for	15	minutes	at	room	temperature	with	a	solution	consisting	of	2%	formaldehyde	and	2	ug/ml	bisbenzimide	in	PBS.	Using	a	scalpel	the	bottom	of	the	insert	was	cut	out	and	mounted	onto	a	slide	using	the	ProLong	Gold	mounting	media	not	containing	DAPI.	Both	sides	of	the	well	were	then	imaged	using	a	Leica	DM6000	fluorescent	microscope.	
	
2.5.4.4	Matrigel	tube	formation	assay	Matrigel	was	plated	and	allowed	to	solidify	in	the	wells	of	a	12	well	plate	at	37°C	for	30	minutes.	140,000	HUVEC	per	well	were	plated	on	the	matrigel.	The	cells	were	then	incubated	for	16	hours	at	37°C	and	5%	CO2	after	which	images	were	taken	for	analysis.		
	
2.5.4.5	Acumen	cell	cycle	cytometry	A	96	well	plate	was	prepared	by	coating	the	appropriate	wells	with	0.1%	gelatin	and	incubated	for	30	minutes	at	37°C.	4000	HUVEC	in	complete	M199	were	added	to	each	well.	There	were	8	repeats	for	each	condition.	The	plates	were	incubated	overnight	at	37°C,	5%	CO2.	The	cells	were	then	fixed	with	85%	ethanol.	The	plates	were	kept	at	4°C	until	staining.		The	cells	were	stained	by	aspiration	of	the	ethanol	fixative	and	addition	of	100	μl	propidium	iodide	staining	solution.	The	plates	were	incubated	at	37°C	for	20	minutes	and	then	imaged	on	the	Acumen	eX3	high	content	screening	machine.	
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2.5.5	HUVEC	and	HDMEC	treatment	with	VEGF	Passage	2	HUVEC	isolates	/	HDMEC	used	within	2	passages	of	receipt,	were	plated	at	a	density	of	14,000	cells	cm-2,	grown	in	low	serum	medium	199	for	16	hours,	then	cultured	±	100	ng/ml	recombinant	human	VEGF	for	24	hours	before	being	harvested	for	western	blot	and	RTqPCR	analysis.		
2.5.6	Transfection	of	Phoenix-Ampho	cells	2x106	Phoenix-Ampho	cells	were	plated	onto	a	60	mm	plate	and	incubated	at	37°C	and	5%	CO2	overnight.	The	cell	culture	media	was	then	replaced	with	optimem	supplemented	with	10	μg	MSCV-LUC	plasmid	DNA	(192)	and	4%	lipofectamine	2000.	The	cells	were	incubated	overnight	at	37°C	and	5%	CO2.	The	optimem	was	then	replaced	with	cDMEM	and	the	cells	incubated	at	32°C	and	5%	CO2.		
2.5.7	Retroviral	Harvesting	Every	day,	for	5	days	after	the	transfection,	the	viral	media	was	collected,	centrifuged	for	10	minutes	at	300	×	g	to	pellet	any	cells.	The	supernatant	was	aspirated,	snap	frozen	on	dry	ice	and	stored	at	-80°C.	The	viral	media	was	replaced	with	fresh	media	and	the	cells	were	once	again	incubated	at	32°C	and	5%	CO2.		
2.5.8	Transduction	of	4T1	cells	4T1	cells	were	plated	at	a	density	of	1x105	cells	per	well	in	a	6	well	plate.	The	cells	were	incubated	overnight	in	culture	medium	at	37°C	and	5%	CO2.	The	culture	media	was	replaced	by	MSCV-LUC	viral	media,	mentioned	in	“2.5.7	Retroviral	Harvesting”,	supplemented	with	8	μg/ml	polybrene.	The	cells	were	then	centrifuged	in	a	plate	
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spinner	at	300	×	g	for	1	hour.	The	viral	media	was	then	replaced	with	fresh	media	and	the	cells	were	incubated	for	48	hours	at	37°C	and	5%	CO2.	
	
2.5.9	MTS	viability	assay	4T1	cells	were	plated	at	a	density	of	5x104	cells	per	well	in	a	6	well	plate.	The	cells	were	incubated	overnight	in	cDMEM	at	37°C	and	5%	CO2.	The	culture	media	was	replaced	by	cDMEM,	containing	puromycin	dihydrochloride	at	various	concentrations.	The	cells	were	then	incubated	at	37°C	and	5%	CO2	for	3	days.	MTS	was	then	added	to	the	media	in	each	well	and	the	plate	was	incubated	at	37°C	and	5%	CO2	for	4	hours.	The	MTS	media	was	transferred	to	a	96	well	plate	and	the	absorbance	at	490	nm,	of	each	well,	was	recorded	by	a	plate	reader.	
	
2.5.10	Puromycin	selection	of	4T1	cells	MSCV-LUC	virally	transduced	4T1	cells	were	plated	at	a	density	of	1x105	cells	per	well	in	a	6	well	plate.	The	cells	were	incubated	overnight	in	culture	medium	at	37°C	and	5%	CO2.	The	culture	media	was	replaced	by	media,	containing	puromycin	dihydrochloride	at	the	appropriate	concentration.	The	cells	were	then	incubated	at	37°C	and	5%	CO2	for	3	days.	Untransduced	4T1	cells	were	plated	alongside	and	treated	in	the	same	way	to	act	as	a	control.	The	4T1	cells	were	re-plated	and	the	cycle	of	puromycin	treatment	repeated	until	the	point	where	the	MSCV-LUC	virally	transduced	4T1	cells	were	completely	confluent	and	the	untransduced	cells	completely	dead.		
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2.5.11	IVIS	analysis	of	4T1	cells	D-luciferin	was	added	at	a	concentration	of	150	μg/mL	to	a	confluent	plate	of	puromycin	selected,	MSCV-LUC	virally	transduced	4T1	cells.	The	bioluminescence	of	the	cells	was	then	determined	using	an	In-Vivo	Imaging	System	(IVIS)	machine.	
	
	
2.6	In	vivo	methods	
	
2.6.1	Sourcing	and	caring	for	mice		Eight	week	old,	BALB/c	mice	(18–25	g)	were	obtained	from	the	Harlan	Laboratories	(UK).	The	mice	were	housed	in	a	ventilated	barrier	rack	in	a	temperature-controlled	facility	on	a	12-hour	photoperiod.	The	mice	were	given	food	and	water	ad	libitum.	Mice	were	handled	and	treated	in	accordance	with	UK	Home	Office	requirements	under	Licence	(PPL.	40/3339).		
2.6.2	RENCA	tumour	and	antibody	localisation	The	RENCA	murine	renal	cell	carcinoma	cell	line	was	used	to	develop	subcutaneous	tumours.	1.25x105	RENCA	cells	were	injected	in	optimem	into	the	flank	of	healthy	male	Balb/c	mice,	using	a	26-gauge	needle.	Tumours	were	permitted	to	grow	to	1	cm3.	Mice	were	then	intravenously	inoculated	with	20	μg	monoclonal	rat	anti-mouse	MCAM	antibodies	one	hour	prior	to	cull.	The	tumours	and	several	other	organs	were	then	collected	snap	frozen	in	liquid	nitrogen	and	stored	at	-80°C	for	sectioning	by	the	University	of	Birmingham	HBRC.		
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2.6.3	Initiation	of	4T1-LUC	tumours	in	the	murine	mammary	fat	pad	2.5x105	4T1	cells	suspended	in	Optimem	and	in	a	volume	of	100	μL,	were	injected	into	the	second	mammary	fat	pad	of	anaesthetised	8-week-old	female	Balb/C	mice,	using	a	26-gauge	needle.		
	
2.6.4	Ex	vivo	imaging	At	the	experimental	endpoint	all	mice	(including	controls)	were	IP	injected	with	150mg	D-luciferin	/	kg	body	weight,	left	for	5	minutes	and	then	culled	at	the	same	time	point.	The	liver,	spleen	and	lungs	were	rapidly	dissected	from	each	mouse	and	imaged	in	parallel	using	the	IVIS	imaging	system.	Luminescent	quantification	was	performed	on	the	two	opposite	sides	of	each	organ	and	the	results	averaged.	
	
2.6.5	Sunitinib	drug	trial	4T1	tumours	were	initiated	in	female	Balb/c	mice	as	described	in	section	“2.6.3	Initiation	of	4T1-LUC	tumours	in	the	murine	mammary	fat	pad”.	After	a	1	week	tumour	establishment	period	the	Sunitinib	treatment	group	received	daily	IP	injections	of	40mg	Sunitinib	per	kg	body	weight	in	PBS	and	3.72%	DMSO.	The	untreated	control	group	received	daily	intraperitoneal	(IP)	injections	of	the	drug	vehicle	(PBS	and	3.72%	DMSO).	Tumour	growth	was	measured	daily	using	a	caliper.	At	the	experimental	endpoint	ex	vivo	imaging	was	performed	as	described	in	section	2.6.4.	Tumour	and	key	organ	tissue	was	collected,	frozen	for	sections,	RTqPCR	and	microarray	analysis,	formalin	fixed	for	paraffin	embedded	sections	or	subjected	to	endothelial	isolation.	
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2.7	Imaging	quantitation	
	
2.7.1	Command	line	for	localisation	quantitation	Antibodies	were	localised	to	tumour	vessels	as	described	in	“2.6.2	RENCA	tumour	and	antibody	localisation”,	the	mouse	tissue	was	sectioned	and	stained	as	described	in	“2.4.2	Immunofluorescent	staining	on	frozen	sections”	and	imaged	with	the	DM6000	fluorescent	microscope.	Quantitation	of	antibody	localisation	was	performed	as	follows.	
	Split	image	file	into	red,	green	and	blue	channels	and	input	into	the	Image	J	software	package	(194).	-	run(”image	file	(green	channel-CD31)");	-	run("16-bit");	-	run("Threshold...");	-	setThreshold(9,	255);	-	run("Convert	to	Mask");	Apply	mask	to	red	channel	-	run("Add	Selection...")	-	selectWindow(“image	file	(red	channel-MCAM)”);	-	run("Measure");	
Readout:	
Measurement	
number	
File	name	 Mean	grey	scale	(pixel	
density)	1	 M6	RENCA	1	red	channel.tif	 14.385	
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2.7.2	Command	lines	for	vascular	density	and	target	staining	quantitation		Sections	were	stained	as	described	in	“2.4.2	Immunofluorescent	staining	on	frozen	sections”	and	imaged	with	the	DM6000	fluorescent	microscope.	Quantitation	of	marker	staining	was	performed	as	follows.	
	Image	file	split	into	red,	green	and	blue	channels	and	input	into	the	Image	J	software	package	(194).	-	run(”image	file");	-	run("16-bit");	-	run("Threshold...");	-	setThreshold(9,	255);	-	run("Convert	to	Mask");	-	run("Measure");	
Readout:	
Measurement	
number	
File	name	 Mean	grey	scale	
(pixel	density)	
%	area	occupied	
by	mask	1	 M1	UT	9	days	red	channel.tif	 3.6802	 1.443	2	 M1	UT	9	days	green	channel.tif	 4.6056	 1.806	
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2.7.3	Quantification	of	metastasis	by	H&E	staining	Three	sections	were	taken	from	liver,	lung	and	spleen	samples	at	~300	μm	intervals	and	stained	by	H&E	as	described	in	“2.4.4	Haematoxylin	and	eosin	(H&E)	stain	on	paraffin	embedded	sections”.	Five	images	were	taken	at	random	by	light	microscopy	from	each	section.	Areas	of	metastasis	in	each	field	were	identified	and	quantified	by	Image	J	software.	Metastatic	burden	was	determined	as	the	average	area	of	metastasis	from	the	fifteen	fields	of	view	corresponding	to	each	organ.	
	
2.7.4	IVIS	ex	vivo	imaging	settings	-	Luminescent	settings-	-	Exposure:	Auto	-	Binning:	medium	-	F/stop:	1	-	Emission	filter:	open	
	
2.7.5	Directions	for	the	quantification	of	ex	vivo	bioluminescence	-	Tool	palette-	ROI	tools	-	Draw	region	of	interest	(ROI)	-	Measure-	set	to	radiance	(photons)	-	Export	
Readout:	
Image	Number	 ROI	 Image	Layer	 Avg	Radiance	[p/s/cm≤/sr]	JWW20130208113504_001	 ROI	1	 Overlay	 2.98E+05	
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2.8	Bioinformatic	methods	
	
2.8.1	Microarray	bioinformatic	analysis	The	microarray	expression	analysis	data	was	normalised,	annotated	and	analysed	using	the	R-software	package	(version	2.15.0.	2012)	along	with	the	marray	(195)	and	limma	(196)	expansions.	Target	selection	was	performed	on	this	data	as	follows:		A	“targets.txt	file”	was	generated	detailing	the	categories	under	which	the	microarray	raw	data	text	files	will	be	compared.	In	this	example	these	categories	are	Cancer	and	Healthy	(highlighted	in	red	below).		Targets.txt	file	
Sample	Number	 									File	Name	 									Condition	1	 																														cancer1.txt	 									cancer	2	 																														cancer2.txt	 									cancer	3	 																														cancer3.txt	 									cancer	4	 																														cancer3.txt	 									cancer		5	 																														healthy1.txt										healthy	6	 																														healthy2.txt										healthy	7	 																														healthy3.txt										healthy	8	 																														healthy4.txt										healthy			The	raw	data	files	plus	the	targets	file	was	placed	in	a	folder	on	the	desktop	named	'files'	(highlighted	in	green	below).		The	following	blue	commands	were	inserted	into	the	R	64bit	console.	Descriptions	of	the	steps	are	in	black.	Select	the	analysis	package:				library(limma)	
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Select	the	data	location:				setwd("~/Desktop/files")		Select	the	targets	file:				targets	<-	readTargets("targets.txt")		Load	the	raw	data	files	into	the	analysis	package	and	set	output	columns:	RG	<-	read.maimages(targets,	path="~/Desktop/files",	columns	=	list(G	=	"gMedianSignal",	Gb	=	"gBGMedianSignal",	R	=	"gProcessedSignal",		Rb	=	"gIsPosAndSignif"),	annotation	=	c("Row",	"Col","FeatureNum",	"ControlType","ProbeName"))		Correct	for	background:			RG	<-	backgroundCorrect(RG,	method="normexp",	offset=16)		Normalise	between	arrays	under	analysis:			RG$G	<-	normalizeBetweenArrays(RG$G,	method="quantile")		
Log2	transform	the	data	intensity	values:			RG$G	<-	log2(RG$G)	
	
Convert	the	RGList	into	an	MAList	for	further	manipulation:	
E	<-	new("MAList",	list(targets=RG$targets,	genes=RG$genes,	source=RG$source,	M=RG$Gb,	A=RG$G))	Use	the	avereps	function	to	average	replicate	spots:		
E.avg	<-	avereps(E,	ID=E$genes$ProbeName)	
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Build	the	design	matrix	for	the	linear	modelling	function:	
f	<-	factor(targets$Condition,	levels	=	unique(targets$Condition))		design	<-	model.matrix(~0	+	f)		colnames(design)	<-	levels(f)		
Apply	the	intensity	values	to	lmFit:			fit	<-	lmFit(E.avg$A,	design)	
	
Create	a	contrast	matrix.	In	this	example,	cancer	–	healthy	(meaning	that	in	the	resultant	analysis,	positive	values	denote	gene	expression	in	cancer	>	healthy	and	negative	values,	cancer	<	healthy):	
contrast.matrix	<-	makeContrasts("cancer-healthy",	levels=design)		
Apply	this	contrast	matrix	to	the	modelled	data	and	compute	statistics	for	the	data	(in	this	case	the	empirical	Bayes	statistical	test):	
fit2	<-	contrasts.fit(fit,	contrast.matrix)		fit2	<-	eBayes(fit2)	Output	the	statistics	for	the	dataset	and	write	them	into	a	data	file	for	further	analysis:	
output	<-	topTable(fit2,	adjust="BH",	coef="cancer-healthy",	genelist=E.avg$genes,	number=66,000)	
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write.table(output,	file="cancer_vs_healthy.txt",	sep="\t",	quote=FALSE)		Following	these	steps	resulted	in	the	generation	of	a	text	file	named,	in	this	example,	cancer_vs_healthy.txt,	with	comparative	analysis	data	of	condition	1	(cancer)	vs.	condition	2	(healthy).		This	was	inserted	into	an	Microsoft	Excel	spreadsheet	and	the	gene	identity	data	was	translated	from	microarray	probe	IDs	to	gene	names,	using	an	annotation	file	corresponding	to	the	microarray	slide	in	use,	downloaded	from	the	Agilent	website.	Human:	028004_D_AA_20120130_annotation.xlsx	Mouse:	028005_D_Mouse_20121126.xlsx			
2.8.2	Ingenuity	bioinformatics	analysis	Bioinformatic	analysis	was	conducted	on	processed	microarray	data,	using	the	Ingenuity	pathway	analysis		(IPA)	software	(Qiagen,	Manchester,	UK).		The	IPA	Core	Analysis	package	was	used	with	the	following	settings:	- Network	interactions	–	Include	genes	and	endogenous	chemicals		- Data	sources	–	All	- Confidence	–	Proven	and	strongly	predicted	interactions	only	- Species	–	All	- Tissue	cell	lines	–	All	- Mutations	–	All	The	Molecule	Activity	Predictor	(MAP)	package	was	used	to	predict	the	impact	of	sunitinib	therapy	on	selected	pathways.	
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2.8.3	Bioinformatic	websites	
	Universal	Probe	Library	Assay	Design	Centre:	https://lifescience.roche.com		NCBI:	http://www.ncbi.nlm.nih.gov		PubMed:	http://www.ncbi.nlm.nih.gov/pubmed		TMHMM	Server	v.	2.0:		
	
2.9	Statistical	methods	
	Excel	(Microsoft,	Redmond,	USA)	was	used	to	generate	graphs.	All	error	bars	depict	the	standard	error	of	the	mean	(SEM).			Mann-Whitney,	Kaplan-Meier,	Chi-squared,	Log-ranks	and	Cox-regression	statistical	analyses	were	performed	using	the	SPSS	statistics	suite	(IBM,	New	York,	USA).		P-value	 Summary	<	0.001	 ***	0.001	to	0.01	 **	0.01	to	0.05	 *	>	0.05	 Not	significant	(NS)			
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3.1	Introduction	
	The	search	for	genuine	tumour	vessels	specific	markers	is	an	on	going	effort.	Despite	considerable	work	and	a	number	of	promising	targets,	discussed	in	chapter	one,	the	need	for	further	targets	is	clear.	Cancer	is	an	extremely	heterogeneous	disease,	or	even	a	loose	collection	of	mildly	similar	diseases	and	tumour	endothelial	marker	expression	is	equally	varied.	This	means	that	the	current	focus	on	the	identification	of	pan-tumour	endothelial	markers,	whilst	still	valid	should	be	mixed	with	an	effort	to	find	truly	specific	targets	in	individual	cancers.	This	principle	guides	the	work	discussed	in	chapters	3-5.		This	chapter	discusses	the	isolation	of	endothelium	from	colorectal	cancer	(CRC),	colorectal	liver	metastasis	(CRM)	and	renal	cell	carcinoma	(RCC)	and	matched	healthy	tissues,	sample	processing	for	microarray	transcriptomic	analysis	and	bioinformatics	processing	of	data	to	find	putative	tumour	endothelial	markers.	
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3.2	Results	
	
3.2.1	Sample	collection	and	endothelial	isolation	In	order	to	facilitate	the	identification	of	novel	tumour	endothelial	markers,	fresh	matched	healthy	and	tumour	tissues	were	collected	from	resections	of	CRC	(n=8,	Table	3.1),	CRM	(n=7,	Table	3.2)	and	RCC	(n=8,	Table	3.3),	which	had	not	received	neoadjuvant	therapy,	and	were	processed	within	three	hours	of	surgery.	The	endothelium	was	isolated	from	these	tissues,	according	to	the	workflow	shown	in	Figure	3.1.	Briefly	the	tissue	was	minced,	digested	with	a	collagenase	V	solution	to	a	single	cell	suspension.	Magnetic	beads	conjugated	to	Ulex	agglutinin	I	were	prepared	and	incubated	with	the	single	cell	suspension.	Ulex	agglutinin	I,	a	lectin	isolated	from	
Ulex	europaeus	binds	specifically	to	the	L-fucose	residues	present	within	glycoproteins	on	the	surface	of	human	endothelial	cells	(197).	The	endothelium	within	the	single	cell	suspension	therefore	became	rossetted	with	beads	allowing	them	to	be	magnetically	isolated.	RNA	was	extracted	using	the	Qiagen	miRNeasy	mini	kit,	by	a	process	of	phenol	and	guanidine	thiocyanate	lysis,	chlorophorm	precipitation,	silica-membrane	based	purification,	selective	digestion	of	unwanted	DNA	and	elution	into	nuclease-free	water.	This	process	resulted	in	the	isolation	of	total	RNA,	by	permitting	the	capture	of	fragments	of	18	nucleotides	or	greater.	This	allowed	for	the	investigation	of	both	macro	and	micro-RNA	expression	profiles.		
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Figure	3.1	Isolation	of	endothelial	cells	using	Ulex	lectin	coated	magnetic	beads.	The	workflow	of	the	main	steps	involved	in	the	endothelial	isolation	procedure.	
	
	
	
3.2.2	RNA	integrity	validation	Successful	transcriptomic	analysis	of	gene	expression	by	RTqPCR	or	microarray	analysis,	requires	RNA	of	high	quality	and	integrity	(198),	although	meaningful	data	can	be	acquired	from	lower	quality	samples	(199).	The	integrity	of	isolated	RNA	was	assessed	by	Agilent	Bioanalyser	according	to	the	workflow	shown	in	Figure	3.2A.	The	bioanalyser	operates	similarly	to	agarose	gel-slab	electrophoresis,	it	however	uses	far	smaller	amounts	of	RNA	and	as	the	concentration	of	RNA	isolated	from	human	tissue	endothelium	was	limited,	it	was	selected.	The	bioanalyser	chip	contains	an	interconnected	network	of	micro-channels	linking	the	wells	into	which	samples	are	added.	The	micro-channels	are	filled	with	a	sieving	polymer	and	fluorescent	dye.	When	
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the	wells	and	channels	are	filled,	the	chip	becomes	an	integrated	circuit	through	which	a	charge	is	applied.	RNA,	as	a	charged	biomolecule	is	driven	by	a	voltage	gradient	formed	within	the	chip.	RNA	has	a	constant	mass-to-charge	ratio,	the	samples	are	therefore	separated	by	charge	but	also	size.	The	fluorescent	dye	within	the	micro-channels	intercalates	into	the	RNA,	permitting	fluorescent	laser	detection.	A	ladder	containing	RNA	fragments	of	known	molecular	size	and	concentration	is	run	alongside	the	samples	under	analysis.	By	comparing	when	the	fluorescently	labelled	RNA	from	the	ladder	and	the	unknown	samples	pass	the	detector	and	the	relative	strength	of	signal,	the	analysis	software	is	able	to	identify	the	size	and	concentration	of	RNA	fragments	within	these	samples.	This	data	is	converted	into	electropherograms	for	interpretation	(Figure	3.2B).	The	software	automatically	identifies	the	ribosomal	RNA	peaks	18s	and	28s	(Figure	3.2B[ii])	and	by	comparing	their	relative	levels	and	the	level	of	background	signal,	an	RNA	integrity	number	(RIN)	is	assigned	to	the	sample,	ranging	from	10	(perfectly	intact)	to	1	(completely	degraded)	(Figure	3.3).	Agilent	Microarray	analysis	requires	a	RIN	of	7	or	greater,	therefore	only	RNA	samples	achieving	this	level	were	taken	forward	for	microarray	transcriptomic	analysis.	
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Figure	3.2	Agilent	bioanalyser	electrophoresis.	A,	flow	diagram	of	bioanalyser	RNA-integrity	analysis.	B,	electropherograms	from	(i)	the	ladder	reference	sample	and	(ii)	an	RNA	sample	with	the	twin	18s	and	28s	ribosomal	RNA	peaks	highlighted.			
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Figure	3.3	Agilent	bioanalyser	electropherograms	of	good	to	perfect	quality	RNA.		
	
	
	
3.2.3	RTqPCR	and	validation	of	endothelial	isolation	In	order	to	ensure	that	endothelial	specific	isolation	had	been	achieved,	the	isolate	samples	along	with	the	matched	endothelial	depleted	fraction,	were	probed	for	the	expression	of	markers	of	common	cell	types	by	two-step	quantitative	reverse	transcription	polymerase	chain	reaction	(RTqPCR),	using	the	Roche	Exiquon	ProbeLibrary	system.	RTqPCR	is	a	commonly	used	technique	to	quantify	RNA	expression.	Total	RNA	is	first	converted	to	complementary	DNA	(cDNA)	by	a	process	of	reverse	transcription,	using	random	primers	and	a	reverse	transcriptase.	In	the	qPCR	
RIN=%7%%(good%quality%RNA)%
RIN=%8%%(excellent%quality%RNA)%
RIN=%9%%(outstanding%quality%RNA)%
RIN=%10%%(perfect%quality%RNA)%
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stage,	primers	are	used	that	are	specifically	designed	to	be	complementary	to	either	end	of	a	small	region	of	the	gene	of	interest	and	to	span	at	least	one	exon-exon	junction,	so	as	to	avoid	polymerisation	of	any	genomic	DNA	contamination,	which	would	not	contain	this	junction.	In	the	Roche	Exiquon	ProbeLibrary	system	this	region	is	designed	to	contain	an	8-9	base	recognition	site	for	one	of	165	unique	fluorescent	probes.	The	cDNA	is	exposed	to	cycling	conditions	wherein	the	primers	bind	and	a	DNA	polymerase	synthesises	the	small	region,	during	which	the	fluorescent	probe	is	incorporated.	When	the	new	DNA	fragment	is	released	from	the	synthesis	machinery	the	probe	is	cleaved,	activating	its	fluorescence,	which	is	then	detected	by	a	laser.	Since	this	amplification	process	can	only	occur	once	per	cycle	it	is	generally	accepted	that	the	population	of	DNA	corresponding	to	this	region	doubles	each	time.	Therefore	the	fluorescent	signal	increases	exponentially	at	a	logarithmic	factor	of	2.	The	delta-delta	cycle	threshold	(ΔΔCT)	method	for	quantifying	RNA	expression	is	based	upon	this	principle.	The	number	of	cycles	it	takes	for	the	fluorescent	signal	to	exceed	a	set	threshold	level	is	used	as	a	relative	marker	of	how	much	cDNA	(and	originally	RNA)	corresponding	to	the	gene	of	interest,	was	present	in	the	original	sample.	To	compare	the	RNA	expression	level	of	a	gene	between	two	samples,	the	expression	of	a	consistently	expressed	“housekeeping	gene,”	in	this	study	flotillin-2,	must	also	be	probed.	This	housekeeping	gene	is	assumed	to	be	expressed	at	the	same	level	in	both	samples	and	is	used	to	normalise	for	differences	in	the	concentration	of	the	samples	as	follows:					
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Delta-delta	cycle	threshold	method	CT	of	target	gene	in	sample	1	(CTgS1)	CT	of	housekeeping	gene	in	sample	1	(CThkS1)	CT	of	target	gene	in	sample	2	(CTgS2)	CT	of	housekeeping	gene	in	sample	2	(CThkS2)		2^[(CThkS1	-	CTgS1)	–	(CThkS2	-	CTgS2)]	=	Fold	expression	difference	for	target	gene				4																																																		in	sample	1	vs.	sample	2			The	expression	of	markers	of	leukocytes	(CD11b),	macrophages	(CD68),	epithelium	(EPCAM),	smooth	muscle	(PDGFRA)	and	endothelium	(PECAM)	was	compared	between	the	endothelial	isolate	fractions	and	the	matched	endothelial	depleted	fractions	by	this	method.	This	analysis	determined	that	endothelium	alone	was	enriched	by	between	7	and	17	fold	in	the	endothelial	isolate	fractions	(Figure	3.4).		
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Figure	3.4	Confirmation	of	endothelial	isolation	efficiency	by	RTqPCR	for	markers	of	leukocytes	(CD11b),	macrophages	(CD68),	epithelium	(EPCAM),	smooth	muscle	(PDGFRA)	and	endothelium	(PECAM)	in	the	endothelial	isolates	(EC)	from	renal	cell	carcinoma	(RCC,	n	=	8),	colorectal	carcinoma	(CRC,	n	=	8),	colorectal	liver	metastases	(CRM,	n	=	7)	and	matched	surrounding	healthy	tissues	(n	=	8,8,7),	standardised	to	flotillin-2	(a	house	keeping	gene)	and	normalised	for	marker	expression	to	patient	matched	bulk	tissue.	The	fold	change	of	marker	expression	between	the	endothelial	and	bulk	fraction	is	shown.	Confidence	limits	are	±	standard	error	of	the	mean	(SEM).	
	
	
3.2.4	RNA	labelling	and	hybridisation	for	microarray	In	order	to	conduct	large-scale	microarray	transcriptomic	analysis,	Cyanine	3	fluorescently	labelled	cRNA	was	first	generated	from	the	RNA	of	selected	samples,	as	described	in	Figure	3.5.	Briefly	cDNA	was	synthesised	from	the	RNA	samples	using	a	primer	containing	poly	dT	and	a	T7	promoter	and	catalysed	by	Affinity	Script	reverse	
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transcriptase.	This	generated	random	cDNA	fragments	with	a	5’	T7-promoter	sequence.	Next,	cRNA	was	synthesised	from	the	cDNA	using	T7-RNA	polymerase,	which	simultaneously	incorporates	Cy3	labelled	nucleotides.	Once	labelled	the	cRNA	samples	were	hybridised	to	an	8-pack	Agilent	microarray	slide	(Figure	3.6).	This	slide	contains	8	distinct	domains,	for	8	samples,	each	spotted	with	66,000	unique	cDNA	fragments	complementary	to	every	known	gene	in	the	genome	(~20,000)	and	selected	micro-RNAs	(miRNAs),	with	an	average	of	3	forms	of	cDNA	per	gene.	During	hybridisation	labelled	cRNA	binds	to	its	complementary	cDNA	fragments.	Each	spot	is	then	probed	and	quantified	by	a	scanning	laser,	generating	data	about	the	relative	expression	levels	of	the	genes	probed	for	computational	analysis.		
Figure	3.5	RNA	labelling	for	microarray	analysis.	Flow	diagram	showing	the	multiple	steps	involved	with	the	synthesis	and	amplification	of	labelled	cRNA	from	isolated	RNA.		
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Figure	3.6	Labelled	cRNA	hybridisation	for	microarray	analysis.	Schematic	showing	the	key	steps	in	the	hybridisation	process	of	labelled	cRNA,	to	specifically	designed	cDNA	fragments,	fused	to	a	microarray	chip.		
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3.2.5	Microarray	data	normalisation	and	generation	of	comparison	matrices	Raw	microarray	data	was	background	corrected	and	normalised	between	the	arrays	under	comparison,	before	being	formatted	into	comparison	matrices.		The	following	comparison	matrices	were	generated	using	this	method:	Colorectal	cancer	–	Healthy	colon	(Table	3.1,	used	in	chapters	4	&	5).	Colorectal	liver	metastasis	–	Healthy	liver	(Table	3.2,	used	in	chapter	5).	Colorectal	liver	metastasis	–	Healthy	colon	(Table	3.1	&	3.2,	used	in	chapter	5).	Renal	cell	carcinoma	–	Healthy	kidney	(Table	3.3,	used	in	chapter	5).			
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3.3	Discussion	
This	chapter	discusses	the	isolation	of	endothelium	from	colorectal	tumours,	colorectal	liver	metastasis	and	renal	cell	carcinoma,	validation	of	the	isolation	process	by	RTqPCR	and	microarray	based	comparative	gene	expression	analysis,	between	the	endothelial	isolates.		Endothelium	was	isolated	from	the	tumour	and	healthy	tissue	resections	with	the	use	of	magnetic	beads	conjugated	to	a	lectin	from	Ulex	europeaus,	which	binds	very	specifically	to	human	endothelial	cells	(197).		It	has	also	been	reported	to	bind	to	blood	group	H,	expressed	on	the	red	blood	cells	of	a	roughly	a	quarter	of	humans	(197),	resulting	in	red	blood	cells	being	isolated	alongside	the	endothelium	in	some	isolates.	As	red	blood	cells	are	not	a	source	of	mRNA,	this	was	not	considered	an	issue	for	molecular	profiling	purposes.		
	
3.3.1	Ulex	lectin	vs.	PECAM-1	Other	endothelial	markers	are	available	for	isolation	purposes,	such	as	Platelet	endothelial	cell	adhesion	molecule	(PECAM-1),	however,	this	marker	is	additionally	expressed	on	a	subset	of	leukocytes	(200),	resulting	in	the	potential	for	considerable	contamination	from	this	cell	type.	In	order	to	remove	this	contamination	a	second	endothelial	marker,	such	as	CD34	or	Von	Willebrand	factor	(VWF)	must	also	be	selected	for.	Two-step	isolation	would	be	difficult	with	magnetic	beads	and	result	in	a	loss	of	sample	and	therefore	single	step	isolation	using	Ulex	lectin	was	favoured.	
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3.3.2	Magnetic	bead	isolation	vs.	fluorescence-activated	cell	sorting	(FACS)	One	approach	that	would	permit	simple	two	way	selection,	thus	excluding	contamination	from	red	blood	cells	or	leukocytes,	would	be	by	fluorescence-activated	cell	sorting	(FACS).	Additionally	this	would	allow	a	direct	assessment	of	the	purity	of	the	sample	in	percentage	terms,	something	the	RTqPCR	analysis	used	in	this	chapter	cannot	replicate.	Unfortunately	from	consultation	with	the	wider	scientific	community,	it	became	clear	that	very	large	samples	or	the	pooling	of	samples	would	be	required	to	generate	enough	RNA	to	conduct	microarray	or	RTqPCR	analysis.	This	would	result	in	a	loss	of	personalised	patient-specific	gene	analysis,	a	far	slower,	more	expensive	process	of	sample	collection	and	certainly	a	considerable	waste	of	a	precious	and	difficult	to	acquire	resource.	Additionally	absolute	purity	is	not	required	at	this	stage	for	the	generation	of	a	short	list	of	candidate	tumour	endothelial	markers.	By	a	subsequent	process	of	literature	searching,	in	silico,	in	vitro	and	molecular	analysis,	detailed	in	chapters	4	and	5,	genuine	targets	were	validated	from	the	lists	generated	in	this	chapter.	Magnetic	bead	isolation	was	found	to	be	an	extremely	efficient	(being	successful	on	small	tissue	samples)	and	effective	(resulting	in	good,	consistent	enrichment)	method	of	endothelial	isolation	and	was	therefore	selected	above	FACS.					
3.3.3	Microarray	analysis	vs.	next-generation	sequencing	Microarray	based	analysis	was	used	to	conduct	transcriptomic	profiling	of	cancer	and	healthy	endothelial	isolates.	This	is	an	effective,	robust	and	reliable	method	of	profiling	however,	others	with	a	potentially	greater	scope	for	investigation	are	available.	As	discussed	in	Wragg	and	Bicknell	2015	(201),	next	generation	sequencing	is	an	exciting	new	method	of	genomic	and	transcriptomic	analysis	allowing	investigation	of	splice	
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variant	and	non-coding	RNA	expression	in	a	way	that	a	limited	probe	based	microarray	system	cannot	replicate.	Certainly	next	generation	sequencing	is	the	future,	however,	despite	becoming	more	efficient	and	sensitive	over	time,	it	still	requires	over	ten	fold	more	RNA	than	microarray	analysis.	It	is	several	times	more	expensive,	depending	on	scale,	to	generate	the	raw	data.	Programs	designed	to	analyse	and	interpret	the	data	are	in	their	infancy	and	difficult	to	use,	often	generating	a	considerable	amount	of	confounding	data	and	requiring	input	from	specialist	bioinformaticians,	often	unfamiliar	with	the	area	of	biology	under	investigation.	For	the	budget	and	time	allotted	a	considerably	fuller	investigation	could	be	achieved	by	the	older	microarray	based	analysis	systems	and	therefore	for	this	investigation	it	was	favoured.	
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4.1	Introduction	
	Colorectal	cancer	is	the	third	most	common	cancer	globally,	making	up	about	10%	of	all	cases	(202).	There	are	over	1.4	million	new	cases	annually,	65%	of	which	are	found	in	developed	countries,	with	695,000	deaths	from	the	disease.	Early	stage	colorectal	cancer,	confined	to	the	wall	of	the	colon,	is	usually	curable	with	surgery.	More	advanced	disease,	making	up	25%	of	cases	in	the	UK,	is	often	treated	with	a	combination	of	surgery,	radio	and	chemotherapy	and	is	usually	incurable	(202).		The	five-year	survival	rate	in	developed	countries	is	around	65%,	however,	this	drops	to	below	10%	with	metastatic	disease	(203).	Curative	treatment	heavily	relies	upon	the	achievement	of	a	histologically	clear	resection	margin	at	surgery	(204,205)	and	although	80%	of	CRC	resections	do	achieve	this,	50%	will	relapse	to	metastatic	disease,	due	to	the	presence	of	micro-metastases	present	at	the	time	of	resection	(203,206).	Improvements	in	treatment	and	prevention	of	metastatic	disease,	are	of	vital	importance	to	achieve	better	outcomes	in	CRC.	It	is	upon	this	premise	that	the	idea	of	targeting	the	tumour	vessels	in	colorectal	cancer	is	based.	As	has	been	mentioned	in	chapter	1,	the	vasculature	is	of	vital	importance	to	cancer	spread	and	development	of	metastasis,	and	indeed	vascular	targeted	anti-angiogenic	drugs	such	as	bevacizumab	are	often	included	alongside	traditional	chemotherapies	in	first	line	and	second	line	treatment	for	advanced	CRC	(207).	Reports	of	its	effectiveness	have	been	mixed	however,	with	two	large	randomised	studies	showing	no	significant	benefit	and	even	a	potential	to	cause	harm	in	the	adjuvant	setting	(208).	Vascular	targeting	approaches	to	treat	CRC	are	therefore	in	need	of	improvement	and	the	identification	of	novel	targets	
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on	colorectal	cancer	vessels,	which	can	be	used	to	localise	therapeutics	to	the	tumour,	could	benefit	the	treatment	of	colorectal	cancer.	
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4.2	Results	
	
4.2.1	Comparative	microarray	analysis	of	CRC	versus	healthy	colon	In	order	to	investigate	the	relative	expression	of	genes	in	the	endothelium	of	colorectal	cancer	and	patient	matched	healthy	colon	tissue,	a	comparison	matrix	was	setup	from	the	microarray	data	generated	in	chapter	3.	This	was:				Colorectal	cancer	–	Healthy	colon		This	analysis	compared	the	microarray	gene	expression	data	from	four	colorectal	cancer	endothelial	isolates	and	patient	matched	healthy	colon	endothelial	samples.	
	
4.2.2	Known	tumour	associated	genes,	matrix	metallopeptidases	and	collagens	A	number	of	known	tumour	associated	angiogenic	genes	were	identified	by	this	analysis	(Table	4.1),	including	interleukin	8,	angiopoietin	2	and	lysyl	oxidase	like	2,	validating	the	approach	as	a	method	for	identifying	genes	enriched	on	tumour	endothelium.	This	analysis	additionally	identified	a	host	of	collagens	(Table	4.2)	and	matrix	metallopeptidases	(Table	4.3),	key	components	of	active	extracellular	matrix	remodelling,	important	for	endothelial	migration	and	angiogenesis	within	the	tissue.	This	data	collectively	implies	a	pattern	of	active	angiogenesis	occurring	within	the	tumour,	outstripping	that	of	the	surrounding	healthy	colon	tissue.				
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Table	4.1.	Known	tumour	associated	or	angiogenic	genes	enriched	in	colorectal	cancer	vessels.		Gene	ID	 Gene	Symbol	 GeneBank	accession	no.	 LogFC	P-value	Interleukin	8	 IL8	 NM_000584	 3.42	 0.00	Angiopoietin	2	 ANGPT2	 NM_001147	 3.40	 0.00	Plexin	domain	containing	1	 PLXDC1	 NM_020405	 3.12	 0.01	Lysyl	oxidase-like	2	 LOXL2	 NM_002318	 3.11	 0.01	Hairy/enhancer-of-split	related	with	YRPW	motif-like	 HEYL	 NM_014571	 3.01	 0.00	Placental	growth	factor	 PGF	 NM_002632	 2.92	 0.01	Platelet-derived	growth	factor	receptor,	beta	polypeptide	 PDGFRB	 NM_002609	 2.82	 0.00	Endothelial	cell-specific	molecule	1	 ESM1	 NM_007036	 2.63	 0.00	CD86	molecule	 CD86	 NM_006889	 2.42	 0.05	Apelin	 APLN	 NM_017413	 1.98	 0.00	Insulin-like	growth	factor	binding	protein	7	 IGFBP7	 NM_001553	 1.93	 0.01	Angiopoietin-like	2	 ANGPTL2	 NM_012098	 1.65	 0.09	Major	histocompatibility	complex,	class	II,	DR	alpha	 HLA-DRA	 NM_019111	 1.65	 0.05	Tenascin	C	 TNC	 NM_002160	 1.42	 0.12	Secreted	protein,	acidic,	cysteine-rich	(osteonectin)	 SPARC	 NM_003118	 1.39	 0.13	Neuropilin	1	 NRP1	 NM_001024629	 1.23	 0.08	Lysyl	oxidase	 LOX	 NM_002317	 1.20	 0.21	Anthrax	toxin	receptor	1	 ANTXR1	 NM_053034	 1.01	 0.20		
Table	4.2.	Collagens	enriched	in	colorectal	cancer	vessels.	
 
Gene	ID	 Gene	Symbol	 GeneBank	accession	no.	 LogFC	 P-value	
Collagen,	type	I,	alpha	1	 COL1A1	 NM_000088	 4.18	 0.00	
Collagen,	type	XII,	alpha	1	 COL12A1	 NM_004370	 3.13	 0.00	
Collagen,	type	IV,	alpha	1	 COL4A1	 NM_001845	 2.86	 0.00	
Collagen,	type	I,	alpha	2	 COL1A2	 NM_000089	 2.79	 0.01	
Collagen,	type	XV,	alpha	1	 COL15A1	 NM_001855	 2.56	 0.01	
Collagen,	type	XVIII,	alpha	1	 COL18A1	 NM_030582	 2.42	 0.00	
Collagen,	type	IV,	alpha	2	 COL4A2	 NM_001846	 2.36	 0.00	
Collagen,	type	V,	alpha	1	 COL5A1	 NM_000093	 2.30	 0.04	
Collagen,	type	VIII,	alpha	1	 COL8A1	 NM_001850	 2.28	 0.02	
Collagen,	type	V,	alpha	2	 COL5A2	 NM_000393	 2.10	 0.03	
Collagen,	type	VII,	alpha	1	 COL7A1	 NM_000094	 2.00	 0.17	
Collagen,	type	V,	alpha	3	 COL5A3	 NM_015719	 1.79	 0.01	
Collagen,	type	X,	alpha	1	 COL10A1	 NM_000493	 1.69	 0.06	
Collagen,	type	III,	alpha	1	 COL3A1	 NM_000090	 1.66	 0.10	
Collagen,	type	XIV,	alpha	1	 COL14A1	 NM_021110	 1.54	 0.08	
Collagen,	type	VI,	alpha	1	 COL6A1	 NM_001848	 1.45	 0.14	
Collagen,	type	VI,	alpha	3	 COL6A3	 NM_004369	 1.44	 0.08	
Collagen,	type	IX,	alpha	1	 COL9A1	 NM_001851	 1.08	 0.11	
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Table	4.3.	Matrix	metallopeptidases	enriched	in	colorectal	cancer	vessels. 	
Gene	ID	 Gene	Symbol	 GeneBank	accession	no.	 LogFC	 P-value	
Matrix	metallopeptidase	3	(stromelysin	1,	progelatinase)	 MMP3	 NM_002422	 5.72	 0.01	
Matrix	metallopeptidase	7	(matrilysin,	uterine)	 MMP7	 NM_002423	 5.54	 0.00	
Matrix	metallopeptidase	12	(macrophage	elastase)	 MMP12	 NM_002426	 4.86	 0.00	
Matrix	metallopeptidase	1	(interstitial	collagenase)	 MMP1	 NM_002421	 4.49	 0.04	
Matrix	metallopeptidase	9	(gelatinase	B)	 MMP9	 NM_004994	 4.10	 0.00	
Matrix	metallopeptidase	11	(stromelysin	3)	 MMP11	 NM_005940	 3.25	 0.01	
Matrix	metallopeptidase	10	(stromelysin	2)	 MMP10	 NM_002425	 2.54	 0.10	
Matrix	metallopeptidase	14	(membrane-inserted)	 MMP14	 NM_004995	 1.94	 0.04	
Matrix	metallopeptidase	2	(gelatinase	A)	 MMP2	 NM_004530	 1.51	 0.16	
Matrix	metallopeptidase	13	(collagenase	3)	 MMP13	 NM_002427	 1.18	 0.11	
	
	
4.2.3	Selection	of	genes	of	interest	In	order	to	identify	potential	endothelial	markers	in	colorectal	cancer,	which	can	then	be	used	to	target	therapeutics	to	the	tumour	vascular	bed,	a	short	list	of	genes	of	interest	was	generated	(Table	4.4).	This	list	detailed	genes	at	least	5	times	enriched	on	colorectal	cancer	vessels	and	with	considerable	evidence	of	trans-plasma-membrane	expression.	This	was	done	to	ensure	that	selected	genes	had	both	considerable	differential	expression,	but	were	also	directly	targetable	from	the	blood.	This	would	simplify	the	mode	of	delivery	of	any	potential	therapeutics	targeted	against	them.	A	literature	review	was	undertaken	on	all	targets,	and	those	with	prior	published	evidence	of	investigation	in	the	context	of	colorectal	cancer	endothelium,	were	excluded	from	further	study.	This	left	eight	candidate	targets;	stimulated	by	retinoic	acid	gene	6	(STRA6),	glutamate	receptor,	ionotropic,	N-methyl	D-aspartate	2D	(GRIN2D),	fibronectin	type	III	domain	containing	1	(FNDC1),	G	protein-coupled	receptor	4	(GPR4),	regulator	of	G-protein	signalling	5	(RGS5),	transglutaminase	2	(TGM2),	potassium	inwardly-rectifying	channel,	subfamily	J,	member	8	(KCNJ8)	and	olfactory	receptor,	family	51,	subfamily	E,	member	1	(OR51E1).		
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Table	4.4.	Trans-membrane	genes	greater	than	5	fold	enriched	in	colorectal	cancer	vessels.		
 Gene	ID	 Gene	Symbol	 GeneBank	accession	no.	 LogFC	 P-value	EGF-like-domain,	multiple	6	 EGFL6	 NM_001167890	 4.86	 0.00	Thrombospondin	2	 THBS2	 NM_003247	 4.26	 0.00	Fibroblast	activation	protein,	alpha	 FAP	 NM_004460	 4.11	 0.00	Leucine	zipper,	putative	tumor	suppressor	1	 LZTS1	 NM_021020	 4.03	 0.00	Thy-1	cell	surface	antigen	 THY1	 NM_006288	 3.87	 0.00	Fc	fragment	of	IgG,	low	affinity	IIIa,	receptor	(CD16a)	 FCGR3A	 NM_000569	 3.58	 0.00	Interleukin	6	(interferon,	beta	2)	 IL6	 NM_000600	 3.40	 0.00	Stimulated	by	retinoic	acid	gene	6	homolog	(mouse)	 STRA6	 NM_001199042	 3.15	 0.00	Plexin	domain	containing	1	 PLXDC1	 NM_020405	 3.12	 0.01	Potassium	inwardly-rectifying	channel,	subfamily	J,	member	8	 KCNJ8	 NM_004982	 2.97	 0.00	Placental	growth	factor	 PGF	 NM_002632	 2.92	 0.01	Pyrimidinergic	receptor	P2Y,	G-protein	coupled,	6	 P2RY6	 NM_176798	 2.87	 0.00	Glutamate	receptor,	ionotropic,	N-methyl	D-aspartate	2D	 GRIN2D	 NM_000836	 2.83	 0.01	Platelet-derived	growth	factor	receptor,	beta	polypeptide	 PDGFRB	 NM_002609	 2.82	 0.00	Frizzled	family	receptor	10	 FZD10	 NM_007197	 2.81	 0.00	Tribbles	homolog	3	(Drosophila)	 TRIB3	 NM_021158	 2.81	 0.01	Regulator	of	G-protein	signalling	5	 RGS5	 NM_003617	 2.79	 0.00	Claudin	2	 CLDN2	 NM_001171092	 2.75	 0.02	Wingless-type	MMTV	integration	site	family	member	2	 WNT2	 NM_003391	 2.75	 0.00	Uncharacterised	LOC541471	 LOC541471	 NR_015395	 2.73	 0.01	Leukocyte	immunoglobulin-like	receptor,	subfamily	B,	member	4	 LILRB4	 BC026309	 2.71	 0.01	Solute	carrier	family	4,	sodium	borate	transporter,	member	11	 SLC4A11	 NM_032034	 2.67	 0.01	Macrophage	receptor	with	collagenous	structure	 MARCO	 NM_006770	 2.67	 0.01	Vasorin	 VASN	 NM_138440	 2.66	 0.00	Transglutaminase	2	 TGM2	 NM_198951	 2.60	 0.00	Sulfatase	1	 SULF1	 NM_015170	 2.58	 0.02	Leucine	rich	repeat	and	Ig	domain	containing	1	 LINGO1	 NM_032808	 2.57	 0.00	SLAM	family	member	8	 SLAMF8	 NM_020125	 2.52	 0.03	Olfactory	receptor,	family	51,	subfamily	E,	member	1	 OR51E1	 NM_152430	 2.50	 0.00	Gap	junction	protein,	alpha	4,	37kDa	 GJA4	 NM_002060	 2.50	 0.00	Interleukin	13	receptor,	alpha	2	 IL13RA2	 NM_000640	 2.45	 0.02	Regulator	of	G-protein	signalling	16	 RGS16	 NM_002928	 2.44	 0.01	Fibronectin	type	III	domain	containing	1	 FNDC1	 NM_032532	 2.39	 0.02	Notch	3	 NOTCH3	 NM_000435	 2.34	 0.00	ArfGAP	with	dual	PH	domains	2	 ADAP2	 NM_018404	 2.27	 0.00	G	protein-coupled	receptor	4	 GPR4	 NM_005282	 2.24	 0.01		
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4.2.4	Validation	of	genes	of	interest	Microarray	based	differential	analysis	suffers	from	two	weaknesses.	First	there	is	a	high	false	positive	rate	of	genes	identified	as	being	significantly	differentially	expressed,	although	this	was	ameliorated	by	the	selection	of	genes	greater	than	five	times	enriched	in	the	tumour	endothelium	with	a	p-value	<	0.05.	Secondly	it	is	unable	to	provide	information	about	the	absolute	expression	level	of	any	of	the	genes	identified,	resulting	in	some	being	expressed	differentially,	but	at	such	a	minute	level	that	they	would	be	impossible	to	target.	RTqPCR	was	conducted	on	the	eight	selected	candidate	targets,	in	order	to	compare	gene	expression	in	colorectal	cancer	EC	and	healthy	colon	EC	(n=8	for	each)	(Figure	4.1).	Gene	expression	was	normalised	to	both	flotillin-2	(per	cell	expression	level)	and	PECAM-1	(per	endothelial	cell	expression	level)	in	order	to	assess	the	level	of	enrichment	of	the	target	in	the	cancer	endothelium	(Table	4.5).	Additionally	target	gene	expression	level	in	the	cancer	EC	was	compared	to	flotillin-2	expression,	in	order	to	ensure	that	genes	were	expressed	at	a	high	enough	level	to	be	of	interest	(Table	4.5).	This	investigation	identified	GRIN2D	alone	as	having	sufficient	cancer	enrichment	and	expression,	to	be	taken	forward	for	further	investigation.								
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Figure	4.1.	Validation	of	putative	colorectal	cancer	vascular	markers	by	RTqPCR.	Quantitative	real-time	analysis	of	relative	candidate	target	gene	levels	in	endothelium	isolated	from	malignant	and	healthy	tissue.	Gene	expression	levels	were	normalised	to	flotillin-2.	Average	gene	expression	±	SEM	(n=8,	Mann-Whitney	U,	***	p<0.0001,	**	
p<0.001,	NS	p>0.05).			
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Table	4.5.	Selection	of	genes	of	interest	for	further	investigation	and	validation	based	on	gene	enrichment	and	expression	level	in	the	tumour	endothelial	isolates					 Flotillin-2	vs.	target	fold	expression	change	 PECAM	vs.	target	fold	expression	change	 Expression	level	relative	to	flotillin-2	(%)	 Selected	genes	STRA6	 30.7	 5.1	 10.6	 	GRIN2D	 35.4	 15.8	 35.0	 GRIN2D	FNDC1	 20.5	 2.4	 16.9	 	GPR4	 22.7	 8.8	 17.3	 	RGS5	 3.7	 1.0	 109.1	 	TGM2	 1.7	 0.5	 841.7	 	KCNJ8	 7.5	 6.25	 4.4	 	OR51E1	 7.1	 4.0	 8.8	 			Differential	expression	of	GRIN2D	was	further	validated	on	the	protein	level	by	immunohistochemistry	(IHC)	on	formalin	fixed	paraffin	embedded	sections	(Figure	4.2).		Immunohistochemistry	is	a	semi-quantitative	method	to	determine	the	expression	and	tissue	localisation	of	a	protein.	This	is	achieved	by	first	the	removal	of	paraffin	from	the	sections	using	a	liquid	in	which	paraffin	is	miscible,	in	this	case,	petroleum	distillates	(Histoclear),	followed	by	a	stepwise	rehydration	of	the	tissue	with	ethanol	and	water	in	varying	combinations.	This	generates	an	environment	within	the	tissue	permissible	to	aqueous	solutions.	An	EDTA	solution	is	then	used	to	restore	the	di-sulphide	bonds	and	the	three	dimensional	structure	of	proteins	within	the	tissue,	destroyed	by	formalin	fixation	and	embedding.	This	permits	the	subsequent	recognition	and	binding	of	antigens	within	the	tissue	to	antibodies.	First	a	primary	antibody,	recognising	the	target	protein,	is	introduced,	then	a	secondary	antibody	that	recognises	and	binds	the	heavy	chain	of	the	primary	antibody.	The	secondary	antibody	is	conjugated	to	a	
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horseradish	peroxidase,	which	catalyses	a	chromogenic	peroxidase	substrate	to	change	colour	and	stain	the	location	of	antibody	binding.	Sections	of	colorectal	cancer	and	healthy	colon	were	stained	for	PECAM-1	(a	marker	of	endothelium)	and	GRIN2D	by	IHC.	This	analysis	determined	that	the	vessels	in	colorectal	cancer	stain	strongly	for	GRIN2D,	however,	vessels	in	the	healthy,	marked	by	PECAM-1	staining	do	not	stain	for	GRIN2D	(Figure	4.2A	and	B).	Additionally	GRIN2D	IHC	staining	was	assessed	by	multi-organ	tissue	array	analysis,	in	order	to	determine	its	global	tumour	and	healthy	tissue	expression	profile	(Figure	4.2C).	This	involved	staining	10	samples	each,	of	12	different	tumour	and	matched	healthy	tissue	sample	for	GRIN2D.	The	analysis	identified	GRIN2D	to	be	positively	expressed	on	the	vessels	of	40%	of	colorectal	cancers,	but	only	10%	of	healthy	colon	samples.	It	was	additionally	expressed	on	a	range	of	cancer	and	healthy	tissues	to	a	lesser	extent.	The	fact	that	GRIN2D	is	expressed	to	a	greater	extent	in	cancerous	tissues	and	in	colon	cancer	in	particular,	is	encouraging	in	that	it	suggests	a	potential	for	vessel	specific	targeting,	but	with	careful	monitoring	for	healthy	tissue	toxicity.			In	order	to	investigate	whether	the	expression	of	GRIN2D	has	any	prognostic	value	in	colorectal	cancer,	90	colorectal	tumours	were	stained	for	GRIN2D	(Figure	4.3).	Key	clinical	data	for	this	cohort	is	shown	in	Table	4.6.	The	survival	of	patients	with	tumours	positive	or	negative	for	GRIN2D	staining	was	compared	by	log-ranks	statistical	analysis	(Figure	4.3).	This	analysis	determined	that	patients	with	positive	vascular	GRIN2D	expression	survived	for	longer	than	those	without,	though	not	to	a	significant	level	(p=0.053).						
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Figure	4.2.	Confirmation	of	colon	cancer	specific	enrichment	of	GRIN2D	by	immunohistochemistry.	Representative	images	of	A,	PECAM	and	B,	GRIN2D	staining	in	healthy	colon	and	colorectal	cancer	(scale	bar	=	50	μm).	C,	multi-organ	tissue	array	analysis	of	GRIN2D	expression,	showing	the	frequency	of	positive	GRIN2D	vascular	staining.		
!!
Flo%llin(2!vs.!target!
fold!expression!
change!
PECAM!vs.!target!
fold!expression!
change!
Expression!level!
rela%ve!to!ﬂo%llin(2!
(%)!
Selected!genes!
STRA6! 30.7! 5.1! 10.6! !
GRIN2D! 35.4! 15.8! 35.0! GRIN2D!
FNDC1! 20.5! 2.4! 16.9! !
GPR4! 22.7! 8.8! 17.3! !
RGS5! 3.7! 1.0! 109.1! !
TGM2! 1.7! 0.5! 841.7! !
KCNJ8! 7.5! 6.25! 4.4! !
OR51E1! 7.1! 4.0! 8.8! !
Table!4.2:!selec%on!of!genes!of!interest!for!further!inves%ga%on!and!valida%on!based!on!gene!
enrichment!and!expression!level!in!the!tumour!endothelial!isolates!!
Colon! CRC!
0!
10!
20!
30!
40!
50!
60!
70!
80!
90!
100!
Co
lon
!
Sto
ma
ch
!!
Ce
rvi
x!
Lym
ph
a%
cs!
Kid
ne
y!
Eso
ph
ag
us
!
Lu
ng
!
En
do
me
tri
um
!
Ga
llb
lad
de
r!
La
ryn
x!
Me
lan
om
a!
Th
yro
id!
%
"o
f"s
am
pl
es
"
Posi-ve"GRIN2D"staining"
Cancer!
Healthy!
C!
Colon! CRC!
A!
B!
PECAM(1! PECAM(1!
GRIN2D! GRIN2D!
	 104	
	
	
Figure	4.3.	GRIN2D	vascular	expression	is	positively	correlated	with	survival	in	colorectal	cancer.	A,	representative	images	of	positive	and	negative	GRIN2D	staining	in	CRC	by	IHC	(scale	bar	=	50	μm).	B,	Kaplan-Meier	analysis	of	survival	in	CRC	with	(red)	or	without	(blue)	GRIN2D	vascular	expression.	Statistical	analysis	=	Log-ranks	test,	P	and	N-numbers	shown.						
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Table	4.6.	Key	clinical	data	for	CRC	cohort	showing	overall	survival	(OS).		Characteristics N	of	patients Median	OS Mean	OS All 90 87.5 112.8 Gender 	 	 	 Male 65 86 107.2 Female 25 122 127.3 Age 	 	 	 above	58 47 122 130.2 below	or	equal	to	58 43 67 93.8 Stage 	 	 	 I/II 44 157.5 148.5 III/IV 46 38 78.6 Tumour	location 	 	 	 Ascending	colon 21 27 63.5 Descending	colon 6 194 183 Sigmoid	colon 31 84 96.6 Transverse	colon 9 186 127.1 Cecum 4 102.5 109 Rectum 19 186 165.6 T-stage 	 	 	 T2 8 187.5 160.5 T3 75 86 105.5 T4 7 122 136.3 N-stage 	 	 	 N0 50 129.5 138.3 N1+ 40 33 80.1 M-stage 	 	 	 M0 75 116 126.3 M1 15 42 45.3 GRIN2D	staining	 	 	 	 Positive	 21	 154	 137.6	Negative	 69	 86	 109.8	
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4.2.5	Analysis	of	the	functional	role	in	endothelium	of	GRIN2D	
	
4.2.5.1	siRNA	knockdown		In	order	to	investigate	the	functional	role	GRIN2D	plays	in	tumour	endothelium,	human	umbilical	cord	vein	endothelial	cells	(HUVEC)	were	transfected	with	small	interfering	RNA	(siRNA)	duplexes	corresponding	to	GRIN2D,	to	selectively	silence	its	expression.	siRNA	are	double	stranded	RNA	molecules	of	20-25	base	pairs	and	when	introduced	to	a	cell,	are	taken	into	the	RNA	interference	(RNAi)	pathway.	This	pathway	evolved	in	eukaryotic	cells	as	an	anti-RNA	virus	response.	When	double	stranded	RNA,	foreign	to	eukaryotic	cells	is	detected,	it	is	unwound	to	single-stranded	RNA	(ssRNA).	One	of	these	strands	(in	this	case	complementary	to	GRIN2D	mRNA)	is	incorporated	into	the	RNA-induced	silencing	complex	(RISC),	where	it	is	used	to	guide	the	complex	into	binding	with	any	complementary	mRNA	in	the	cell.	The	common	outcome	is	the	cleavage	of	the	mRNA	catalysed	by	Argonaute,	a	component	of	the	RISC,	thus	achieving	post-translational	silencing	of	the	target	gene	(or	destruction	of	viral	RNA).	
	
4.2.5.2	RTqPCR	and	western	blot	GRIN2D	silencing	validation	Comparative	RTqPCR	for	GRIN2D	expression	in	cells	transfected	with	siRNA	duplexes,	corresponding	to	GRIN2D	in	two	locations	or	a	scrambled	non-mammalian	sequence,	was	performed	to	assess	the	efficacy	of	siRNA	for	GRIN2D	silencing	(Figure	4.4A).	This	revealed	a	60-70%	reduction	in	GRIN2D	expression	in	the	presence	of	GRIN2D	siRNA	duplexes.	For	a	functional	effect	to	be	observed	the	protein	level	of	GRIN2D	must	also	be	reduced.	To	ensure	this	was	the	case,	western	blot	analysis	of	GRIN2D	gene	expression	was	
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performed.	In	this	assay	proteins	from	the	lysate	of	cells	under	investigation	are	sodium	dodecyl	sulphate	(SDS)	denatured	and	drawn	through	a	polyacrylamide	gel	under	a	charge.	Proteins	are	retarded	by	the	acrylamide	mesh,	separating	them	based	on	their	size.	The	separated	proteins	are	then	transferred	from	the	gel	to	a	PVDF	membrane,	again	under	a	charge.	This	membrane	then	undergoes	immunological	probing	for	the	gene	of	interest.	It	is	first	incubated	with	milk	protein	to	block	non-specific	antibody	binding,	then	incubated	with	an	antibody	recognising	the	gene	of	interest	and	finally	washed	and	incubated	with	an	antibody	recognising	the	heavy	chain	of	the	first	antibody,	conjugated	to	horseradish	peroxidase.	A	luminescent	peroxidase	substrate	is	then	introduced	to	the	membrane,	causing	the	location	of	any	proteins	trapped	on	the	membrane	and	recognised	by	the	antibodies,	to	luminesce	in	a	quantitative	manner.	The	membrane	is	used	to	expose	photosensitive	film,	the	analysis	of	which	permits	the	relative	quantitation	of	protein	expression	between	samples.	By	this	method	GRIN2D	protein	level	was	found	to	be	reduced	by	45-60%	by	treatment	with	GRIN2D	siRNA	duplexes	(Figure	4.4B	and	C).	
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Figure	4.4.	siRNA	duplexes	successfully	knockdown	GRIN2D	expression	on	the	RNA	and	protein	level.	Analysis	of	GRIN2D	expression	in	three	cords	of	HUVEC	treated	with	a	scrambled	duplex	or	two	GRIN2D	targeting	duplexes,	by	A,	RTqPCR	(normalised	to	flotillin-2)	or	B,	western	blot	(normalised	to	Tubulin)	(n=3,	average	expression	±	SEM).	C,	representative	western	blot	images	(GRIN2D	band	-	70	kDa,	Tubulin	band	–	55	kDa).	
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4.2.5.3	Matrigel	tube	forming	assay		The	cell-to-cell	communication	required	for	endothelial	cells	to	differentiate	into	vessel	tubes	is	vitally	important	for	their	healthy	function.	To	assess	the	impact	that	the	partial	loss	of	GRIN2D	expression	has	on	this	process,	a	matrigel	tube-forming	assay	was	performed.	Endothelial	cells	are	sparsely	cultured	in	matrigel,	a	gelatinous	protein	mixture,	secreted	by	Engelbreth-Holm-Swarm	(EHS)	mouse	sarcoma	cells	that	generates	a	growth	matrix	resembling	the	complex	extracellular	environment	found	in	many	tissues	(209).	Endothelial	cells	grown	in	this	matrix	form	spiderweb	like	networks,	reminisent	of	microvascular	capillary	systems	(210).	By	assessing	the	complexity	of	network	endothelial	cells	are	able	to	form,	their	functionality	can	be	determined.	This	is	done	by	quantifying	the	number	of	nodes	(network	intersections)	and	sprouts	per	node,	in	this	model	of	endothelial	capillary	formation.	The	capillary	networks	formed	by	endothelial	cells	from	three	HUVEC	cords	showed	significant	reduction	in	both	the	number	of	nodes	(p<0.001)	and	sprouts	per	node	(p<0.001)	when	treated	with	either	GRIN2D	siRNA	duplex,	compared	to	with	the	scrambled	control	duplex,	suggesting	GRIN2D	plays	some	role	in	the	endothelial	capillary	tube	formation	(Figure	4.5).							
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Figure	4.5.	Loss	of	GRIN2D	impairs	endothelial	matrigel	tube	formation.	GRIN2D	was	knocked	down	by	transfection	of	two	siRNA	duplexes	into	3	separate	HUVEC	isolates.	The	cells	were	plated	on	matrigel	and	endothelial	tube	formation	and	integrity	observed	over	16	hours.	A,	representative	images	of	tube	formation	in	each	condition.	B,	the	average	number	of	nodes	per	field	of	view	±	SEM.	C,	the	average	number	of	sprouts	per	node	±	SEM.	(N=6	per	condition	[3]	and	isolate	[3])	(Mann-Whitney	U,	***	
p<0.0001).	
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4.2.5.4	Scratch	wound	assay	The	speed	of	endothelial	cell	migration	is	an	important	indicator	of	functionality.	To	determine	the	effect	GRIN2D	knockdown	has	on	endothelial	migration,	scratch	wound	assays	were	performed.	In	this	assay,	scratches	are	scored	through	a	confluent	monolayer	of	endothelial	cells.	Three	scratches	are	scored	from	top	to	bottom	and	three	from	left	to	right,	generating	nine	intersection	sites	into	which	endothelial	cells	will	migrate,	closing	the	scratch.	By	determining	the	percentage	of	the	scratch	wound	still	open	at	the	point	where	the	control	duplex	is	90%	closed,	the	rate	of	endothelial	migration	can	be	compared.		The	percentage	scratch	wound	closure	was	significantly	reduced	by	GRIN2D	knockdown	with	both	duplexes,	when	compared	to	the	scrambled	control	(p<0.001),	suggesting	that	GRIN2D	plays	a	significant	role	in	endothelial	migration	(Figure	4.6).	
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Figure	4.6.	Loss	of	GRIN2D	impairs	scratch	wound	closure.	GRIN2D	was	knocked	down	by	transfection	of	two	siRNA	duplexes	into	3	separate	HUVEC	isolates.	The	cells	were	plated,	allowed	to	grow	to	confluence,	the	monolayer	was	scratched	and	wound	closure	observed	at	nine	scratch	intersections	over	time.	A,	representative	images	of	wound	closure	from	initial	scratch	to	end-stage.	B,	quantification	of	percentage	wound	closure	over	the	time	course	of	the	experiment	±	SEM.	(n=9	per	condition	[3]	and	isolate	[3])	(Mann-Whitney	U,	***	p<0.0001).						
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4.2.5.5	Transfilter	(modified	Boyden	chamber)	assay	Endothelial	migration	takes	many	forms,	the	functionality	of	which	the	scratch	wound	assay	alone	cannot	accurately	assess.	The	transfilter	assay	tests	the	ability	of	the	endothelial	cell	to	transmigrate	through	a	filter,	stimulated	by	a	growth	factor	and	mitogen	concentration	gradient.	In	order	to	assess	the	effect	the	loss	of	GRIN2D	has	on	transmigration,	this	assay	was	performed.	The	experimental	set	up	is	outlined	in	Figure	4.7A,	briefly	both	sides	of	a	membrane	insert,	with	8	µm	pores,	were	gelatine	coated	generating	a	receptive	environment	for	endothelial	cells	to	cross	the	membrane.	HUVEC	were	introduced	on	the	upper	side	of	the	membrane	in	a	low	serum/	growth	factor	environment	(M199	with	1%	fetal	calf	serum	(a	source	of	the	mitogens,	sphingosine-1-phosphate	[S1P]	and	lysophosphatidic	acid [LPA])	and	no	brain	extract	(a	source	of	FGF).	On	the	lower	side	of	the	membrane	a	growth	factor	rich	environment	was	set	up	(M199	with	10%	FCS	and	0.2%	brain	extract)	creating	a	growth	factor	gradient	across	the	membrane.	HUVEC	were	allowed	to	migrate	across	this	membrane	for	16	hours,	after	which	the	cells	on	either	side	of	the	membrane	were	nuclear	stained	(with	bisbenzamide)	and	quantified	by	fluorescent	imaging.	By	determining	the	percentage	of	cells	that	have	migrated	across	the	membrane,	endothelial	transmigration	can	be	assessed.	The	percentage	of	cells	that	have	migrated	across	the	membrane	was	significantly	reduced	by	GRIN2D	knockdown	with	both	duplexes	when	compared	to	the	scrambled	control	(p<0.001),	suggesting	that	GRIN2D	plays	a	role	in	endothelial	transmigration	(Figure	4.7B).	
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Figure	4.7.	Loss	of	GRIN2D	impairs	endothelial	cell	transmigration	and	chemotaxis.	GRIN2D	was	knocked	down	by	transfection	of	two	siRNA	duplexes	into	3	separate	HUVEC	isolates.	The	cells	were	subjected	to	the	transfilter	(modified	Boyden	chamber)	assay	the	set	up	of	which	is	shown	in	A.	B,	quantification	of	the	average	percentage	of	endothelial	cells	that	have	migrated	through	the	filter,	after	16	hours,	per	field	of	view	±	SEM	(n=6	per	condition	[3]	and	isolate	[3]).	(Mann-Whitney	U,	***	p<0.0001).		
	
4.2.5.6	Acumen	cell	cytometry	Knockdown	of	genes	important	for	cellular	function	can	lead	to	a	reduction	in	cell	survival,	proliferation	and	movement	through	the	cell	cycle,	which	could	in	turn	effect	cellular	migration,	chemotaxis	and	formation	into	a	capillary-like	network,	in	a	manner	not	specific	to	those	particular	functions.	In	order	to	assess	the	effect	GRIN2D	knockdown	has	on	the	cell	cycle,	apoptosis	and	proliferation,	Acumen	cell	cycle	analysis	was	performed.		Cells	were	sparsely	plated	into	the	wells	of	a	96	well	plate,	fixed	with	ethanol	and	stained	for	DNA	content	with	propidium	iodide	(Figure	4.8A).	The	Acumen	cell	imager,	by	quantifying	DNA	content	on	a	single	cell	basis,	is	able	to	split	the	cell	population	into	G0/G1	phase	cells,	dead	or	dying	cells	(less	nuclear	material)	and	dividing	cells	(up	to	twice	as	much	nuclear	material)	at	each	stage	of	the	cell	cycle.	In	this	way	the	health	of	a	cell	population	can	be	assessed,	with	a	healthy	population	
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profile	shown	in	Figure	4.8B	and	an	unhealthy	(highly	apoptotic)	population	profile	shown	in	Figure	4.8C.			This	assessment	revealed	no	significant	shift	in	population	profile	between	the	scrambled	control	duplex	treated	cells	and	those	treated	with	either	GRIN2D	duplex,	with	all	the	profiles	resembling	that	of	the	healthy	population	(Figure	4.8D,	E	and	F).	This	suggests	that	loss	of	GRIN2D	does	not	cause	any	cell	cycle	defect	or	loss	of	cell	viability	and	proliferation,	meaning	that	effects	on	endothelial	cell	migration,	chemotaxis	and	formation	into	a	capillary-like	network	are	likely	to	be	specific.																						
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Figure	4.8.	siRNA	knockdown	of	GRIN2D	in	HUVEC	does	not	affect	cell	viability,	proliferation	or	progression	through	the	cell	cycle.	siRNA	treated	cells	were	fluorescently	labelled	and	imaged	using	the	Acumentm	cell	imager	(TTP	Labtech).	The	cells	were	sorted	by	quantity	of	nuclear	material	into	dead	(black),	apoptosing	(yellow),	G0/1-phase	(green),	S-phase	(orange)	and	G2/M-phase	(purple).	A,	representative	image	of	fluorescently	labelled		cellular	DNA.	The	histograms	shown	illustrate	the	proportion	of	cells	at	each	phase	in	a	plate	of,	B,	healthy	HUVEC,	C,	dying	HUVEC,	and	HUVEC	treated	with	either,	D,	scrambled	siRNA,	or	E,	GRIN2D	siRNA	duplex	1	and	F,	GRIN2D	siRNA	duplex	2.		
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4.3	Discussion	
	Microarray	transcriptomic	analysis	on	freshly	isolated	endothelium	from	colorectal	cancer	and	matched	healthy	colon	identified	a	panel	of	putative	colorectal	tumour	endothelial	markers.	Of	these	the	glutamate	receptor	GRIN2D	emerged	as	the	most	interesting	target.	GRIN2D	was	shown	to	have	vessel-restricted	expression	in	colorectal	cancer	by	RTqPCR	and	IHC	analysis.	Multi-organ	tissue	array	analysis	identified	GRIN2D	to	be	predominantly	expressed	in	tumour	tissue,	particularly	in	colorectal	malignancies,	where	its	expression	was	shown	to	be	associated	with	increased	survival.	
In	vitro	analysis	of	GRIN2D’s	endothelial	function	showed	it	to	be	important	in	endothelial	migration	and	capillary	tube	formation	in	matrigel.			GRIN2D	is	primarily	studied	as	a	neuronal	ionotropic	glutamate	receptor,	involved	in	long-term	potentiation,	which	underlies	certain	types	of	learning	and	memory.	GRIN2D	is	a	component	of	the	N-methyl-D	aspartate	(NMDA)	receptor	calcium	channels,	which	are	heteromers	formed	from	a	combination	of	GRIN1	and	GRIN2	subunits	(211).	It	is	widely	expressed	within	the	brain,	in	particular	the	developing	diencephalon,	however,	selective	knockout	mice	develop	normally	both	pre-	and	post-natally,	with	normal	mating	behaviour	(212).	There	was	no	observed	effect	in	motor	activity	or	anxiety	tests,	however,	due	to	the	loss	of	function	of	certain	NMDA	receptors,	mice	showed	altered	emotional	behaviour	in	forced	swimming	and	light/dark	box	stress	tests	(213).	This	led	to	the	suggestion	of	its	role	in	the	glutaminergic	theory	of	schizophrenia,	which	has	been	a	focus	of	GRIN2D	research,	reviewed	in	Moghaddam	and	Javitt,	2012	(214).		
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Neuronal	and	vascular	cells	share	an	embryonic	stem	cell	lineage,	leading	to	considerable	cross-expression	of	endothelial	and	neuronal	genes	and	many	similarities	in	the	processes	that	govern	the	modelling	of	vascular	and	neuronal	architecture	(215).	With	this	in	mind	it	is	unsurprising	that	a	traditionally	neuronal	glutamate	receptor	GRIN2D	should	be	found	to	be	expressed	on	endothelial	cells.			GRIN2D’s	identity	as	a	component	of	a	calcium	channel	could	be	responsible	for	its	observed	role	in	angiogenesis.	VEGF,	a	potent	stimulatory	growth	factor	of	angiogenesis,	promotes	endothelial	migration,	proliferation	and	capillary	formation	in	part	via	VEGF	mediated	calcium	influx	(216).	Increased	intracellular	calcium	concentration,	observed	or	induced	by	arachidonic	acid	has	been	reported	to	promote	endothelial	migration	and	tube	formation	in	angiogenesis	assays	(217,218).	Loss	of	GRIN2D	by	siRNA	knockdown	results	in	reduced	endothelial	migration,	tube	formation	and	transmigration,	which	could	be	in	part	due	to	reduced	calcium	influx	into	the	endothelial	cells,	curtailing	the	efficiency	of	growth	factor	mediated	endothelial	function,	although	this	theory	requires	further	investigation.		The	functioning	of	GRIN2D	in	neuronal	calcium	channels	is	distinct	from	that	of	other	NMDA	receptor	components,	in	that	it	promotes	calcium	influx	over	an	extended	period,	mediating	its	role	in	long	term	potentiation	(219,220).	It	is	therefore	easy	to	see	how,	by	offering	long-term	calcium	influx,	the	promotion	of	GRIN2D	containing	calcium	channels	in	tumour	endothelium	could	offer	a	survival	advantage	and	even	prime	endothelial	cells	to	respond	to	pro-angiogenic	growth	factor	signalling	within	the	tumour.	Calcium	flux	and	metabolism	has	been	suggested	as	a	target	for	anti-
	 119	
angiogenic	therapy	(221)	and	targeted	inhibition	of	GRIN2D	could	be	a	potential	method	for	achieving	this.			Multiple	links	have	been	described	between	glutamate	receptor	function	and	tumour	biology,	with	knockdown	of	some	non-GRIN2D	glutamate	receptor	subunits	resulting	in	both	pro	and	anti-tumour	effects	(222).	Additionally	increased	serum	levels	of	glutamate	have	been	reported	as	a	marker	of	malignant	potential	in	prostate	cancer	(223),	where	it	has	also	been	observed	to	be	positively	related	to	advancing	Gleason	grade	(224).	It	has	been	proposed	that	this	is	due	to	glutamate	acting	to	cause	a	genetic	switch	within	the	tumour,	reducing	the	threshold	for	oncogenic	k-ras	signalling	(225).	This	is	of	particular	relevance	in	colorectal	cancer	as	mutations	in	the	k-ras	oncogene	is	strongly	implicated	in	the	progression	of	colorectal	cancer	(226).	
	GRIN2D	shows	a	promising	tumour	specific	endothelial	expression	profile	in	a	number	of	tumours,	in	particular	colorectal	cancer.	However,	it	also	appears	to	be	expressed	in	a	small	subset	of	healthy	tissues	of	the	colon,	stomach,	esophagus	and	larynx	as	well	as	its	reported	expression	throughout	the	brain	and	autonomic	and	enteric	nervous	systems	(227).	The	integrity	of	the	blood	brain	barrier	(BBB)	and	other	nervous	system	protective	structures	must	be	ensured	and	maintained	to	avoid	potentially	serious	side	effects	from	GRIN2D	guided	therapies.	If	the	BBB	is	intact	the	safety	of	immunological	therapies	should	still	be	maintained,	as	large	proteins	like	antibodies,	cannot	pass	through	the	tight	endothelial	junctions	of	the	BBB	(228).	However,	in	2-3%	of	cases	of	advanced	CRC,	patients	develop	brain	metastases	leading	to	disruption	of	the	BBB	(229).	This	could	make	targeting	GRIN2D	potentially	unwise	in	this	setting.	With	this	in	
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mind,	care	will	have	to	be	taken	in	the	selection	of	patients	in	which	GRIN2D	targeted	therapies	can	be	safely	used.		Intriguingly	GRIN2D	expression	in	the	vessels	of	colorectal	cancer	appears	to	be	associated,	albeit	not	quite	significantly,	to	improved	patient	survival.	The	expression	of	tumour	endothelial	markers	being	associated	with	survival	in	this	way	is	not	without	precedent.	Expression	of	the	tumour	specific	orphan	receptor	ELTD1	has	been	reported	to	be	associated	with	improved	survival	in	head	and	neck,	colorectal	and	ovarian	cancers	(55).	Increased	expression	of	ROBO4,	CLEC14A	and	ECSCR	have	also	been	associated	with	improvements	in	survival	in	non-small	cell	lung	cancer	(230).	It	has	been	suggested	that	the	expression	of	these	pro-angiogenic	TEMs	could	be	associated	with	vascular	normalisation	within	tumours.	Indeed	ROBO4-Slit2	signalling	has	been	implicated	in	the	normalisation	of	VEGF	induced	chaotic	vascular	structures	(231).	This	vascular	normalisation	could	in	turn	lead	to	improved	perfusion	of	the	tumours	leading	to	greater	responsiveness	to	systematic	blood-borne	chemotherapeutics	and	therefore	increased	survival	(55,230).			In	conclusion	GRIN2D	is	a	promising	vascular	target	in	colorectal	cancer	for	both	treatment	and	prognostication.	Endothelial	function	is	impaired	by	siRNA-mediated	disruption	of	gene	function	in	in	vitro	angiogenesis	assays.	This	effect	may	be	due	to	reduced	calcium	flux	within	the	endothelial	cells,	although	this	theory	requires	further	investigation.	The	expression	profile	of	GRIN2D	throughout	the	body	must	be	further	assessed	in	order	to	ascertain	the	safety	of	systemic	administration	of	GRIN2D	targeted	therapies.	
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5.1	Introduction	
	One	of	the	difficulties	encountered	with	identifying	tumour	endothelial	markers	from	data	derived	from	only	one	tumour	type	is	one	of	considerable	false	positivity.	However,	as	shown	in	chapter	4,	it	can	be	effective	for	the	identification	of	cancer	type	specific	markers,	such	as	GRIN2D.	In	order	to	address	this	issue,	data	from	microarray	analysis	of	vessels	from	renal	cell	carcinoma	and	colorectal	liver	metastasis	generated	in	chapter	3	were	combined	with	the	colorectal	data	discussed	in	chapter	4.	With	this	analysis	a	pan-tumour	endothelial	marker	expression	profile	was	generated,	hopefully	improving	the	identification	of	targets,	not	just	in	CRC,	but	also	RCC	and	CRM.		Approximately	271,000	new	cases	of	renal	cancer	are	diagnosed	each	year	worldwide,	3%	of	all	cancers,	with	the	highest	incidence	rate	found	in	North	America	(232).	By	far	the	most	common	form	of	kidney	cancer	is	renal	cell	carcinoma	(RCC),	accounting	for	90-95%	of	cases	(232).	Initial	treatment	is	most	commonly	surgical,	with	this	approach	remaining	the	primary	curative	intervention	(233).	Unfortunately	as	RCC	is	often	asymptomatic	until	the	tumour	is	advanced	or	metastatic,	curative	surgical	treatment	is	often	not	possible.	Five	year	survival	drops	from	65-90%	in	operable	cases	to	less	than	10%	in	metastatic	disease	(234).	It	is	therefore	clear	that	new	prognostic/diagnostic	biomarkers	for	RCC	are	urgently	needed.		Inoperable	or	recurrent	RCC	is	difficult	to	treat	with	the	success	rate	of	traditional	chemo	or	radiotherapy	at	4-5%	(235).	Because	of	this,	a	multitude	of	alternative	therapies	have	been	trialled	and	shown	efficacy	in	metastatic	RCC	(mRCC),	including	vascular	endothelial	growth	factor	(VEGF)	targeted	antiangiogenic	therapies,	sunitinib,	
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bevacizumab,	sorafenib	and	axitinib	(236).	RCC	being	a	cancer	characteristic	for	and	highly	dependent	on	excessive	VEGF	production,	due	to	the	common	loss	of	the	tumour	suppressor	Von	Hippel-Lindau	(237)	in	clear	cell	RCC	(ccRCC),	anti-VEGF	therapies	have	improved	the	outlook	for	mRCC	(236).	Despite	this,	5-year	survival	remains	low	and	antiangiogenic	treatment	relapse	is	very	common	(236).	Because	of	this,	it	was	decided	that	renal	cell	carcinoma	would	be	an	ideal	tumour	type,	alongside	colorectal	cancer,	in	which	to	identify	and	target	tumour	vascular	markers	for	therapy.		
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5.2	Results		
	
5.2.1	Identification	of	a	pan-tumour	endothelial	expression	profile	As	described	in	chapter	3	endothelial	cells	from	renal	cell	carcinoma,	colorectal	carcinoma	and	liver	metastasis	from	colorectal	cancer	were	isolated	and	subjected	to	microarray	analysis.	Four	comparison	matrices	were	set	up,	RCC	vs.	Kidney,	CRC	vs.	Colon,	CRM	vs.	Colon	and	CRM	vs.	Liver.	The	CRM	data	was	compared	to	the	colon	as	well	as	the	liver	from	which	its	vessels	are	derived,	in	order	to	set	up	a	direct	comparison	between	the	markers	induced	by	the	colorectal	primary	tumour	and	the	colorectal	metastasis.	This	analysis	identified	multiple	collagens	consistently	up-regulated	within	the	three	tumour	types	studied.	Collagen	type	IV	family	members	in	particular	were	altered	in	their	expression	levels,	whilst	alpha	1	and	2	were	up-regulated	in	the	tumours,	alpha	3,	4	and	5	were	down-regulated	(Table	5.1).	Many	matrix	metallopeptidases	were	also	modulated	by	exposure	to	the	tumour	environment.	In	particular	MMP9,	MMP12	and	MMP14,	whilst	MMP7	and	11	were	consistently	up-regulated	in	the	vessels	of	tumours	derived	from	colorectal	malignancy	alone	(Table	5.2).									
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Table	5.1.	Collagen	regulation	across	tissue	types	(Gene	expression	comparison	shown	as	Log2	fold	change).	
 
Gene	ID Gene	symbol GenBank	accession	no. 
RCC	vs.	
Kidney 
CRC	vs.	
Colon 
CRM	vs.	
Colon 
CRM	vs.	
Liver 
Collagen,	type	I,	alpha	1 COL1A1 NM_000088 1.47 4.18 3.88 3.17 
Collagen,	type	I,	alpha	2 COL1A2 NM_000089 1.18 2.79 2.36 2.20 
Collagen,	type	III,	alpha	1 COL3A1 NM_000090 0.62 1.66 1.64 1.41 
Collagen,	type	IV,	alpha	1 COL4A1 NM_001845 1.85 2.86 3.13 1.70 
Collagen,	type	IV,	alpha	2 COL4A2 NM_001846 1.19 2.36 2.08 1.31 
Collagen,	type	IV,	alpha	3 COL4A3 NM_000091 -1.29 -0.36 -0.09 -0.63 
Collagen,	type	IV,	alpha	4 COL4A4 NM_000092 -1.29 -0.97 0.39 -1.48 
Collagen,	type	IV,	alpha	5 COL4A5 NM_033380 -1.32 -1.20 -2.67 -1.73 
Collagen,	type	V,	alpha	1 COL5A1 NM_000093 1.02 2.30 2.23 2.09 
Collagen,	type	V,	alpha	2 COL5A2 NM_000393 1.24 2.10 1.80 2.25 
Collagen,	type	V,	alpha	3 COL5A3 NM_015719 1.29 1.79 0.23 -0.19 
Collagen,	type	VI,	alpha	1 COL6A1 NM_001848 0.75 1.45 -0.27 -0.08 
Collagen,	type	VI,	alpha	2 COL6A2 NM_058175 1.71 0.23 0.97 0.25 
Collagen,	type	VI,	alpha	3 COL6A3 NM_004369 0.52 1.44 1.22 1.72 
Collagen,	type	VI,	alpha	6 COL6A6 NM_001102608 -0.42 0.07 -0.01 -1.93 
Collagen,	type	VII,	alpha	1 COL7A1 NM_000094 -1.39 2.00 1.22 1.15 
Collagen,	type	VIII,	alpha	1 COL8A1 NM_001850 2.09 2.28 2.94 1.31 
Collagen,	type	VIII,	alpha	2 COL8A2 NM_005202 0.73 0.93 0.56 1.26 
Collagen,	type	IX,	alpha	1 COL9A1 NM_001851 0.11 1.08 0.24 0.40 
Collagen,	type	IX,	alpha	3 COL9A3 NM_001853 0.29 -0.19 1.07 1.70 
Collagen,	type	X,	alpha	1 COL10A1 NM_000493 -0.05 1.69 3.03 2.40 
Collagen,	type	XII,	alpha	1 COL12A1 NM_004370 0.75 3.13 1.53 1.03 
Collagen,	type	XIV,	alpha	1 COL14A1 NM_021110 0.34 1.54 0.75 -0.09 
Collagen,	type	XV,	alpha	1 COL15A1 NM_001855 1.18 2.56 1.73 1.23 
Collagen,	type	XVI,	alpha	1 COL16A1 NM_001856 0.50 0.48 0.55 1.11 
Collagen,	type	XVII,	alpha	1 COL17A1 NM_000494 -0.37 -0.39 -0.81 2.49 
Collagen,	type	XVIII,	alpha	1 COL18A1 NM_030582 0.65 2.42 2.01 1.08 
Collagen,	type	XXI,	alpha	1 COL21A1 NM_030820 2.39 -0.84 -0.36 -1.29 
Collagen,	type	XXII,	alpha	1 COL22A1 NM_152888 -0.39 0.47 0.40 1.01 
Collagen,	type	XXIII,	alpha	1 COL23A1 NM_173465 1.53 0.10 0.15 0.08 													
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Table	5.2.	Matrix	metallopeptidase	regulation	across	tissue	types	(Gene	expression	comparison	shown	as	Log2	fold	change).		 Gene	ID	 Gene	symbol	 GenBank	accession	no.	 RCC	vs.	Kidney	 CRC	vs.	Colon	 CRM	vs.	Colon	 CRM	vs.	Liver	Matrix	metallopeptidase	1	 MMP1	 NM_002421	 0.16	 4.49	 -0.57	 2.12	Matrix	metallopeptidase	2	 MMP2	 NM_004530	 0.63	 1.51	 -0.80	 -0.32	Matrix	metallopeptidase	3	 MMP3	 NM_002422	 0.02	 5.72	 -1.66	 0.75	Matrix	metallopeptidase	7	 MMP7	 NM_002423	 -1.01	 5.54	 6.25	 1.78	Matrix	metallopeptidase	9	 MMP9	 NM_004994	 3.60	 4.10	 5.03	 2.98	Matrix	metallopeptidase	10	 MMP10	 NM_002425	 -0.01	 2.54	 -0.06	 0.69	Matrix	metallopeptidase	11	 MMP11	 NM_005940	 0.28	 3.25	 3.16	 4.70	Matrix	metallopeptidase	12	 MMP12	 NM_002426	 0.68	 4.86	 3.79	 5.76	Matrix	metallopeptidase	13	 MMP13	 NM_002427	 0.28	 1.18	 -0.11	 0.26	Matrix	metallopeptidase	14	 MMP14	 NM_004995	 0.87	 1.94	 1.77	 1.58	Matrix	metallopeptidase	16	 MMP16	 NM_005941	 1.03	 0.56	 0.81	 0.50	Matrix	metallopeptidase	23B	 MMP23B	 NM_006983	 0.13	 0.38	 1.14	 0.44			In	order	to	generate	a	shortlist	of	consistently	up-regulated	tumour	endothelial	markers	(TEMs),	comparative	Venn	analysis	was	performed	on	genes	2	fold	up-regulated	in	the	cancer	with	a	p-value	<	0.001,	from	each	of	the	four	comparison	matrices,	together	with	a	list	of	known	endothelial	genes	identified	previously	by	in	
silico	analysis	(59)	(Figure	5.1).	From	this	analysis	a	shortlist	of	key	genes	of	interest	was	generated	(Table	5.3).	This	list	included	a	number	of	well-known	pan-tumour	endothelial	markers	such	as	angiopoietin	2,	lysyl	oxidase,	apelin	and	neuropilin,	validating	the	approach	as	a	method	of	identifying	tumour	endothelial	markers.	One	of	the	most	consistently	up-regulated	genes	in	this	analysis	was	Laminin-alpha-4	(LAMA4)	a	component	of	the	laminin	complex,	a	major	non-collagenous	constituent	of	the	basal	lamina.	The	recently	identified	endothelial	receptor	for	LAMA4,	melanoma	cell	adhesion	molecule	(MCAM)	(238)	was	also	identified	by	this	analysis	as	consistently	up-regulated	in	cancer.	It	was	therefore	decided	to	investigate	these	two	interacting	proteins	further.		
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A	list	of	consistently	down-regulated	genes	from	the	analysis	was	also	generated	(Table	5.4),	which	could	be	of	interest	therapeutically,	potentially	to	restore	normality	to	the	tumour	and	its	vessels	via	gene	therapy,	for	example.	However,	for	the	purposes	of	this	investigation,	genes	up-regulated	in	tumour	vessels	were	the	focus.				 	
	
	
Figure	5.1.	Venn	diagram	showing	the	commonality	of	genes	at	least	2	fold	up-regulated	in	four	tumour	vs.	healthy	tissue	analyses	and	present	in	a	list	of	known	endothelial	restricted	genes.	
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5.2.2	Validation	of	MCAM	and	LAMA4	as	tumour	endothelial	markers	In	order	to	confirm	the	findings	of	the	microarray	analysis,	RTqPCR	was	performed	to	assess	mRNA	expression	levels	of	MCAM	and	LAMA4	in	endothelial	isolates	from	RCC	(n=8),	CRC	(n=8)	and	CRM	(n=6)	and	associated	healthy	tissues	(n=8,	8,	6).	This	analysis	showed	a	pronounced	and	consistent	up-regulation	of	both	genes	in	the	endothelium	of	the	cancers	when	compared	to	the	matched	healthy	tissues	(Figure	5.2).		
	
	
Figure	5.2:	Confirmation	of	cancer	specific	enrichment	of	MCAM	and	LAMA4	by	RTqPCR	on	endothelial	isolates	from	RCC,	(n	=	8),	CRC,	(n	=	8),	CRM,	(n	=	6)	and	associated	healthy	tissues	(n	=	8,8,6).	Mean	expression	standardised	to	flotillin-2,	±	SEM.	Mann-Whitney	U	test,	***	p	<	0.001,	**	p	<	0.01,	*	p	<	0.05).	
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The	identity	of	these	genes	as	markers	of	tumour	endothelium	was	further	confirmed	by	semi-quantitative	analysis	of	their	protein	expression	level	by	immunohistochemistry	(IHC),	compared	to	that	of	the	pan-endothelial	marker	PECAM-1	(Figure	5.3).	Vessels	of	both	RCC	and	CRC	strongly	stained	for	MCAM	and	LAMA4,	while	the	vessels	of	the	associated	healthy	kidney	and	colon	did	not	stain,	or	stained	only	weakly	at	equivalent	antibody	concentrations.	This	was	particularly	apparent	in	healthy	kidney	tissue	where	PECAM-1	was	strongly	stained	within	the	glomerulus,	a	highly	vascular	structure,	whereas	neither	MCAM	nor	LAMA4	staining	was	detected	in	glomeruli.	Immunohistochemical	staining	for	both	targets	was	absent	in	a	small	cohort	of	colorectal	liver	metastases	probed	(n=6,	data	not	shown).	
	
	
	
Figure	5.3.	Confirmation	of	cancer	specific	enrichment	of	MCAM	and	LAMA4	by	immunohistochemistry	(IHC).	Representative	images	of	kidney	(arrows	show	glomeruli),	RCC,	colon	and	CRC	stained	for	PECAM	(endothelial	marker),	MCAM	and	LAMA4,	scale	bar	=	50	μm.			
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In	order	to	identify	the	tissue	specific	expression	profile	of	MCAM	and	LAMA4,	10	samples	each	of	18	common	cancers	and	associated	healthy	tissues	were	stained	and	scored	for	strength	of	staining	(Figure	5.4).	Both	MCAM	and	LAMA4	demonstrated	markedly	specific	vascular	expression	profiles,	with	vessels	the	primary	source	of	staining	in	all	tissues	other	than	melanoma,	where	MCAM	expression	was	primarily	found	on	the	tumour	cells	(data	not	shown).	Of	note,	90%	of	kidney	tumours	showed	strong	vascular	staining	for	MCAM,	in	excess	of	any	healthy	tissue	and	most	cancerous	tissues	examined,	highlighting	MCAM	as	a	promising	vascular	target	in	RCC.	LAMA4	on	the	other	hand	was	shown	to	be	highly	expressed	in	a	broad	range	of	both	tumour	and	healthy	tissues	(Figure	5.4).	
	
	
	
Figure	5.4.	MCAM	expression	is	specifically	enriched	on	the	vasculature	of	renal	cancer.	A,	representative	images	of	MCAM	IHC	staining	on	renal	cell	carcinoma	demonstrative	of	scoring	used	for	analysis,	scale	bar	=	50	μm.	
None% Weak%
Moderate% Strong%
(i)% (ii)%
(iii)% (iv)%
A	
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Figure	5.4.	B,	multi-organ	tissue	and	cancer	array	analysis	of	MCAM	and	LAMA4	expression	by	IHC.	The	proportion	of	tissues	matching	or	exceeding	the	weak,	moderate	or	strong	staining	thresholds	is	shown.	
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5.2.3	MCAM	expression	is	induced	by	vascular	endothelial	growth	factor	(VEGF)	MCAM	expression	on	tumour	vessels	appears	to	be	highly	RCC	specific.	High	VEGF	expression,	due	to	the	loss	of	the	tumour	suppressor	Von-Hippel-Lindau	(VHL),	is	common	in	cases	of	clear	cell	RCC	(237)	as	previously	discussed.	In	order	to	investigate	whether	enhanced	VEGF	production	within	the	tumour	could	be	the	cause	of	high	MCAM	expression,	isolated	human	umbilical	cord	vein	endothelium	(HUVEC)	and	commercially	purchased	human	dermal	micro-vascular	endothelial	cells	(HDMEC)	were	exposed	to	recombinant	VEGF.	Six	HUVEC	isolates	and	two	multisource	HDMEC	isolates,	each	used	in	triplicate,	were	serum	starved	for	16	hours	and	then	cultured	with	or	without	100	ng/ml	recombinant	VEGF	for	24	hours,	before	being	harvested.	RTqPCR	and	western	blot	analysis	for	both	cell	types	showed	that	MCAM	was	significantly	up-regulated	by	VEGF	(Mann-Whitney	U	test,	p<0.01)	(Figure	5.5).			Clear	cell	RCC	alone	is	characteristic	for	high	VEGF	expression	and	all	the	RCC	tumours	in	the	multi-organ	expression	analysis	were	clear	cell.	In	order	to	investigate	whether	MCAM	expression	is	specific	for	ccRCC,	tissues	from	multiple	other	types	of	renal	malignancy	were	stained	by	IHC.	This	analysis	revealed	that	a	far	greater	proportion	of	clear	cell	tumours	(61%,	n=64)	stained	strongly	for	MCAM	than	transitional	cell	(47%,	n=15),	carcinoma	sarcomatodes	(33%,	n=6),	squamous	cell	(14%,	n=7)	or	papillary	cell	(13%,	n=8)	(Table	5.5).	This	result	supports	the	suggestion	that	VEGF	is	playing	a	part	in	enhancing	MCAM	expression	in	ccRCC.	Additionally	this	result	suggested	that	ccRCC	should	be	the	focus	of	investigation.		
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Figure	5.5.	VEGF	significantly	induces	MCAM	expression	in	endothelial	cells.	HUVEC	isolates	(n=6)	and	HDMEC	(n=6)	were	serum	and	growth	factor	starved	for	16	hours,	then	cultured	with	serum	depleted	media	±	100	ng/ml	recombinant	human	VEGF	(hVEGF),	MCAM	expression	was	determined	by	western	blot	and	RTqPCR.	Confidence	limits	±	SEM,	statistical	analysis:	Mann-Whitney	U	test,	**	p<0.01	for	both	western	blot	and	RTqPCR	analysis.	Western	blot:	MCAM	band	–	120	kDa,	tubulin	band	–	55	kDa.	
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Table	5.5.	Key	clinical	data	for	different	types	of	kidney	cancer	and	metastasis.	Characteristics Clear	cell Transitional	cell Papillary	cell Squamous	cell	 Sarcomatodes 
Tumours 64 15 8 7 6 Gender 	 	 	 	 	 Male 50 13 7 5 2 Female 14 2 1 2 4 Age 	 	 	 	 	 Above	60 29 11 0 2 2 Below	60 35 4 8 5 4 T-stage 	 	 	 	 	 No	information 30 0 0 0 1 T1 23 14 8 4 0 T2 8 1 0 2 4 T3 3 0 0 1 1 M-stage 	 	 	 	 	 M0 56 15 7 7 5 M1 8 0 1 0 1 MCAM	staining 	 	 	 	 	 Strong 39 7 1 1 2 Weak 25 8 7 6 4 
%	strong	staining 60.94 46.67 12.50 14.29 33.33 
	 	 	 	 	 	 
Metastasis 15 2 2 2 1 Gender 	 	 	 	 	 Male 13 0 2 2 1 Female 2 2 0 0 0 Age 	 	 	 	 	 Above	60 11 2 0 2 1 Below	60 4 0 2 0 0 Location 	 	 	 0 	 Adrenal	gland 3 0 0 0 0 Bone 1 0 0 0 0 Lymph	node 4 2 2 2 0 Lung 3 0 0 0 0 Thyroid 1 0 0 0 0 Intestine 1 0 0 0 0 Spleen 0 0 0 0 1 Retroperitoneum 2 0 0 0 0 MCAM	staining 	 	 	 	 	 Strong 11 0 2 1 0 Weak 4 2 0 1 1 
%	strong	staining 73.33 0.00 100.00 50.00 0.00 
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5.2.4	Identification	of	strong	MCAM	and	LAMA4	expression	as	potent	adverse	
prognostic	indicators	in	RCC	In	order	to	investigate	whether	the	strong	expression	of	MCAM	and	LAMA4	in	the	vessels	of	many	RCC	and	CRC	tumours	could	have	some	prognostic	value,	excised	tissue	from	cohorts	of	ccRCC	(n=81[cohort	1],	48	[cohort	2],	n=47	[cohort	3])	and	CRC	(n=90)	were	stained	by	IHC	for	each	marker	and	semi-quantitatively	scored.	Demographic	information	is	shown	for	each	cohort	in	Tables	5.6	(RCC	cohort	1),	5.7	(RCC	cohort	2),	5.8	(RCC	cohort	3)	and	5.9	(CRC	cohort).		For	effective	investigation	of	prognostic	linkage	to	marker	expression,	the	analytical	tools	must	be	sensitive	to	the	full	range	of	marker	expression	within	the	cohort.	As	the	multi-organ	tissue	array	staining	for	MCAM	resulted	in	90%	of	renal	cell	carcinoma	samples	staining	strongly,	the	antibody	concentration	was	titrated	down	from	0.6	to	0.3	μg/ml,	to	a	level	where	a	range	of	MCAM	staining	in	RCC	could	be	observed.	0.6	μg/ml	was	used	for	the	results	listed	in	Figures	5.3	and	5.4,	0.3	μg/ml	was	used	for	all	other	IHC	analyses.	Each	cohort	was	split	into	tumours	exhibiting	strong	or	weak	marker	staining,	as	judged	by	three	independent	scorers.	Thresholds	were	set	as	described	in	Figure	5.4	(weak	=	none/weak,	strong	=	moderate/strong).	Tumour	marker	staining	was	correlated	with	patient	survival	by	Kaplan-Meier	analysis	(Figure	5.6).	This	analysis	identified	a	significant	decrease	in	survival	in	patients	whose	tumours	exhibited	strong	MCAM	and	LAMA4	staining,	in	both	RCC	cohort	1	(log-ranks-p=0.001	&	0.0005	respectively)	and	cohort	2	(p=0.08	&	0.001	respectively)	(Figure	5.6).	In	patients	with	tumours	exhibiting	strong	staining	for	both	MCAM	and	LAMA4	together,	this	effect	was	more	pronounced,	with	only	18%	surviving	to	date,	versus	75%	in	tumours	that	were	
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not	strongly	stained	for	either	marker,	in	RCC	cohort	1	and	27%	vs.	81%	in	RCC	cohort	2	(p<0.0005,	both	cohorts)	(Figure	5.6).	In	the	CRC	cohort	there	was	no	significant	association	between	survival	and	strong	MCAM	(p=0.809)	or	LAMA4	(p=0.353)	expression	alone	or	when	co-expressed	(p=0.713)	(Figure	5.6).	This	suggests	that	MCAM	and	LAMA4	play	a	unique,	tumour-specific	role	in	ccRCC	patient	survival.		No	significant	survival	effect	was	observed	in	RCC	cohort	3,	with	the	exception	of	where	the	markers	were	co-expressed	(p=0.013).	RCC	cohorts	1	and	2	are	primarily	made	up	non-metastatic	tumours,	with	only	five	with	metastasis	across	the	two	cohorts	and	survival	to	last	check	up	is	64%	and	66%	respectively	(Tables	5.6	and	5.7).	These	types	of	cohort	are	ideal	for	looking	at	survival	effects,	as	the	potential	for	a	separation	in	survival	between	two	groups	is	great.	RCC	cohort	3	is	entirely	made	up	of	metastatic	tumours	and	survival	to	last	check	up	is	21%	(Table	5.8).	It	is	therefore	reasonable	to	suggest	that	a	single	marker	survival	effect	is	not	seen	as	too	few	patients	survive.	This	does	however,	suggest	that	prognostication	using	MCAM	and	LAMA4	marker	expression	will	find	its	greatest	utility	in	early-stage	disease.										
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Figure	5.6.	High	MCAM	and	LAMA4	tumour	vessel	expression	has	a	significant	detrimental	effect	on	the	survival	of	RCC	patients	but	not	CRC	patients.	Kaplan-Meier	survival	analysis	of	patients,	from	RCC	cohort	1,2	and	3	and	the	CRC	cohort,	with	strong	vs.	weak	staining	for	MCAM,	LAMA4	and	marker	co-expression.	Statistical	analysis:	Log-ranks	test,	p-values	and	n-numbers	for	each	test	are	shown.	Crosses	mark	censored	cases.		
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Table&5.6.!Key!clinical!data!for!clear!cell!RCC!cohort!1,!showing!overall!survival!(OS).!Characteristics N!of!patients Median!OS Mean!OS All 81 69.5 63.7 Gender ! ! ! Male 48 71 65.2 Female 33 68 61.6 Age ! ! ! Above!/=60 41 69 65.1 Below!60 40 70 62.3 Grade ! ! ! G1 30 72 64.3 G1R2 10 66 59.4 G2 26 71 64.2 G2R3 4 68 61.8 G3/4 11 70 67.5 Stage ! ! ! No!information 4 R R I 55 69.5 66.1 II 16 71 59.3 III 4 63.5 58.0 IV 2 69.5 69.5 TRstage ! ! ! No!information! 2 R R T1a 34 70 66.2 T1b 24 69 61.9 T2a 13 70 57.8 T2b 3 76 76.0 T3 5 68 62.0 MRstage ! ! ! M0 79 69.5 63.5 M1 2 69.5 69.5 MCAM!staining! ! ! ! Strong 34 71 67.2 Weak 47 69 61.4 LAMA4!staining ! ! ! Strong 30 72 66.0 Weak 51 69 61.8 MCAM!and!LAMA4!coRstaining ! ! ! Both!strong 16 69 62.3 Both!weak 33 68 56.5 MCAM!strong!LAMA4!weak 18 73.5 73.5 MCAM!weak!LAMA4!strong 14 74 69.7 !!!!!
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Table&5.7.!Key!clinical!data!for!clear!cell!RCC!cohort!2,!showing!overall!survival!(OS).!Characteristics N!of!patients Median!OS Mean!OS All 48 104 86.9 Gender ! ! ! Male 35 104 81.5 Female 13 110 101.5 Age ! ! ! Above!58 26 103.5 80.9 Below!58 22 104.5 94.04 TQstage ! ! ! T1a 9 108 97.3 T1b 12 102 86.8 T2a 7 105 96 T2b 3 115 83 T3a 15 97 80.8 T3b 1 101 101 T4 1 22 22 MQstage ! ! ! M0 45 104 86.7 M1 3 110 90.3 MCAM!staining ! ! ! High 21 97 77.6 Low 27 105 94.2 LAMA4!staining ! ! ! High 17 90 71.7 Low 31 105 96.1 MCAM!and!LAMA4!coQstaining ! ! ! MCAM!and!LAMA4!strong 11 65 64.7 MCAM!and!LAMA4!weak 21 105 98.1 MCAM!strong!LAMA4!weak 10 103.5 91.8 MCAM!weak!LAMA4!strong  6 107.5 80.3 !!!!!!!!!
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Table&5.8.!Key!clinical!data!for!clear!cell!RCC!cohort!3,!showing!overall!survival!(OS).!Characteristics! N!of!patients! Median!OS! Mean!OS!All! 47! 41.50! 48.02!Gender! !! !! !!Male! 37! 43.67! 53.18!Female! 10! 24.48! 28.97!Age! !! !! !!Above!60! 27! 67.82! 68.30!Below!60! 20! 56.37! 53.41!TQstage! !! !! !!No!information! 7! !! !!T1! 6! 61.83! 58.51!T2! 1! 127.47! 127.47!T3! 31! 29.60! 37.66!T4! 2! 32.77! 32.77!MQstage! !! !! !!M0! 0! !! !!M1! 16! 48.37! 59.37!M2! 18! 29.37! 39.24!M3! 13! 29.90! 41.51!MCAM!staining! !! !! !!High! 37! 33.87! 42.96!Low! 10! 59.68! 66.76!LAMA4!staining! !! !! !!High! 34! 38.32! 44.09!Low! 13! 49.97! 58.31!MCAM!and!LAMA4!coQstaining! !! !! !!MCAM!and!LAMA4!strong! 29! 29.90! 36.04!MCAM!and!LAMA4!weak! 5! 31.57! 42.71!MCAM!strong,!LAMA4!weak! 8! 80.95! 68.05!MCAM!weak,!LAMA4!strong! 5! 88.20! 90.81!!!!!!!!!!
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Table	5.9.	Key	clinical	data	for	the	CRC	cohort,	showing	overall	survival	(OS).	Characteristics N	of	patients Median	OS Mean	OS All 90 87.5 112.8 Gender 	 	 	 Male 65 86 107.2 Female 25 122 127.3 Age 	 	 	 Above	58 47 122 130.2 Below	58 43 67 93.8 Stage 	 	 	 I/II 44 157.5 148.5 III/IV 46 38 78.6 Tumour	location 	 	 	 Ascending	colon 21 27 63.5 Descending	colon 6 194 183 Sigmoid	colon 31 84 96.6 Transverse	colon 9 186 127.1 Cecum 4 102.5 109 Rectum 19 186 165.6 T-stage 	 	 	 T2 8 187.5 160.5 T3 75 86 105.5 T4 7 122 136.3 N-stage 	 	 	 N0 50 129.5 138.3 N1+ 40 33 80.1 M-stage 	 	 	 M0 75 116 126.3 M1 15 42 45.3 MCAM	staining	 	 	 	 Strong 42 86 108.6 Weak 48 89 115.6 LAMA4	staining 	 	 	 Strong 10 119 108 Weak 80 86 113.4 MCAM	and	LAMA4	co-staining 	 	 	 MCAM	and	LAMA4	strong 7 122 115.1 MCAM	and	LAMA4	weak 45 89 118.1 MCAM	strong	LAMA4	weak 35 85 108 MCAM	weak	LAMA4	strong 3 116 91.3 				
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Multivariate	cox-regression	analysis	on	the	largest	RCC	cohort,	cohort	1,	identified	MCAM	(p=0.006),	LAMA4	(p=0.007)	individually	and	in	combination	(p=0.002)	as	independent	risk	factors	for	reduced	survival	in	patients	with	tumours	exhibiting	strong	staining,	independent	of	gender,	age,	histopathological	tumour	grade	or	T-stage	(Table	5.10).	This	analysis	additionally	identified	a	considerably	greater	risk	of	death	in	patients	exhibiting	strong	MCAM	and	LAMA4	expression:	MCAM,	odds	ratio	3.4,	confidence	interval	1.4-8.1;	LAMA4,	OR	3.3,	CI	1.4-7.9;	Co-expression,	OR	4.1,	CI	1.7-10	(Table	5.10).	
	
	
Table	5.10.	Multivariate	analysis	(Cox	regression)	of	prognostic	markers	in	RCC	cohort	1	(n	=	81),	censored	cases	n	=	52	(64.2%).	p	<	0.05	are	in	bold.	
Prognostic	factor	 Relative	
Risk	Exp(B)	
95%	Confidence	
Interval	
P-value	
M	and	L	
P-value	
MCAM	
P-value	
LAMA4	
M	and	L	co-expression	(high	vs.	low)	 4.102	 1.690-9.954	 0.002	 		 		
MCAM	(high	vs.	low)	 3.402	 1.419-8.157	 		 0.006	 		
LAMA4	(high	vs.	low)	 3.297	 1.379-7.884	 		 		 0.007	
Sex	(female	vs.	male)	 0.624	 0.270-1.442	 0.27	 0.164	 0.835	
Age	(over	60	vs.	under	60)	 1.811	 0.780-3.862	 0.076	 0.058	 0.246	
Grade	(G2	and	above	vs.	G1)	 2.233	 0.881-5.660	 0.091	 0.319	 0.223	
T-stage	(T2	and	above	vs.	T1)	 2.363	 0.923-6.049	 0.073	 0.002	 0.041			
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5.2.5	MCAM	and	LAMA4	expression	is	enhanced	in	locally	invasive	and	metastatic	
disease	Metastatic	disease	is	the	area	of	most	therapeutic	need	for	renal	cell	carcinoma,	survival	is	lowest	and	there	is	the	greatest	need	for	new,	systemic	therapies.	A	tumour	vascular	target	would	ideally	have	utility	in	this	setting.	In	order	to	investigate	the	expression	of	MCAM	and	LAMA4	in	metastatic	disease,	tumours	from	ccRCC	cohorts	1,	2	and	3	were	grouped	based	on	their	metastatic	status.	This	revealed	that	the	proportion	of	metastatic	tumours	exhibiting	strong	marker	staining	is	significantly	greater	than	in	tumours	with	no	known	metastases	(76%	vs.	41%-MCAM,	68%	vs.	36%-LAMA4,	chi-squared-p<0.001)	(Figure	5.7A).	It	should	be	borne	in	mind	however,	that	the	majority	metastatic	tumours	are	from	one	cohort	and	non-metastatic	tumours	from	another	and	possible	differences	in	tissue	preparation	may	have	affected	the	result.	An	additional	analysis,	grouping	the	tumours	based	on	T-stage	found	that	both	markers	are	significantly	enriched	in	tumours	exhibiting	greater	local	invasion	(chi-squared-p<0.001)	(Figure	5.7B).	In	the	case	of	metastatic	disease	it	is	not	just	the	primary	tumour	that	must	be	treated,	but	also	the	metastases,	therefore	MCAM	staining	in	metastases	from	clear	cell	RCC	tumours	was	investigated	(Figure	5.7C).	This	analysis	revealed	that	73%	of	clear	cell	RCC	metastases	(n=15)	exhibit	strong	MCAM	staining	regardless	of	metastasis	location	(Table	5.5).	MCAM	expression	was	additionally	observed	in	metastases	from	papillary	and	squamous	cell	RCC,	however,	sample	number	(n=2,2)	was	too	low	to	make	any	significant	conclusions	(Table	5.5).	This	data	collectively	identifies	MCAM	and	LAMA4	as	markers	of	advanced	disease	and	MCAM	as	an	ideal	target	for	the	treatment	of	metastatic	renal	cell	carcinomas	of	the	clear	cell	type.	
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Figure	5.7.	MCAM	and	LAMA4	expression	is	enhanced	in	metastatic	and	locally	advanced	clear	cell	RCC.	A,	pie-chart	proportional	representation	of	strong	(black)	vs.	weak	(white)	marker	expression	in	metastatic	and	non-metastatic	RCC,	determined	by	IHC	on	RCC	cohorts	1,2	and	3.	Statistical	analysis:	Chi-squared,	***	p<0.001.	B,	pie-chart	proportional	representation	of	strong	(black)	vs.	weak	(white)	marker	expression	at	different	RCC	T-stages,	determined	by	IHC	on	RCC	cohorts	1,2	and	3.	Statistical	analysis:	Chi-squared,	***	p<0.001.	C,	representative	images	of	MCAM	staining	in	clear	cell	RCC	metastases	to	various	organs,	generated	by	IHC.	Scale	bar	=	50	μm.	
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5.2.6	Monoclonal	anti-MCAM	antibodies	specifically	localise	to	murine	RCC	
tumour	vessels	The	abundance	and	specificity	of	MCAM	expression	in	renal	tumours	opens	the	possibility	of	using	it	as	a	targeting	ligand	for	therapeutic	agents.	In	order	to	investigate	this	potential	utility,	the	localisation	of	a	monoclonal	rat	anti-MCAM	antibody	was	determined,	following	intravenous	injection	into	murine	renal	cell	carcinoma	(RENCA)	tumour	bearing	mice.		The	RENCA	model	was	chosen	as	the	tumours	have	previously	been	shown	to	express	VEGF	at	a	high	level	(160),	closely	modelling	the	majority	of	human	renal	cell	cancers.	Additionally	subcutaneous	RENCA	tumours	were	shown	to	strongly	express	MCAM	on	their	vessels	by	immunofluorescence	(Figure	5.8A),	identifying	it	as	an	ideal	model	for	use	in	this	situation.	Immunofluorescence	works	on	the	same	principle	as	immunohistochemistry,	with	the	exception	that	a	fluorophore,	rather	than	an	HRP-activated	chromogen,	is	used	to	mark	the	expression	of	the	target	protein,	which	is	quantified	by	fluorescence	microscopy.		An	hour	after	antibody	infusion,	the	mice	were	culled,	the	organs	harvested	and	then	processed	for	frozen	sectioning.	Tissues	from	the	RENCA	tumour,	stomach,	heart,	liver,	colon,	kidney,	skin	and	lung	from	two	mice	were	probed	for	PECAM-1	(vessels)	and	also	fluorescently	labelled	anti-Rat	IgGs,	to	detect	localised	anti-MCAM	antibodies.	In	order	to	quantify	the	fluorescence	emanating	from	localised	anti-MCAM	antibody	within	the	vessels	of	each	tissue,	images	were	taken	and	processed	in	Image	J.	A	mask	was	generated	to	select	only	the	vessels	within	the	tissue	as	a	region	of	interest,	using	the	green	(PECAM)	channel.	The	average	optical	density	of	the	red	(localised	anti-MCAM	antibody)	channel	was	then	quantified	within	this	region	of	interest.	This	
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analysis	demonstrated	an	at	least	25	fold	greater	localisation	of	antibody	in	the	vessels	of	the	RENCA	tumours	than	any	other	tissue	probed	(Figures	5.8B	and	C).	This	finding	suggests	that	renal	cell	carcinoma	therapies	could	potentially	use	anti-MCAM	antibodies	to	localise	therapeutics	to	the	tumour	vasculature	specifically,	permitting	a	functional	anticancer	effect.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	5.8.	A	monoclonal	anti-MCAM	antibody	specifically	localises	to	murine	RCC	tumour	vessels.	A,	triple	immunofluorescent	staining	of	a	murine	RCC	(RENCA)	tumour	for;	PECAM	(green),	MCAM	(red)	and	DAPI	(blue).	Scale	bar	=	25	μm.	B	&	C,	20	μg	of	MCAM	monoclonal	antibody	was	intravenously	injected	into	RENCA	tumour	bearing	mice	1	hour	prior	to	cull.	The	tumour	and	selected	organs	were	collected.	Frozen	sections	were	stained	with	anti-rat	IgGs	(red),	PECAM	(green)	and	DAPI	(blue).	B,	the	average	optical	density	of	fluorescence	detected	in	the	anti-rat	IgG	(red)	channel,	within	regions	of	vascular	(PECAM)	staining	was	quantified.	The	tissue	from	two	mice	was	assessed,	with	six	regions	of	interest	randomly	selected	for	each	organ	and	mice	(n=12),	confidence	limits	±	SEM.	C,	representative	images	of	MCAM	monoclonal	antibody	localisation.	Scale	bar	=	12.5	μm.	
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5.3	Discussion	
	The	aim	of	this	study	was	to	identify	vascular	markers	with	pan-tumour	expression	and	demonstrate	their	utility	as	specific	ligands	against	which	to	target	immunological	therapies.	This	study	identified	MCAM	and	LAMA4	as	promising	markers	with	specific	overexpression	in	endothelial	isolates	from	both	colorectal	and	renal	malignancies.	A	significant	link	between	high	expression	of	these	markers	and	poor	patient	survival,	invasive	local	disease	and	metastasis,	was	demonstrated	in	RCC,	but	not	CRC.	MCAM	expression	was	found	to	be	highly	enriched	in	the	vessels	of	clear	cell	RCC,	in	excess	of	other	tumour	and	healthy	tissues,	possibly	due	to	VEGF	induction	demonstrated	in	this	study.	This	data	highlighted	MCAM	as	a	potential	specific	target	in	renal	cell	carcinoma	and	this	utility	was	demonstrated	by	specific	localisation	of	MCAM	monoclonal	antibodies	to	the	tumour	vessels	in	a	model	of	RCC.		Our	comparative	analysis	of	vessels	derived	from	colorectal	carcinoma	(CRC),	colorectal	liver	metastasis	(CRM)	and	renal	cell	carcinoma	(RCC)	with	patient	matched	healthy	tissues,	identified	a	small	group	of	endothelial	genes	consistently	up-regulated	in	these	tumours.	Many	of	these	genes	are	stimulatory	to	angiogenesis	and	tumour	invasion,	such	as	LOX	(239),	MCAM	(240),	LAMA4	(241),	NRP1	(242),	MMP1	(243),	APLN	(244)	and	SPARC	(245)	suggesting	a	signature	characterised	by	active	angiogenesis.			
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One	of	the	most	consistent	pan-tumour	endothelial	markers	in	our	analysis	was	laminin	alpha	4	(LAMA4)	an	extracellular	matrix	glycoprotein	and	component	of	the	laminin	complex.	Laminins	are	made	up	of	three	chains,	alpha,	beta	and	gamma	and	have	been	implicated	in	a	wide	variety	of	cellular	processes	from	cell	attachment	and	differentiation,	to	influences	on	cell	shape	and	movement,	maintenance	of	tissue	phenotype,	and	promotion	of	tissue	survival	(246).	The	function	of	individual	laminin	chains	is	poorly	understood,	however,	LAMA4,	a	constituent	of	laminin-8,	9	and	14	(247),	has	been	shown	to	have	an	endothelial	specific	expression	pattern	and	also	to	promote	angiogenesis	(241).	LAMA4	has	been	shown	to	co-distribute	and	interact	with	integrins	αvβ3,	α3β1,	and	together	with	α6β1	mediate	endothelial	cell-LAMA4	interactions	and	blood	vessel	formation	(241).		The	exact	role	LAMA4	plays	in	cancer	is	unclear.	In	this	study	it	was	shown	to	be	strongly	up-regulated	on	tumour	blood	vessels	in	colorectal	and	renal	malignancies	when	compared	to	surrounding	non-malignant	tissue.	Its	tissue	distribution	appears	to	be	diverse	when	more	broadly	investigated	however,	appearing	in	both	healthy	and	tumour	tissues.	This	analysis	suggests	that	using	LAMA4	as	a	target	for	cancer	therapy	could	be	problematic.	This	study	did,	however,	demonstrate	a	highly	significant	link	between	LAMA4	expression	in	RCC	and	poor	patient	survival,	which	was	not	shared	in	CRC.	A	strong	association	between	LAMA4	expression	and	both	metastasis	and	local	invasion	was	also	shown.	LAMA4	has	previously	been	associated	with	increased	tumour	invasion	and	metastasis	in	hepatocellular	carcinoma	(248),	the	transition	from	premalignant	to	malignant	breast	carcinomas	and	reduced	relapse-free	survival	in	estrogen	receptor	negative	breast	cancer	patients	(249),	marking	LAMA4	as	a	useful	
	 152	
prognostic	marker	in	certain	cancers,	not	least	renal	cell	carcinoma.	A	recombinant	form	of	the	LAMA4	chain	containing	laminin-411	(laminin-8)	has	been	reported	to	have	an	anti-adhesive	effect	on	RCC	cells	grown	on	fibronectin	(250).	This	report,	combined	with	our	observations	suggests	a	potential	mechanism	in	which	heightened	vascular	LAMA4	might	impair	RCC	tumour	adhesion	and	thereby	increase	metastasis,	negatively	impacting	patient	survival.	The	functional	relevance	of	this	mechanism	warrants	further	investigation.		This	study	also	identified	MCAM	as	a	potent	vascular	marker	in	clear	cell	renal	cell	carcinoma.	The	role	of	MCAM	on	the	vascular	endothelium	is	poorly	understood,	but	it	is	thought	to	promote	angiogenesis	(240)	and	act	as	a	co-receptor	for	VEGFR-2,	thus	enhancing	endothelial	migration	and	micro-vessel	formation	(251).	Endothelial	conditional	knock	out	of	MCAM	in	mice,	results	in	impaired	vessel	formation	in	VEGF-dependent	angiogenesis	assays	(251).		MCAM	is	also	thought	to	play	a	role	in	cell-to-cell	junctions	and	vascular	permeability	(252).	Besides	this,	MCAM	over	expression	has	been	associated	with	pro-survival	signalling	including	protein	kinase	B	(PKB)	phosphorylation	and	down-regulation	of	BCL2-Associated	Agonist	Of	Cell	Death	(BAD)	expression	(253).	It	is	therefore	plausible	that	up-regulation	of	MCAM	in	tumor	vessels	could	act	as	a	survival	mechanism,	as	well	as	impacting	on	angiogenesis	and	vascular	integrity.			MCAM	was	first	identified	as	a	marker	on	the	carcinoma	cells	of	malignant	melanoma,	emerging	as	a	potential	prognostic	indicator	of	cancer	progression	(254).	MCAM	expression	has	also	been	reported	on	the	carcinoma	cells	of	prostate	(255),	breast	
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(256)	and	ovarian	cancer	(257),	suggesting	that	MCAM	could	be	a	widely	expressed	tumour	antigen.	However,	in	this	study,	MCAM	expression	was	only	occasionally	observed	on	the	tumour	cells	of	tissue	examined,	with	MCAM	expression	being	almost	exclusively	reserved	to	tumour	vessels	in	all	malignancies	aside	from	melanoma,	calling	into	question	the	relative	importance	of	tumour	and	endothelial	cell	MCAM	expression	in	these	malignancies.		A	significant	association	was	demonstrated	in	this	study,	between	high	vascular	MCAM	expression	and	poor	RCC	patient	survival,	increased	metastasis	and	increased	local	invasion.	Heightened	MCAM	mRNA	expression	has	previously	been	reported	in	bulk	tumour	tissue	from	patients	with	RCC,	with	the	highest	levels	observed	in	metastatic	disease,	indicating	a	direct	correlation	between	increasing	MCAM	expression	and	disease	progression	(258),	partially	corroborating	our	observations.	We	further	this	finding	by	highlighting	vascular	MCAM	as	key	to	this	process	and	demonstrating	a	direct	survival	impact.	High	MCAM	expression	has	additionally	been	associated	with	poor	survival	in	patients	with	non-small	cell	lung	adenocarcinoma	(but	not	squamous	cell	carcinoma)	(259).	This	data	highlights	MCAM	as	an	important	prognostic	marker	in	cancer,	in	particular	ccRCC,	where	co-expression	with	its	recently	identified	extracellular	ligand	LAMA4	(238),	was	shown	to	be	highly	predictive	of	very	poor	patient	survival.	This	observation	suggests	that	the	expression	and	interaction	of	MCAM	and	LAMA4	could	be	highly	significant	in	RCC	progression	and	should	be	further	investigated.	MCAM	interaction	with	the	LAMA4	containing	laminin-9	complex	has	been	shown	to	promote	migration	of	tumour	cells	when	associated	with	α6β1	integrin	
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(260),	but	the	importance	of	this	interaction	for	endothelial	cell	or	cancer	biology	is	unknown.		Multi-tissue	analysis	identified	MCAM	as	highly	specific	to	RCC	in	its	expression.	Whilst	it	is	present	in	other	tissues,	its	expression	in	ccRCC	vessels	is	greatly	in	excess.	This	study	identified	VEGF-mediated	induction	of	MCAM	in	endothelial	cells	as	a	potential	explanation	for	this.	This	is	the	first	study	to	demonstrate	that	VEGF,	a	growth	factor	highly	expressed	in	ccRCC	(237),	will	induce	MCAM	expression	in	endothelial	cells.	The	regulation	of	MCAM	on	vessels	is	poorly	understood.	The	expression	of	MCAM	in	HUVEC	was	found	to	be	up-regulated	by	culture	with	media	conditioned	with	a	hepatoma	cell	line	(240),	however,	the	exact	mechanism	was	not	determined.	Tumour	necrosis	factor	has	been	reported	to	induce	the	formation	of	a	soluble	form	of	MCAM	in	various	cell	types	including	endothelium	(261,262).	Of	note,	insulin-like	growth	factor-binding	protein	4	(IGFBP-4)	has	been	reported	to	induce	MCAM	in	renal	cell	carcinoma.	IGFBP-4	transfected	renal	tumour	cells	were	found	to	exhibit	enhanced	cell	growth,	invasion	and	motility,	as	well	as	enhancing	MCAM	expression	(263).	However,	as	has	been	discussed,	in	this	study	MCAM	expression	was	primarily	observed	on	tumour	vasculature,	with	no	discernable	RCC	tumour	cell	expression,	so	the	significance	of	IGFBP-4	induced	MCAM	expression	on	RCC	tumour	cells	in	human	cancer,	is	unclear.		Non-metastatic	renal	tumours	are	primarily	treated	by	nephrectomy	and	whilst	tumour	vascular	targeting	could	be	of	use	in	this	setting,	as	adjuvant	therapy	to	downsize	the	tumour	prior	to	removal,	or	as	a	post-operative	maintenance	therapy,	this	approach	is	likely	to	have	most	therapeutic	impact	in	the	metastatic	setting		
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The	finding	that	MCAM,	a	cell	surface	glycoprotein,	was	highly	specific	to	RCC	vessels	and	expressed	at	its	highest	level	in	the	metastatic	setting,	an	area	of	great	therapeutic	need,	marked	it	out	as	an	ideal	target	for	anti-cancer	immunological	therapies.	This	study	demonstrates	this	utility	by	showing	that	a	monoclonal	anti-MCAM	antibody	will	specifically	localise	to	the	vessels	of	a	murine	model	of	RCC,	accumulating	in	the	tumour	at	at	least	25	fold	greater	density.	This	constitutes	a	striking	level	of	antibody	specificity	to	cancer,	in	excess	of	other	successful	tumour	localisation	studies	(91,261).	It	should	be	noted,	however,	that	no	control	antibody	was	used	in	this	investigation.	It	is	therefore	possible	that	the	specificity	of	the	anti-MCAM	antibody	was	not	exclusively	the	result	of	the	differential	expression	of	MCAM	in	the	tumour	vs.	healthy	tissue	sites,	but	was	instead	mediated	by	tumour	exclusive,	non-specific	binding,	or	by	environmental	factors,	such	as	poor	drainage	within	the	tumour,	leading	to	the	accumulation	of	the	antibody	in	this	site.	The	use	of	an	isotype	control	would	determine	whether	this	was	the	case	and	therefore	this	form	of	control	should	be	used	in	any	further	validation	of	this	approach	in	the	future.		A	number	of	successes	in	anti-cancer	cell	targeting	using	antibodies	have	been	achieved	including	FDA	approved	ADCs	brentuximab	vedotin	in	Hodgkins	lymphoma	(264)	and	trastuzumab	emtansine	in	breast	cancer	(265).	However,	as	mentioned	in	the	main	introduction	the	targeting	of	tumour	blood	vessels	does	offer	a	number	of	advantages;	the	blood	vessels	are	easily	accessible	for	ligand	targeting;	up	to	100	tumour	cells	are	dependent	on	a	single	endothelial	cell	(3)	for	survival,	making	the	vessels	an	extremely	efficient	target;	the	vasculature	is	thought	to	be	more	genetically	stable	and	so	more	homogenous	in	terms	of	marker	expression	(7)	and	finally	therapeutics	disrupting	the	vessels	have	been	shown	to	cause	preferential	lysis	in	the	core	of	large	tumour	(266),	a	
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region	poorly	treated	by	antiangiogenics	and	traditional	chemotherapeutics	(44).	This	study	therefore	identifies	and	validates	MCAM	as	a	new	ligand	with	which	to	specifically	target	therapeutics	against	renal	cell	carcinoma	vessels,	potentially	improving	treatment	of	this	malignancy.	
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Chapter	Six	
	
	
	
	
An	In	Vivo	Breast	Cancer	Model	of	
Sunitinib	Resistance	
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6.1	Introduction	
	Breast	cancer	is	the	leading	cause	of	cancer	in	women,	accounting	for	a	quarter	of	cases	(267).	Survival	in	the	developed	world	is	generally	good	with	80-90%	survival	to	5	years	(267),	although	survival	is	highly	dependent	on	the	type	and	stage	of	disease.	Stage	1,	2	and	3	cancers	have	reasonably	good	prognosis,	being	primarily	treated	with	a	combination	of	surgery,	chemotherapy,	radiation	and	targeted	therapy,	however,	the	situation	changes	drastically	with	stage	4,	metastatic	cancer.	Stage	4	cancer	is	treated	with	a	similar	combination	of	therapies,	however,	surgery	is	often	not	curative	and	other	treatments	focus	on	tumour	maintenance	rather	than	cure.	In	this	setting	10-year	survival	is	between	5-10%	depending	on	the	effectiveness	of	therapy	(202).		One	of	the	major	factors	governing	treatment	efficacy	is	the	cancer	marker	expression	profile.	80%	of	breast	tumours	are	highly	dependent	on	estrogen	and/or	progesterone	for	their	survival	and	can	be	well-managed	using	hormone	blocking	therapies.	These	inhibit	the	progesterone	and	estrogen	receptors	(tamoxifen)	or	block	the	production	of	the	hormones	(anastrozole	/	letrozole)	(268,269).	25-30%	of	breast	cancers	overexpress	the	human	epidermal	growth	factor	receptor	2	(HER2)	and	can	be	targeted	with	a	HER2	monoclonal	blocking	antibody	therapy	(trastuzumab)	(270).	This	therapy	very	effectively	prevents	growth	factor	activation	of	the	HER2	receptor	inhibiting	cancer	growth,	leading	to	an	overall	survival	in	this	cohort	of	over	95%	(270).	However,	there	is	a	small	cohort	(~14%)	negative	for	both	hormone	receptors	and	HER2,	which	are	far	harder	to	treat	(271).	It	is	triple	negative	breast	cancers	(TNBC),	particularly	in	
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the	metastatic	setting,	where	there	is	most	interest	in	the	use	of	anti-angiogenic	therapies.		Sunitinib	malate	is	a	multi-target	oral	tyrosine	kinase	receptor	(RTK)	inhibitor	(Table	6.1)	(272).	Among	its	targets	are	the	pro-angiogenic	platelet	derived	growth	factor	receptors	alpha	and	beta	as	well	as	the	vascular	endothelial	growth	factor	receptors	on	endothelial	cells.	It	additionally	inhibits	the	tumourgenic	KIT	receptor,	colony	stimulating	factor	type	1	receptor	(CSF-1R),	glial	cell	line	neutrophic	factor	receptor	(RET)	and	fms-like	tyrosine	kinase	receptor-3	(FLT-3)	on	tumour	cells	(Table	6.1).	The	therapy	therefore	targets	both	the	tumour	and	vascular	compartments.		
Table	6.1.	IC50	values	for	sunitinib	inhibition	of	receptor	tyrosine	kinases	(272).		
Kinase	 Sunitinib	drug	IC50	(nM)	VEGFR1	 15	±	1	VEGFR2	 38	±	11	VEGFR3	 30	±	6	PDGFRα	 69	±	15	PDGFRβ	 55	±	1	CSF-1R	 35	±	6	Flt-3	 21	±	5	Kit	 1-10	Ret	 224	FGF-R1	 675	±	69	Src	 1000	Abl	 610	CDK1	 2600			Initial	phase	II	clinical	trial	results,	for	the	use	of	sunitinib	as	a	monotherapy	to	treat	metastatic	breast	cancer,	were	encouraging	(152,273).	However,	subsequent	phase	II	and	III	clinical	trials	in	both	the	metastatic	and	triple	negative	setting	have	not	achieved	their	objectives	of	prolonged	survival	compared	with	standard-of-care	(274,275),	
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although	some	efficacy	has	been	reported	in	combination	with	docetaxel	(276).		This	has	lead	Pfizer	to	discontinue	multiple	clinical	trials	involving	sunitinib	in	breast	cancer.	Efforts	continue	however,	to	broaden	its	use	into	breast	cancer	therapy,	in	combination	with	crizotinib,	in	clinical	trials	(Information	retrieved	from:	http://clinicaltrials.gov	and	http://www.cancer.gov		[accessed:	18.8.2015]).		A	weakly	responsive	tumour	type	appeared	the	ideal	model	with	which	to	investigate	sunitinib	drug	resistance,	as	it	should	rapidly	display	resistant	activity.	Sunitinib	resistance	in	breast	cancer	has	not	been	extensively	investigated,	although	intrinsic	resistance	to	devascularisation	and	enhancement	of	lung	tumour	cell	seeding	has	been	reported	(174).	The	4T1	tumour	is	a	murine	stage	4	(metastatic)	breast	cancer,	that	faithfully	models	the	pattern	of	human	metastasis	(186).	It	represents	a	major	target	of	interest	for	sunitinib	treatment,	metastatic	breast	cancer,	and	was	therefore	selected	for	this	investigation.	Triple	negative	tumours	have	been	generated	from	4T1	cells	by	cell	selection	(277),	although	the	strain	used	for	this	investigation	was	not	from	this	background.	This	study	did	however,	suggest	that	4T1	tumour	cells	are	heterogeneous	in	their	marker	expression,	with	a	considerable	population	of	triple	negative	cells	(277),	modelling	the	initial	stages	of	TNBC	encountered	in	the	clinic.	The	4T1	tumour	was	derived	from	Balb/c	mice	allowing	a	syngeneic,	immuno-competent	model	of	breast	cancer	to	be	generated	that	can	be	inoculated	orthotopically	into	the	mammary	fat	pad,	providing	a	faithful	model	of	metastatic	breast	cancer.	In	this	model	the	full	range	of	resistance	mechanisms	can	be	investigated.	In	this	chapter	the	effects	sunitinib	has	on	metastasis	and	tumour	vascular	patterning	are	reported.				
	 161	
6.2	Results	
	
6.2.1	Production	of	4T1-luc	cells	In	order	to	generate	a	tumour	cell	line	that	permits	bioluminescent	imaging	and	quantification	of	tumour	growth	and	metastasis,	4T1	cells	were	virally	transduced	to	express	the	firefly	luciferase	gene.	The	MSCV-puro-luc	plasmid	was	used	for	this	purpose	(Figure	6.1).	When	introduced	into	a	cell,	this	plasmid	leads	to	the	expression	of	both	the	luciferase	and	puromycin	resistance	genes.		
	
Figure	6.1.	Map	of	the	of	the	MSCVpuro	plasmid	used	for	retroviral	transduction	of	the	luciferase	gene	into	4T1	cells.	The	luciferase	gene	is	inserted	between	the	EcoRI	and	XhoI	restriction	sites.	Image	reproduced	with	permission	(www.snapgene.com/resources).				
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Puromycin	is	an	antibiotic	that	inhibits	protein	synthesis	and	is	therefore	toxic	to	many	cells,	including	mammalian.	Puromycin	resistance	was	therefore	used	as	a	selectable	marker	for	cells	with	successful	transduction	of	the	plasmid.	The	inherent	puromycin	tolerance	of	the	4T1	cells	was	determined	by	culturing	them	with	between	0.16	and	20	μg/ml	puromycin	and	then	assessing	cell	viability	after	72	hours,	using	the	MTS	assay.	In	this	assay	MTS,	a	yellow	tetrazole,	is	added	to	the	cells.	Viable,	metabolically	active,	cells	reduce	this	compound	to	purple	formazan,	which	has	an	absorbance	maximum	of	490	nm.	By	determining	the	absorbance	of	the	solution	at	490	nm	after	4	hours	of	incubation,	relative	cell	viability	can	be	quantified.	In	this	way	it	was	determined	that	between	2	and	10	μg/ml	puromycin	would	be	suitable	for	selection	(Figure	6.2A).		The	MSCV-puro-luc	plasmid	was	packaged	by	Phoenix-Ampho	cells	into	retroviral	particles,	which	were	released	into	cultured	media	over	time.	This	media	was	then	supplemented	with	polybrene,	to	promote	viral	uptake,	and	introduced	to	4T1	cells.	The	cells	were	centrifuged	in	a	plate	spinner	with	the	viral	media	for	1	hour,	before	being	washed	and	new	media	applied,	containing	between	2	and	10	μg/ml	puromycin.	Cells	were	selected	for	48	hours	after	which	cell	viability	was	determined	by	assessment	under	the	microscope	(Figure	6.2B).	It	was	found	that	transduced	cells	treated	with	2-8	μg/ml	puromycin	had	good	viability	whilst	untranduced	cells	cultured	with	2	μg/ml	were	almost	entirely	dead.	Transduced	4T1	cells	were	cultured	with	puromycin	for	2	further	passages,	after	which	the	luminosity	of	the	cells	was	determined	by	bioluminescent	imaging	with	the	CCD	camera	of	the	IVIS	machine	(Figure	6.2C	and	D).	D-luciferin	was	introduced	to	the	cells.	The	luciferase	enzyme	produced	by	the	cells	catalyses	the	reaction	converting	this	substrate	to	L-luciferin,	
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releasing	a	photon	of	light.	By	this	method	it	was	determined	that	cells	selected	with	8	μg/ml	puromycin	were	brightest,	with	over	275	fold	greater	luminosity	than	blank	4T1	cells	(Figure	6.2D)	and	were	therefore	expanded	over	2	passages	and	frozen	down	for	murine	tumour	inoculation.							
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Figure	6.2.	Retroviral	transduction	of	the	MSCV-puro-luc	plasmid	into	4T1	cells	and	puromycin	selection.	A,	4T1	cells	were	treated	with	0.16-20	μg/ml	puromycin	and	subjected	to	the	MTS	cell	viability	assay.	Absorbance	of	the	resultant	solution,	from	cells	treated	with	each	concentration	of	puromycin	is	shown	(mean	±SEM).	4T1	cells	were	transduced	with	the	MSCV-puro-luc	plasmid	and	selected	with	8	μg/ml	puromycin.	Images	showing	the	apparent	cell	viability,	B,	and	bioluminoscity,	C,	of	transduced	versus	untransduced	cells	are	provided.	D,	quantitation	of	bioluminescence	in	transduced	and	untransduced	4T1	cells	under	selection	with	0-8	μg/ml	puromycin.	
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6.2.2	4T1	tumour	growth	under	sunitinib	treatment	4T1-luc	cells	were	revived	from	liquid	nitrogen	storage	and	grown	for	2	days.	2.5	×105	4T1-luc	cells	were	injected,	in	optimem,	into	the	3rd	mammary	fat	pad	of	female	Balb/c	mice.	The	tumours	were	grown	for	7	days	prior	to	the	commencement	of	treatment	with	40	mg/kg	sunitinib,	or	vehicle	only	control.	Once	tumours	reached	1300	mm3	in	size,	mice	were	culled	and	tumour	collected	(Figure	6.3).			
	
Figure	6.3.	Experimental	set	up	for	sunitinib	drug	trial.	2.5	×	105	4T1	cells	were	injected	into	the	third	mammary	fat	pad	of	female	Balb/C	mice.	The	tumours	were	grown	for	1	week,	prior	to	drug	treatment.	Tumours	were	measured	daily	by	calipers	for	the	period	of	the	experiment,	then	culled,	with	selected	organs	subjected	to	ex	vivo	imaging.				Daily	caliper	measurements	were	performed	to	track	the	development	of	these	tumours	over	time.	This	analysis	revealed	that	whilst	untreated	tumours	grew	at	a	fairly	linear	rate	throughout	the	experiment,	sunitinib	treated	tumours	appeared	to	fall	
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into	two	groups.	Some	showed	no	response	to	sunitinib	treatment	and	shared	a	similar	growth	profile	with	the	untreated	tumours.	These	were	classified	as	non-responsive,	whilst	others	appeared	to	have	retarded	growth	for	the	first	9	days,	after	which	the	tumours	started	to	grow	at	a	similar	rate	to	the	other	two	groups	(Figure	6.4A).	In	order	to	determine	whether	these	two	treated	groups	could	be	considered	distinct,	the	distribution	of	tumour	sizes	at	day	8,	the	point	of	greatest	disparity	between	responsive	and	non-responsive	tumour	growth,	was	investigated	for	this	and	subsequent	experiments	(Figure	6.4B).	This	analysis	revealed	that	whilst	the	untreated	tumours	appeared	to	follow	a	close	to	normal	distribution,	the	treated	group	had	two	populations,	one	considerably	smaller	than	the	vast	majority	of	untreated	tumours	(responsive)	and	the	other	with	similar	tumour	size	and	distribution	to	the	untreated	group	(non-responsive).	The	best	point	of	distinction	between	the	two	groups	appeared	to	be	whether	they	were	larger	or	smaller	than	250	mm3	at	day	8,	therefore	this	cut-off	point	was	selected.	Of	note,	the	term	“responsive”,	used	here	and	later	in	the	manuscript,	refers	to	the	cohort	from	which	the	tumour	is	derived,	based	on	its	growth	pattern,	not	its	current	resistance	status.	Therefore	“responsive”	tumours	collected	at	1300	mm3	display	sunitinib	resistant	behavior,	but	only	after	an	initial	sensitive	phase.				Broadly	this	experiment	generated	3	cohorts	of	tumours,	(i)	naïve/	untreated,	(ii)	those	that	show	no	response	to	sunitinib,	modelling	innate	resistance	and	(iii)	those	that	after	an	initial	sensitive	period	become	resistant	to	sunitinib	growth	inhibition,	mirroring	the	response	pattern	of	acquired	or	adaptive	resistance,	encountered	in	the	clinic.			
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Figure	6.4.	Sunitinib	therapy	bisects	the	treated	group	into	responsive	and	non-responsive	cohorts.	A,	Tumour	growth	curves	from	the	initial	sunitinib	drug	trials,	with	endpoint	set	at	1300	mm3.	Measurements	begin	one	week	after	tumour	inoculation	and	on	the	day	sunitinib	treatment	began.	Subsequent	experimental	endpoints	were	set	based	on	these	growth	curves	and	there	intersections	with	this	data	are	shown.	B,	histogram	plot	showing	the	distribution	of	tumour	sizes	at	day	8	of	treatment.	Sunitinib	treated	tumours	exceeding	250	mm3	in	size	were	identified	as	falling	into	the	non-responsive	cohort.	
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In	order	to	investigate	the	process	of	resistance	further,	it	was	decided	to	harvest	tumours	at	key	time	and	size	points	for	further	analysis.	The	tumours	of	a	cohort	of	15	treated	and	15	untreated	mice	were	collected	at	day	9	(the	end	of	the	treatment	sensitive	period	in	the	responsive	group)	(Figure	6.5A)	and	at	600	mm3	(a	size	point	at	which	all	initially	responsive	tumours	are	growing	at	the	same	rate	as	their	untreated	counterparts	(Figure	6.5B).	Of	note,	in	each	experiment	there	was	a	roughly	60-40%	split	between	responsive	to	non-responsive	tumours	and	by	log-ranks	statistical	analysis	it	was	determined	that	sunitinib	treatment	had	a	significant	effect	on	the	time	it	took	responsive	tumours	to	grow	to	both	600	mm3	and	1300mm3,	versus	non-responsive	or	untreated	tumours,	confirming	that	sunitinib	has	a	significant,	if	transient,	effect	on	tumour	growth,	restricted	to	the	responsive	group	(Figures	6.5B	and	C).															
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Figure	6.5.	Sunitinib	treatment	significantly	retards	growth	of	responsive	tumours.	A,	growth	curves	for	tumours	grown	to	the	day	9	endpoint	(mean	±	SEM).	B	&	C,	Kaplan-Meier	comparative	analysis	of	time	to	endpoint	of	tumours	grown	to	600	mm3	and	1300	mm3.	Log	ranks	statistical	analysis	of	significant	results	is	shown.			
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6.2.3	Differential	sunitinib	mediated	effects	on	tumour	vascular	patterning		Tumours	collected	at	either	day	9,	600	mm3	or	1300	mm3	in	size	where	assessed	both	macro-	and	microscopically	for	effects	of	sunitinib	treatment	on	vascular	patterning	(Figure	6.6).	This	assessment	revealed	distinct	patterns	of	vascularisation	in	each	cohort.	Untreated	tumours	appeared	macroscopically	well	vascularised	throughout	the	experiment	(Figure	6.6A)	and	showed	modest	increases	in	vascularity	(%	of	microscopic	tumour	area	PECAM-1	positive)	(Figure	6.6B).	Responsive	sunitinib	treated	tumours	appeared	macroscopically	avascular	at	day	9,	by	600mm3	they	had	an	apparent	avascular	core,	possibly	derived	from	growth	up	to	day	9,	around	which	was	a	crest	of	greater	vascularity	(post	day	9	growth)	which	by	1300	mm3	had	encompassed	the	entire	outside	of	the	tumour.	Of	note	the	yellow	hue	clearly	observable	on	all	responsive	day	9	tumours,	which	was	presumably	derived	from	the	accumulation	of	sunitinib	in	the	tumours,	due	to	the	drug	being	yellow	in	colour,	had	disappeared	by	600	mm3	in	the	majority	of	cases	(all	but	one,	data	not	shown),	suggesting	that	the	drug	had	been	removed	by	some	process	or	could	not	gain	entry	to	the	core	of	the	tumour	at	this	time	point,	contributing	to	drug	resistance	(Figure	6.6A).	Possibly	due	to	the	maintenance	of	an	avascular	core,	average	microscopic	vascular	density	in	the	responsive	group	was	consistently	less	than	the	untreated	group	(Figure	6.6B).	Intriguingly	the	non-responsive	cohort	appeared	to	split	into	two	groups,	one	macroscopically	resembling	the	responsive	group	(day	9	n=3,	600	mm3	n=2,	1300	mm3	n=?)	and	another	macroscopically	resembling	the	untreated	group	(day	9	n=3,	600	mm3	n=4,	1300	mm3	n=?).	This	hinted	at	a	possible	further	subdivision	of	cohorts,	in	that	some	non-responsive	tumours	did	not	respond	to	sunitinib	at	all	and	appeared	to	be	untreated,	whilst	others	showed	signs	of	sunitinib	induced	vascular	inhibition,	but	
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continued	to	grow	regardless,	possibly	due	to	support	from	their	surrounding	environment	(Figure	6.6A).	Microscopic	assessment	of	vascular	density	suggested	that	non-responsive	tumours	had	an	intermediate	level	of	vascularity,	between	the	responsive	and	untreated	groups,	possibly	due	to	the	pooling	of	data	from	the	two	non-responsive	groups	(Figure	6.6B).	This	subdivision	of	the	non-responsive	cohort,	based	on	macroscopic	appearance,	was	not	taken	forward	for	further	investigation,	firstly	because	it	would	have	resulted	in	the	n-numbers	of	an	already	small	cohort	being	further	diminished,	and	secondly	because	based	on	macroscopic	assessment	alone	it	was	impossible	to	divide	the	1300	mm3	tumours	as	they	all	bear	roughly	the	same	appearance.	In	a	larger	investigation	it	may	be	possible	to	reliably	subdivide	these	groups	by	microscopic	assessment	of	vascular	patterning.	Assessment	of	the	comparative	level	of	vascularity	found	in	the	outer	and	core	regions	of	600	mm3	tumours	supported	observations	made	on	the	macroscopic	level,	in	that	untreated	tumours	have	a	consistent	level	of	vascularity,	responsive	tumours	have	a	clear	reduction	of	vascularity	in	the	core	of	the	tumour	with	non-responsive	tumours	resembling	either	one	or	the	other	of	these	groups	(Figure	6.6C).	By	this	method	it	may	be	possible	in	the	future	to	divide	the	groups	reliably	at	each	time	and	size	point	for	further	investigation	of	the	different	mechanisms	behind	innate	resistance.			
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Figure	6.6.	Sunitinib	treatment	reduces	vascularity	and	impacts	the	vascular	patterning	of	4T1	tumours.	A,	representative	images	of	tumours	from	each	cohort	and	experimental	endpoint,	showing	macroscopic	vascular	patterning,	not	to	scale.	B,	bar	chart	of	vascular	density	of	tumours	from	each	cohort	and	experimental	endpoint,	determined	by	the	average	percentage	of	PECAM-1	immunofluorescent	staining	across	5-6	fields	of	view	(mean	±	SEM,	Mann-Whitney,	**	p<0.01,	*	p<0.05,	n-numbers	as	displayed	in	Figure	6.5).	C,	representative	images	of	immunofluorescent	PECAM-1	staining	in	the	core	and	outer	regions	of	tumours,	from	each	cohort	of	tumours	taken	at	600	mm3.	Scale	bar	=	50	μm.	
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6.2.4	Sunitinib	enhances	metastasis	in	innately	resistant	tumours	Anti-angiogenic	drugs	have	been	reported	to	enhance	tumour	metastasis	in	certain	circumstances	(149).	The	utility	of	ex	vivo	bioluminescent	imaging	of	resected	organs	for	signs	of	metastasis	was	investigated	as	a	reliable	method	for	quantifying	metastasis.	Key	sites	of	4T1	metastasis	(the	liver,	lungs	and	spleen)	were	probed	by	both	ex	vivo	bioluminescent	imaging	and	H&E	staining	(Figure	6.7A	and	B).	For	details	of	both	approaches	see	sections	2.7.3	to	2.7.5).	The	apparent	metastatic	burden,	from	10	mice	where	tumours	had	been	harvested	at	1300	mm3,	was	quantified	by	each	method	and	correlated.	There	was	a	good	level	of	correlation	of	metastatic	burden	between	the	two	approaches	on	a	individual	organ	level,	although	it	must	be	noted	that	this	correlation	was	not	shared	between	organs	(Figure	6.7C).	The	ratio	of	apparent	metastasis	quantified	in	the	direct,	but	time	consuming,	H&E	manner	and	the	indirect,	but	rapid,	bioluminescent	manner,	varies	between	organs,	likely	due	to	differences	in	the	size,	density	and	absorbance	of	the	tissues.	As	bioluminescent	imaging	appeared	to	provide	metastasis	quantification	consistent	with	more	conventional	pathological	staining	methods,	but	in	a	fraction	of	the	time,	it	was	selected	as	the	method	by	which	the	metastatic	burden	of	the	mice	of	each	treatment/response	cohort	was	quantified	and	compared.						
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Figure	6.7.	Ex	vivo	bioluminescent	imaging	and	H&E	staining	correlate	as	methods	to	determine	metastatic	tumour	burden.	A,	representative	image	of	liver,	spleen	and	lung	whole	organs	undergoing	bioluminescent	imaging	by	the	IVIS	(overlay	of	blue-green-red	colouring	represents	bioluminescence	of	increasing	intensity.	B,	representative	images	of	H&E	staining	of	4T1	tumour	and	metastasis	in	spleen,	lungs	and	liver	(metastasis	marked	by	white	arrows).	Scale	bar	=	100	μm.	C,	correlation	between	metastatic	burden,	as	determined	by	measurement	of	average	metastatic	area	across	6	fields	of	view,	in	organs	stained	by	H&E	and	by	whole	organ	bioluminescent	pixel	density,	in	spleen,	liver	and	lung	tissues	(mean	±	SEM,	n=10).	
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This	analysis	revealed	that	the	liver	and	lungs	of	mice	with	non-responsive	primary	tumours	developed	a	significantly	greater	metastatic	burden,	compared	to	those	of	both	responsive	and	untreated	cohorts	at	1300	mm3,	whereas	in	the	spleen,	the	untreated	cohort	developed	the	greatest	metastatic	burden	(Figure	6.8).	Of	note	this	shift	is	only	observed	at	the	later	time-point.	At	day	9,	metastasis	from	untreated	tumours	is	greater	than	either	treated	group.	This	suggests	that	sunitinib	initially	inhibited	metastasis,	possibly	by	blocking	the	development	of	vasculature	and	lymphatics,	however,	in	the	non-responsive	group	this	inhibition	was	not	only	overcome,	but	reversed	(Figure	6.8).												
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Figure	6.8.	Sunitinib	treatment	enhances	4T1	tumour	metastasis,	but	only	in	the	innately	resistant	setting.	Distribution	plots	of	bioluminescence	from	each	organ,	cohort	and	experimental	endpoint.	The	level	of	background	auto-fluorescence	measured	by	imaging	of	organs	from	mice	with	no	tumour	is	also	displayed.	Statistical	analysis:	Mann-Whitney,	***	p<0.001,	*	p<0.05.	N-numbers:	Day	9,	responsive	(R)=5,	non-responsive	(NR)=5,	untreated	(UT)=10;	600mm3,	R=4,	NR=6,	UT=10;	1300mm3,	R=12,	NR=7,	UT=17.	
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6.3	Discussion	
4T1	tumour	cells	engineered	to	express	luciferase	were	used	to	set	up	a	model	of	breast	cancer	tumour	growth	and	metastasis.	The	effect	daily	sunitinib	treatment	had	on	these	tumours	was	investigated.	This	study	identified	4T1	tumours	responding	to	treatment	in	3	distinct	manners.	One	group	were	initially	sensitive	to	therapy,	with	retarded	tumour	growth	for	the	first	9	days	of	treatment,	after	which	tumour	growth	followed	the	same	rate	as	the	untreated	cohort.	These	tumours	displayed	marked	devascularisation	during	the	period	of	inhibition,	and	evidence	of	revascularisation	once	insensitive.	This	cohort	additionally	displayed	significantly	reduced	metastasis	over	the	period	of	the	experiment.	A	second	cohort,	showed	complete	insensitivity	to	the	sunitinib	treatment,	with	no	growth	retardation	or	vascular	patterning	effects,	relative	to	the	untreated	cohort.	A	third	group	again	showed	no	growth	rate	response,	however,	the	tumours	did	show	evidence	of	devascularisation	in	response	to	sunitinib	treatment,	on	both	the	macro	and	microscopic	levels.	Additionally	the	pooled	growth	insensitive	tumour	cohorts	displayed	significantly	enhanced	metastatic	growth	in	the	liver	and	lungs.	In	conclusion	a	model	of	sunitinib	resistance	in	metastatic	breast	cancer	has	been	set	up,	with	cohorts	displaying	both	acquired	and	innate	resistance.	A	key	finding	was	that	sunitinib	does	enhance	metastasis	but	only	in	the	innately	resistant	setting.		The	presence	of	3	groups	of	tumours	showing	differing	responses	to	sunitinib	treatment	could	be	seen	as	surprising.	A	genetically	identical	(albeit	heterogeneous)	population	of	4T1	cells	were	injected	into	another	genetically	identical	population	of	Balb/c	mice.	The	natural	variance	observed	in	any	tumour	experiment	is	usually	
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explained	by	slight	differences	in	tumour	cell	placement	and	other	factors	that	then	impact	on	how	well	it	thrives.	These	factors	are	likely	to	be	playing	a	part	in	the	segregation	of	the	populations	based	on	size,	however,	as	is	explored	in	this	chapter,	the	difference	in	the	populations	goes	beyond	tumour	size.	20-27%	of	treated	tumours	showed	no	devascularisation	or	growth	inhibition	in	response	to	sunitinib,	while	another	13-20%	grew	at	the	same	rate	as	the	untreated	group,	despite	showing	signs	of	devascularisation.	The	genetic	and	environmental	factors	underlying	this	response	profile	warrant	investigation	and	could	provide	insight	into	the	factors	leading	to	resistance,	which	could	have	clinical	utility.						
	The	existence	of	a	cohort	of	tumours	displaying	no	response	to	sunitinib	is	well	established	in	the	clinic.	A	recent	phase	III	clinical	trial	investigating	sunitinib	in	combination	with	docetaxel	as	a	treatment	for	advanced	breast	cancer,	reported	a	response	rate	of	only	55%	(276),	while	(278)	reported	an	objective	response	rate	of	11%	with	sunitinib	used	as	a	monotherapy	in	HER2-negative	advanced	breast	cancer.	The	identification	of	markers	that	will	allow	the	prediction	of	which	tumours	are	likely	to	respond	to	sunitinib,	has	the	potential	to	considerably	improve	the	use	and	effectiveness	of	this	drug	and	this	is	one	of	the	focuses	of	investigation	in	chapter	7.		
	62%	of	treated	tumours	did	respond	to	sunitinib,	resulting	in	devascularisation	and	tumour	growth	retardation.	However,	this	effect	was	only	maintained	for	9	days	of	treatment,	after	which	their	growth	resumed	unabated	and	a	crest	of	vascularised	tumour	tissue	formed	around	the	avascular	core.	Broadly	this	group	model	another	form	of	resistance	observed	in	the	clinic,	acquired	resistance	(279).	Another	one	of	the	
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focuses	of	chapter	7	is	the	investigation	of	the	molecular	profile	of	tumours	exhibiting	this	form	of	resistance,	so	that	strategies	designed	to	slow	or	circumvent	this	resistance	can	be	formulated.		The	presence	of	tumour	metastases	are	one	of	the	major	risk	factors	for	death	in	all	cancers	and	anti-angiogenic	therapies,	including	sunitinib	have	been	implicated	in	increasing	the	risk	of	this	eventuality,	as	previously	discussed.	This	may	seem	counter-intuitive,	as	sunitinib	has	been	shown	to	not	only	block	vascular	angiogenesis,	but	also	through	the	inhibition	of	vascular	endothelial	growth	factor	3	(VEGFR-3),	lymph-angiogenesis.	Sunitinib	effectively	shuts	down	two	of	the	major	routes	to	metastasis	for	a	tumour,	however,	both	Yin	et	al.,	2014	(280)	and	Welti	et	al.,	2012	(174),	report	enhanced	lung	metastasis	and	tumour	infiltration	in	models	of	breast	cancer.	Admittedly	the	tumour	cells	in	Welti	et	al.,	2012	(174)	were	injected	intra-venously,	therefore	were	already	circulating	and	did	not	have	to	escape	the	tumour.	The	observations	detailed	in	this	chapter	add	to	the	story.	Metastasis	was	significantly	enhanced	to	the	liver	and	lungs	by	sunitinib	treatment	at	the	1300	mm3	stage,	but	only	in	the	innately	resistant	cohort.	The	majority	of	this	cohort	displayed	no	devascularisation	and	therefore	the	anti-metastatic	effects	of	inhibiting	vascular	and	lymph	angiogenesis	would	likely	not	apply.	The	question	therefore	is,	why	once	circulating,	do	the	tumour	cells	more	readily	infiltrate	other	organs,	under	the	influence	of	sunitinib.	A	number	of	potential	mechanisms	have	been	suggested.	The	up-regulation	of	angiogenesis	and	metastasis	associated	cytokines	and	growth	factors	in	response	to	treatment	(281),	the	mobilisation	of	bone-marrow	derived	cells	discussed	in	chapter	one	could	generate	a	pre-metastatic	niche	(282),	host	micro-environmental	
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responses	to	cellular	inhibition	or	injury	(283),	could	promote	tumour	metastasis,	in	a	similar	manner	to	that	reported	with	radiation	or	chemotherapeutic	agents	(284-286)	and	finally	high	dose	treatment	with	sunitinib	has	been	reported	to	lead	to	pericyte	depletion,	likely	through	PDGF	signalling	inhibition,	in	lung	vasculature,	which	is	correlated	with	enhanced	breast	tumour	seeding	(174).	This	latter	observation	is	supported	by	pericyte	depletion	studies	in	which	they	found	that	loss	of	pericytes	in	advanced	tumours,	inhibited	growth	but	enhanced	lung	metastasis	(287).			It	should	be	noted	that	the	usual	human	dosing	for	sunitinib	is	37.5	mg	/	day,	and	as	the	average	human	body	weight	is	62	kg	(288),	the	40	mg/kg	sunitinib	treatment	of	the	mice	used	in	this	investigation	and	many	other	studies,	(174,289,290),	is	clearly	in	great	excess.	This	factor	could	be	leading	to	systematic	effects,	such	as	pericyte	depletion,	that	are	not	observed	in	the	clinic.	Therefore	metastatic	effects	identified	in	animal	models	require	validation	in	the	human	setting.	
	The	sunitinib	responsive	cohort	displays	unchanged	or	reduced	metastasis	relative	to	the	untreated	cohort	at	the	1300	mm3	stage.	This	suggests	that	the	inhibited	vascularisation	and	tumour	growth,	experienced	up	to	day	9,	did	retard	the	progress	of	metastasis	in	this	group.	In	support	of	this	Weidner	et	al.,	1991	(291)	report	a	strong	independent	link	between	micro-vascular	density	and	metastasis	in	invasive	breast	cancer.	This	is	supported	by	the	observation	of	no	significant	metastasis	in	the	treated	group	at	day	9,	relative	to	the	untreated	group.	After	this	point	tumour	cells	do	escape	and	colonise	the	spleen,	liver	and	lungs	and	continued	sunitinib	treatment	does	not	appear	to	inhibit	this.	However,	the	initial	retardation	experienced	up	to	day	9	means	
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that	by	the	time	the	primary	tumour	is	1300	mm3	in	size,	the	development	of	metastases	is	still	lagging	behind	the	untreated	cohort.		
	The	broad	pattern	of	the	data	is,	where	primary	tumour	growth	is	retarded	and	vascular	production	inhibited,	metastasis	is	slowed	by	sunitinib	therapy.	On	the	other	hand	when	the	primary	tumour	is	non-responsive	to	treatment	the	presence	of	sunitinib	enhances	the	tumour	metastasis,	possibly	due	to	pericyte	depletion	in	the	target	organs	or	host	pro-metastatic	micro-environmental	responses	to	treatment.	This	data	further	highlights	the	need	for	reliable	markers	for	the	prediction	of	sunitinib	response,	as	inappropriate	treatment	could	potentially	not	only	waste	time	and	money,	but	also	enhance	metastasis.			
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7.1	Introduction	
	The	investigation	of	tumour	growth	and	metastasis	in	a	model	of	sunitinib	drug	resistance	in	breast	cancer,	detailed	in	chapter	6,	generated	three	cohorts	divided	by	their	response	to	the	drug.	(i)	A	naïve	cohort	never	treated	with	the	drug	(termed-untreated),	(ii)	a	cohort	treated	with	sunitinib	that	initially	showed	drug	induced	tumour	stasis	for	9	days,	after	which	the	tumours	grew	at	a	similar	rate	to	the	naïve	cohort,	but	with	reduced	metastasis	(modelling	acquired	resistance	and	termed	responsive)	and	(iii)	a	cohort	treated	with	sunitinib	that	showed	no	tumour	growth	response	and	grew	at	a	similar	rate	to	the	naïve	cohort	but	with	enhanced	metastasis	(modelling	innate	resistance	and	termed	non-responsive).		This	chapter	presents	data	from	high	throughput	microarray	transcriptomic	analysis	of	both	the	tumours	and	the	tumour	vessels	(the	primary	target	of	therapy),	from	each	of	these	cohorts	and	downstream	validation	of	the	findings.	This	investigation	attempts	to	elucidate	the	molecular	profile	of	acquired	and	innate	resistance	to	sunitinib,	in	this	model	of	metastatic	breast	cancer.			
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7.2	Results	
	
7.2.1	Murine	tumour	endothelial	isolation	and	microarray	analysis	In	order	to	investigate	the	impact	sunitinib	therapy	has	on	the	tumour	vessels,	endothelium	was	isolated	from	the	untreated,	responsive	and	non-responsive	cohorts,	using	magnetic	beads.	Sheep	anti-rat	coated	dynabeads	were	coupled	with	rat	anti-mouse	PECAM-1	antibodies	and	used	to	rosette	and	magnetically	isolate	endothelium	from	collagenase	V	digested	4T1	tumours	(Figure	7.1).	PECAM-1	is	also	a	marker	of	a	small	subset	of	leukocytes,	therefore	RTqPCR	was	performed	on	the	isolates	to	confirm	specific	endothelial	enrichment.	Relative	expression	of	markers	of	leukocytes	(CD11b),	macrophages	(CD68),	epithelial	cells	(EPCAM),	smooth	muscle	cells	(PDGFRA)	and	endothelium	(PECAM),	was	assessed	between	matched	endothelial	isolates	and	endothelial	depleted	fractions,	by	RTqPCR.	This	analysis	confirmed	that	PECAM	expression	alone	was	enriched	25-30	fold	in	the	endothelial	isolates,	suggesting	a	very	good	level	of	endothelial	enrichment	(Figure	7.1).			Two	tumour	bulk	samples	each,	from	the	responsive	and	untreated	cohorts	harvested	at	day	9	and	600	mm3,	along	with	four	representative	endothelial	isolate	samples	and	bulk	samples	from	each	of	the	responsive,	non-responsive	and	untreated	cohorts	taken	at	1300	mm3,	were	selected	for	microarray	transcriptomic	analysis	(individual	growth	curves	shown	in	Figure	7.2).			
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Figure	7.1.	Endothelial	isolation	from	murine	breast	tumours.	A,	workflow	of	the	main	steps	involved	in	the	murine	endothelial	cell	isolation	procedure.	B,	RTqPCR	for	markers	of	leukocytes	(CD11b),	macrophages	(CD68),	epithelium	(EPCAM),	smooth	muscle	(PDGFRA)	and	endothelium	(PECAM)	in	the	endothelial	isolates	(EC)	from	responsive,	untreated	and	non-responsive	tumours	(n=4,4,4)	standardised	to	β-actin	(a	house	keeping	gene)	and	normalised	for	marker	expression	to	matched	bulk	tissue.	Mean	fold	change	of	marker	expression	between	the	endothelial	and	bulk	fraction	is	shown	±	SEM.			 	
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Figure	7.2.	Representative	tumours	from	the	non-responsive	(square),	responsive	(circle)	and	untreated	(cross)	group	at	each	time	period,	were	subjected	to	microarray	transcriptomic	analysis.	Graphs	showing	individual	tumour	growth	data	points	and	mean	tumour	size	of	the	selected	tumours	over	the	period	of	the	experiment.	N-numbers	for	each	experiment	are	shown.				
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7.2.2	The	impact	of	sunitinib	treatment	on	tumour	and	endothelial	gene	
expression		Microarray	analysis	of	the	selected	samples	facilitated	the	transcriptional	characterisation	of	the	tumour	and	associated	endothelium,	from	naïve	(untreated),	innately	resistant	(non-responsive)	and	adaptively	resistant	(responsive)	tumours,	at	key	stages	of	resistance	acquisition	(day	9,	600	mm3	and	1300	mm3).	This	was	done	by	the	investigation	of	the	comparative	expression	profile	between	these	cohorts,	of	genes	known	(or	predicted	by	the	Qiagen	Ingenuity	pathway	prediction	software	database,	on	stringent	settings)	to	be	associated	with	sunitinib	response	(Tables	7.1	and	7.2),	metastasis	(Tables	7.3	and	7.4),	and	endothelial	migration	and	angiogenesis	(Tables	7.5	and	7.6).	Gene	expression	in	the	signaling	pathways	of	selected	targets	of	sunitinib	drug	activity	(VEGFR-1&2,	PDGFR-α&β	and	FLT3)	was	also	investigated	(Appendix	figures	A,	B	and	C).			
7.2.2.1	Comparative	analysis	of	genes	associated	with	sunitinib	response	In	order	to	characterise	the	responsiveness	of	the	tumours	and	associated	endothelium	to	sunitinib	therapy,	during	the	course	of	the	experiment,	on	a	transcriptomic	level,	a	list	of	genes	associated	with	sunitinib	response	was	collated	as	described	previously	and	their	expression	analysed	between	arrays.	This	analysis	revealed	that	at	day	9,	tumours	from	the	“responsive”	cohort	do	indeed	display	an	expression	profile	in	line	with	that	predicted	of	response	to	sunitinib	therapy,	when	compared	to	the	untreated	cohort.	Five	out	of	six	genes	with	expression	>2	fold	changed,	are	altered	in	line	with	predicted	sunitinib	response	(Table	7.1).	This	response	profile	is	lost	however,	at	later	time	points,	in	line	the	loss	of	sunitinib	
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induced	growth	retardation	in	the	“responsive”	cohort,	discussed	in	chapter	6	(Table	7.1).	This	analysis	when	applied	to	endothelial	isolates	from	the	responsive,	non-responsive	and	untreated	cohorts,	at	1300	mm3	agreed	with	the	bulk	tumour	data,	as	regards	the	“responsive”	(but	now	having	acquired	resistance)	group,	showing	no	obvious	sensitivity	to	sunitinib	treatment,	in	terms	of	gene	expression	(Table	7.2).	Conversely,	gene	expression	of	sunitinib	target	genes	is	reduced	in	the	non-responsive	cohort,	relative	to	the	responsive	cohort,	suggesting	that	despite	displaying	innate	resistance	from	the	outset	of	the	experiment,	in	terms	of	growth	profile,	on	the	transcriptomic	level	the	endothelium	of	this	cohort	were	more	sensitive	to	sunitinib	treatment	than	the	“responsive”	cohort	(Table	7.2).					
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7.2.2.2	Comparative	analysis	of	genes	expression	in	sunitinib	targeted	pathways	An	analysis	of	the	pattern	of	expression	of	genes	downstream	of	selected	sunitinib	targeted	pathways	(VEGFR-1&2,	PDGFR-α&β),	broadly	agrees	with	but	also	recapitulates	the	findings	of	section	7.2.2.1.	This	analysis	is	therefore	briefly	mentioned	here,	but	is	further	discussed	in	the	appendix.	Using	similar	comparison	matrices	to	those	mentioned	previously,	it	was	determined	that	expression	of	genes	downstream	of	each	of	the	selected	targeted	pathways	were	modulated	in	line	with	predicted	response	to	sunitinib	(Appendix	figures	A,	B	and	C	(i)),	at	day	9,	in	bulk	tumour	samples	from	the	responsive	cohort,	when	compared	to	the	untreated	cohort	(Appendix	figures	A,	B	and	C	(ii:1)).	This	modulation	was	lost	at	later	stages	(Appendix	figures	A,	B	and	C	(ii:2&3)),	concurrent	with	the	loss	of	tumour	growth	retardation	reported	in	chapter	6	and	in	agreement	with	the	patturn	of	gene	expression	reported	for	genes	associated	with	sunitinib	response	(section	7.2.2.1).	This	suggests	that	these	initially	“responsive”	tumours	acquired	resistance,	accelerating	tumour	growth	and	vascularisation,	via	a	loss	of	sensitivity	in	sunitinib	targeted	pathways.	Conversely,	at	the	1300	mm3	tumour	stage,	gene	expression	in	the	non-responsive	cohort,	when	compared	with	both	the	responsive	and	untreated	cohorts,	was	still	modulated	in	line	with	response	to	sunitinib	(Appendix	figures	A,	B	and	C	(ii:4-8)).	This	was	particularly	apparent	in	the	VEGFR-1&2	pathways	(Appendix	figure	A	(ii:4-8)).	This	finding	is	in	agreement	with	that	reported	for	the	expression	of	sunitinib	response	genes	(section	7.2.2.1),	suggesting	that	these	“innately	resistant”	tumours	are	still	sensitive	to	sunitinib	therapy	as	regards	its	gene	expression	modulatory	activity,	but	maintain	tumour	growth	and	vascularity,	potentially	via	alternative	unaffected	mechanisms.		
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7.2.2.3	Comparative	analysis	of	genes	associated	with	metastasis	Besides	effects	on	tumour	growth	and	vascularisation,	metastasis	was	significantly	affected	by	sunitinib	treatment	and	response,	as	discussed	in	chapter	6.	In	order	to	investigate	this	on	a	molecular	level,	a	list	of	genes	known	to	enhance	metastasis	was	compiled	from	the	Ingenuity	online	database,	and	their	expression	analysed	between	arrays		(Table	7.3	and	7.4).	Metastasis	signalling	in	the	responsive	tumours	appears	to	be	quite	strongly	inhibited	at	day	9,	when	compared	to	the	untreated	cohort	at	the	same	time	period	(Table	7.3).	Fifteen	known	or	predicted	pro-metastatic	genes	were	>2	fold	down-regulated	by	sunitinib	treatment	at	this	stage.	Five	pro-metastatic	genes	were	>2	fold	up-regulated	at	this	stage	in	the	treated	tumours,	however,	the	pattern	of	signalling	was	primarily	inhibitory	to	metastasis.	This	expression	pattern	was	progressively	reversed	at	subsequent	harvesting	points,	with	a	third	of	>2	fold	altered	pro-metastatic	genes	up-regulated	at	600	mm3	and	three	quarters	at	1300	mm3.	In	the	non-responsive	cohort	too	the	majority	of	pro-metastatic	genes	>2	fold	altered	were	up-regulated	at	1300	mm3,	when	compared	to	the	untreated	cohort	(Table	7.4).	Intriguingly	however,	when	comparing	the	two	treated	cohorts,	it	was	the	responsive	group	that	displayed	the	more	pro-metastatic	profile,	with	five	genes	stimulatory	to	metastasis,	up-regulated	in	the	responsive	group,	over	the	non-responsive	cohort.	This	data	overall	agrees	with	the	observed	metastatic	profile	of	the	tumours	explored	in	chapter	6,	with	sunitinib	initially	inhibiting	metastasis	up	to	day	9,	and	even	600	mm3,	but	by	1300	mm3	metastasis	and	the	signalling	for	it,	was	enhanced	by	sunitinib	treatment.	The	strong	metastatic	signalling	in	tumours	of	the	“responsive”	cohort	is	in	disagreement	with	the	chapter	6	metastatic	profile	data	(Figure	6.8).	Metastasis,	as	assessed	by	IVIS	imaging,	was	reduced	in	this	cohort	relative	to	non-responsive	and	
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untreated	tumours,	however,	according	to	transcriptomic	analysis	at	the	1300	mm3	stage,	signaling	for	metastasis	was	enhanced	in	this	cohort	above	the	other	two	groups.	This	begs	the	question,	had	the	mice	been	left	for	longer,	would	the	level	of	metastasis	in	the	initially	responsive	cohort	have	caught	up	or	even	overtaken	that	of	the	non-responsive	cohort?	
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7.2.2.4	Comparative	analysis	of	genes	associated	with	endothelial	migration	One	of	the	major	targets	of	sunitinib	therapy	is	angiogenesis.	In	order	to	explore	the	effect	sunitinib	treatment	had	on	pro-angiogenic	gene	expression	over	the	course	of	the	experiment,	a	list	of	genes	known	to	enhance	endothelial	migration	(a	key	component	of	angiogenesis)	was	compiled	from	the	Ingenuity	online	database,	and	their	expression	investigated	in	each	of	the	comparison	matrices	used	previously.	At	day	9	pro-angiogenic	signalling	was	primarily	inhibited	in	the	responsive	group	versus	the	untreated	group,	with	the	majority	of	>2	fold	altered	genes	being	down-regulated	at	this	stage,	presumably	in	response	to	sunitinib	angiogenesis	inhibition	(Table	7.5).	This	pattern	of	inhibition	was	lost	at	later	time	points,	with	even	a	few	pro-angiogenic	genes	showing	enhanced	expression	in	the	treated	group.	However,	there	was	no	obvious	pattern	of	angiogenic	signalling	maintained	between	tumours	harvested	at	600	and	1300	mm3.	This	data	is	in	agreement	with	the	observed	vascularisation	patterns	reported	in	chapter	6	for	the	responsive	cohort,	with	a	greater	level	of	vascularization	signalled	for	by	pro-angiogenic	gene	expression	at	later	time	points.	At	1300	mm3	genes	stimulatory	to	endothelial	migration	were	both	up	and	down-regulated	in	the	endothelium	of	non-responsive	tumours,	versus	the	untreated	cohort	(Table	7.6).	This	suggests	that	despite	the	observed	similarity	in	tumour	growth	and	vascularisation	between	the	groups,	the	methods	of	vascularisation	could	be	quite	distinct.	This	observation	suggests	that	despite	sensitivity	to	sunitinib	signalling	inhibition	potentially	being	maintained,	as	reported	in	Table	7.2,	the	use	of	alternative	angiogenic	pathways	permits	the	continued	growth	and	vascularisation	of	this	cohort.	The	responsive	group	on	the	other-hand	displayed	an	endothelial	expression	pattern	primarily	stimulatory	to	endothelial	migration	with	the	expression	of	pro-angiogenic	
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molecules,	such	as	endothelial	cell	specific	adhesion	molecule	(ESAM),	endothelin	1	(EDN1)	and	pleiotrophin	(PTN)	enhanced	versus	the	untreated	group.	The	same	pattern	was	observed	when	comparing	expression	profiles	with	the	non-responsive	cohort.	Endothelial	migration	signalling	appears	to	be	enhanced	in	the	responsive	group	at	the	1300	mm3,	beyond	that	found	in	the	other	cohorts,	but	not	via	the	same	alternative	pathways	utilised	by	the	non-responsive	group.			
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7.2.3	The	selection	and	validation	of	acquired	resistance	markers	In	order	to	investigate	and	validate	this	observed	up-regulation	of	sunitinib	targeted	pathways	and	angiogenesis	in	general,	in	the	vessels	of	the	initially	responsive	cohort,	after	resistance	has	been	acquired,	a	matrix	comparing	responsive	tumour	endothelium	to	untreated	tumour	endothelium	was	set	up.	This	analysis	identified	a	strikingly	large	number	of	angiogenic	genes	>2	fold	up-regulated	in	the	responsive	group,	such	as	the	prolactin	receptor	(PRLR),	aquaporin	1	(AQP1),	angiopoietin	2	(ANGPT2),	the	duffy	blood	group	receptor	(DARC),	multimerin	2	(MMRN2)	among	others	(Table	7.7).	Interestingly	the	RET	proto-oncogene	and	VEGF	receptor	2,	targets	of	sunitinib	inhibition	were	also	both	up-regulated	in	the	responsive	group,	possibly	suggesting	a	mechanism	of	resistance	by	the	up-regulation	of	the	target	genes	(Table	7.7).		
	
	
Table	7.7.	Genes	significantly	enriched	in	the	endothelial	isolates	from	responsive	vs.	untreated	tumours	harvested	at	1300	mm3.	
	Gene	ID	 Gene	Symbol	 GeneBank	accession	no.	 Fold	change	 P-value	Prolactin	receptor	 PRLR	 NM_011169	 4.32	 0.01	Pleiotrophin	 PTN	 NM_008973	 2.91	 0.01	Aquaporin	1	 AQP1	 NM_007472	 2.76	 0.00	Ret	proto-oncogene	 RET	 NM_001080780	 2.40	 0.00	Angiopoietin	2	 ANGPT2	 NM_007426	 2.34	 0.00	Duffy	blood	group,	chemokine	receptor	 DARC	 NM_010045	 2.30	 0.01	Leptin	receptor	 LEPR	 NM_001122899	 2.30	 0.00	Endothelial	cell	surface	expressed	chemotaxis	regulator	 ECSCR	 NM_001033141	 2.25	 0.00	Tetraspanin	7	 TSPAN7	 NM_019634	 2.25	 0.00	Stanniocalcin	2	 STC2	 NM_011491	 2.12	 0.00	Endothelial	cell-specific	adhesion	molecule	 ESAM	 NM_027102	 2.10	 0.00	Multimerin	2	 MMRN2	 NM_153127	 2.06	 0.00	Kinase	insert	domain	protein	receptor	 KDR	(VEGFR2)	 NM_010612	 2.06	 0.00	Endothelin	1	 EDN1	 NM_010104	 2.03	 0.00			
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In	order	to	validate	the	differential	expression	of	the	14	candidate	genes	arising	from	the	microarray	analysis	(Table	7.7),	RTqPCR	analysis	comparing	the	expression	level	of	each	of	these	genes	between	responsive	EC	and	untreated	EC,	used	for	the	microarray	analysis,	was	performed	(Table	7.8).	Genes	of	interest	warranting	further	investigation	must	be	suitably	enriched	in	the	responsive	cohort	compared	to	the	untreated	cohort	EC,	as	well	as	being	sufficiently	expressed	to	realistically	have	an	impact	of	cellular	behaviour.	Candidate	selection	was	therefore	based	on	fold	expression	change,	normalised	to	β-actin	(per	cell	level)	and	PECAM-1	(per	endothelial	cell	level),	as	well	as	on	gene	expression	level	relative	to	β-actin.	Genes	identified	by	RTqPCR	analysis,	with	a	fold	enrichment	of	>3	times	and	expressed	at	>5%	of	the	expression	level	of	β-actin,	were	taken	forward	(Table	7.8).	This	left	ANGPT2,	AQP1,	DARC,	MMRN2,	PRLR	and	VEGFR2,	as	the	key	genes	of	interest	for	further	investigation.	
	
	
Table	7.8.	Selection	of	genes	of	interest	for	further	analysis	by	RTqPCR,	in	EC	isolates	from	responsive	vs.	untreated	tumours,	harvested	at	1300	mm3	(n=4).	Selected	genes	(green)	exhibit	>3	fold	enrichment	in	responsive	tumours	standardised	to	both	β-actin	and	PECAM	and	have	>	5%	of	the	expression	of	β-actin.	Rejected	genes,	highlighted	red.		Identified	targets	 β-actin	vs.	target	fold	expression	change	 PECAM	vs.	target	fold	expression	change	 Expression	level	relative	to	β-actin	(%)	 Selected	genes	ANGPT2	 5.75	 3.57	 41.39	 ANGPT2	AQP1	 4.93	 4.19	 240.42	 AQP1	DARC	 6.79	 5.66	 30.83	 DARC	ECSCR	 1.86	 1.70	 0.89	 	EDN	1	 3.04	 2.41	 1.98	 	ESAM	 2.49	 1.74	 10.33	 	LEPR	 5.44	 3.75	 2.26	 	MMRN2	 3.23	 2.59	 11.58	 MMRN2	PRLR	 9.81	 10.20	 5.23	 PRLR	PTN	 2.25	 2.72	 0.01	 	RET	 9.02	 7.85	 0.27	 	STC2	 27.22	 18.02	 0.04	 	TSPAN7	 0.50	 0.64	 0.03	 	VEGFR2	 4.69	 3.49	 11.65	 VEGFR2	
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7.2.4	Expression	changes	of	candidate	markers	of	acquired	resistance	over	time	In	order	to	investigate	the	expression	of	the	candidate	genes	at	key	stages	of	tumour	development,	in	the	full	set	of	isolates	of	different	cohorts,	RTqPCR	was	performed	on	endothelial	isolates	from	day	9,	600	mm3	and	1300	mm3,	in	the	responsive,	non-responsive	and	untreated	cohorts	(Figure	7.3).	This	analysis	revealed	a	significant	shift	in	the	expression	of	all	the	candidate	genes,	except	for	PRLR,	between	the	responsive	and	untreated	tumour	endothelium	at	1300	mm3.	Aquaporin-1	alone	however,	had	an	additional	significant	shift	in	expression	between	the	responsive	and	non-responsive	cohorts	at	1300	mm3,	marking	it	out	as	a	key	distinguishing	gene,	enriched	in	the	responsive	cohort	alone,	at	this	time	point.	Interestingly	the	expression	of	each	of	the	candidate	genes	is	only	significantly	up-regulated	in	the	responsive	cohort	at	the	1300	mm3	stage,	suggesting	a	distinct	change	has	occurred	in	the	tumour	vessel	transcriptome	at	this	stage	compared	to	other	stages.		
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Figure	7.3.	Aquaporin	is	significantly	enriched	in	the	vessels	of	responsive	tumours	over	those	of	untreated	and	non-responsive	tumours.	A,	RTqPCR	for	the	relative	expression	of	the	six	genes	of	interest	in	endothelial	isolates	from	untreated,	responsive	and	non-responsive	tumours	harvested	at	9	days,	600	mm3	and	1300	mm3	(mean	expression	±SEM,	***	p<0.001,	*	p<0.05,	NS	–	Not	Significant,	Mann-Whitney).	B,	N-numbers	for	each	group	used	in	the	analysis.	
	
0	
0.2	
0.4	
0.6	
0.8	
1	
U
nt
re
at
ed
	
9	
da
ys
	
60
0	
m
m
³	
13
00
	m
m
³	
Re
sp
on
siv
e	
9	
da
ys
	
60
0	
m
m
³	
13
00
	m
m
³	
N
on
-r
es
po
ns
iv
e	
9	
da
ys
	
60
0	
m
m
³	
13
00
	m
m
³	
MMRN2	
0	
0.2	
0.4	
0.6	
0.8	
1	
1.2	
U
nt
re
at
ed
	
9	
da
ys
	
60
0	
m
m
³	
13
00
	m
m
³	
Re
sp
on
siv
e	
9	
da
ys
	
60
0	
m
m
³	
13
00
	m
m
³	
N
on
-r
es
po
ns
iv
e	
9	
da
ys
	
60
0	
m
m
³	
13
00
	m
m
³	
VEGFR2	
0	
0.5	
1	
1.5	
2	
2.5	
3	
U
nt
re
at
ed
	
9	
da
ys
	
60
0	
m
m
³	
13
00
	m
m
³	
Re
sp
on
siv
e	
9	
da
ys
	
60
0	
m
m
³	
13
00
	m
m
³	
N
on
-r
es
po
ns
iv
e	
9	
da
ys
	
60
0	
m
m
³	
13
00
	m
m
³	
DARC	
0	
0.05	
0.1	
0.15	
0.2	
0.25	
U
nt
re
at
ed
	
9	
da
ys
	
60
0	
m
m
³	
13
00
	m
m
³	
Re
sp
on
siv
e	
9	
da
ys
	
60
0	
m
m
³	
13
00
	m
m
³	
N
on
-r
es
po
ns
iv
e	
9	
da
ys
	
60
0	
m
m
³	
13
00
	m
m
³	
PRLR	
0	
5	
10	
15	
20	
25	
30	
35	
40	
U
nt
re
at
ed
	
9	
da
ys
	
60
0	
m
m
³	
13
00
	m
m
³	
Re
sp
on
siv
e	
9	
da
ys
	
60
0	
m
m
³	
13
00
	m
m
³	
N
on
-r
es
po
ns
iv
e	
9	
da
ys
	
60
0	
m
m
³	
13
00
	m
m
³	
Re
la
%v
e	
ex
pr
es
si
on
	 Aqp1	
0	
0.5	
1	
1.5	
2	
2.5	
3	
3.5	
U
nt
re
at
ed
	
9	
da
ys
	
60
0	
m
m
³	
13
00
	m
m
³	
Re
sp
on
siv
e	
9	
da
ys
	
60
0	
m
m
³	
13
00
	m
m
³	
N
on
-r
es
po
ns
iv
e	
9	
da
ys
	
60
0	
m
m
³	
13
00
	m
m
³	
Angpt2	
Responsive	 Non-responsive	 Untreated	
Day	9	 5	 5	 10	
600	mm3	 4	 6	 10	
1300	mm3	 13	 7	 18	
***	 *	 ***	 NS	
***	 NS	
***	 NS	 ***	 NS	
A	
B	
Figure	7.4	
Figure	7.4.	Aquapori 	i iﬁcantly	enriched	in	the	vessels	of	responsive	tumours	
over	those	of	untreated	and	non-responsive	tu CR	for	the	relaVve	
expression	of	the	six	genes	of	interest	in	end t li l	i l t s	fro 	untreated,	
responsive	and	non-responsive	tu ste 	at	9	days,	60 	mm3	and	1300	
mm3.	(mean	expression ±SEM,	***	p<0.001,	*	p<0.05,	NS	–	Not	Signiﬁcant,	Mann-
Whitn y).	B,	N-numbers	for	 ach	group	used	in the	analysis.	
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7.2.5	Validation	of	aquaporin	on	the	protein	level	In	order	to	further	validate	aquaporin	as	a	specific	marker	of	acquired	resistance	on	the	protein	level,	immunohistochemistry	and	immunofluorescence	was	conducted,	comparing	marker	expression	in	sections	cut	from	responsive,	non-responsive	and	untreated	cohort	tumours,	harvested	at	day	9,	600	mm3	and	1300	mm3.	The	analysis	compared	the	optical	density	of	marker	fluorescence	(green	channel),	normalised	to	the	PECAM-1	fluorescence	(red	channel),	between	the	groups	of	tumour	samples.	In	this	way	it	was	confirmed	that	AQP1	was	enriched	in	the	vessels	of	responsive	tumours	specifically	at	the	1300	mm3	stage	(Figure	7.4).							
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Figure	7.4.	Aquaporin	is	significantly	enriched	in	the	vessels	of	responsive	tumours	over	those	of	untreated	and	non-responsive	tumours	on	the	protein	level.	A,	representative	images	of	AQP1	staining	in	untreated,	responsive	and	non-responsive	tumours	by	IHC	and	IF.	Tumours	triple	stained	by	IF	for	DAPI	(nuclei,	blue),	PECAM-1	(vessels,	red)	and	AQP1	(green).	B,	quantitation	of	pixel	density	of	staining	by	IF	for	AQP1	standardised	to	PECAM-1	staining	(mean	±	SEM,	***	p<0.001,	*	p<0.05,	Mann-Whitney,	n-numbers	[see	Figure	7.3B],	6	fields	of	view	each)		
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7.3	Discussion	
	A	key	requirement	in	the	drive	to	improve	the	use	of	antiangiogenic	therapies	is	to	understand	the	processes	by	which	drug	resistance	is	acquired.	This	chapter	presents	data	from	an	exploration	of	the	processes,	used	by	two	groups	of	sunitinib	treated	tumours,	showing	distinct	resistance	profiles.	In	tumours	that	showed	initial	growth	retardation	in	response	to	treatment,	signalling	within	the	tumour	was	altered	during	the	sensitive	period,	in	a	manner	closely	matching	that	predicted	of	sunitinib	treatment.	Sunitinib	target	or	responsive	genes	were	inhibited	and	both	metastatic	and	angiogenic	signalling	reduced,	relative	to	untreated	tumours.	After	this	period	of	roughly	9	days,	the	tumours	started	to	grow	at	a	rate	roughly	matching	that	of	the	untreated	cohort	and	at	this	point	signalling	changed.	The	inhibition	of	the	VEGF,	PDGF	and	FLT-3	pathways	was	lost	and	both	endothelial	migration	and	metastasis	signalling	was	progressively	enhanced.	This	profile	was	suggestive	of	an	acquired	loss	of	sensitivity	to	sunitinib	therapy	after	day	9,	in	both	tumour	growth	rate	and	signalling.	In	tumours	that	didn’t	show	sensitivity	to	sunitinib	therapy	in	terms	of	growth	rate	from	the	outset,	this	effect	was	not	observed.	Even	at	the	latest	size-point,	1300	mm3,	the	tumours	still	appeared	to	be	sensitive	to	sunitinib	therapy.		Sunitinib	target	genes	were	still	inhibited,	however,	metastasis	and	endothelial	migration	signalling	in	general	was	not.	This	suggests	that	this	cohort	of	tumours	utilised	a	separate,	uninhibited	mechanism	for	continued	tumour	growth	and	metastasis	and	therefore	had	an	innate	resistance	to	sunitinib	therapy.	Intriguingly	direct	transcriptomic	comparisons	of	the	initially	responsive	and	non-responsive	cohorts,	revealed	that	the	acquired	resistance	of	the	responsive	group	was	not	gained	via	the	same	mechanism	by	which	the	non-responsive	tumours	
	 206	
achieved	innate	resistance,	but	rather	by	a	separate	mechanism	that	involved	the	up-regulation	of	a	number	pro-angiogenic	genes	in	the	endothelium.	Some	of	these	genes	are	known	to	be	targeted	by	sunitinib	for	inhibition.	Further	analysis	of	this	phenomenon	revealed	that	the	up-regulation	of	aquaporin	1	was	characteristic	of	tumours	displaying	acquired	resistance.	
	
7.3.1	Innate	resistance	Innate	resistance	to	antiangiogenic	therapies,	has	been	suggested	to	occur	due	to	the	development	of	tumour	dependence	on	uninhibited	mechanisms	of	growth	and	vascularisation.	This	is	thought	not	to	be	in	response	to	therapy,	but	due	to	incidental	selective	pressures	exerted	by	the	tumour	microenvironment	(149).	This	appears	to	be	broadly	what	has	occurred	in	the	non-responsive	group.	Transcriptomic	profiling	of	non-responsive	versus	untreated	endothelium	at	1300	mm3	suggested	that	a	quite	distinct	method	of	angiogenesis	was	favored	in	each	group.			The	expression	of	nine	pro-angiogenic	genes	were	at	least	2	fold	enhanced	in	the	untreated	cohort,	including	leptin	(LEP),	the	reduction	of	which,	significantly	correlates	with	response	to	sunitinib	in	RCC	and	prostate	cancer	(292,293),	chemokine	ligand-1	(CXCL1),	the	release	of	which	is	induced	by	VEGF	signalling	(294)	and	S1P	receptor	3,	an	endothelial	mitogen	receptor	that	operates	synergistically	with	PDGFR-β	and	is	known	to	be	down-regulated	by	sunitinib	treatment	in	breast	cancer	(295).	This	profile	is	suggestive	of	active	sunitinib	inhibition	in	the	non-responsive	tumours.	The	expression	of	twelve	other	proangiogenic	genes	however,	was	enhanced	in	the	non-responsive	tumours,	including	pleiotrophin	(PTN),	an	angiogenic	cytokine,	highly	
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expressed	in	60%	of	breast	cancers	(296).	Additionally	the	expression	of	PTN	has	been	shown	to	be	specifically	enhanced	in	response	to	VEGF	signalling	blockade,	in	three	separate	pre-clinical	tumour	models	(296),	suggesting	that	it	may	form	part	of	an	adaptive	response	to	VEGF	targeted	therapies.	Intriguingly	PTN	is	additionally	up-regulated	in	the	vessels	of	initially	responsive	tumours	at	1300	mm3.	This	suggests	that	PTN	may	be	playing	an	important	role	in	mediating	the	evasion	of	sunitinib	angiogenic	blockade	in	both	cohorts,	either	as	an	acquired	resistance	mechanism	in	the	responsive	group,	or	an	innate	one	in	the	non-responsive	group.	However,	the	analyses	detailed	in	this	chapter	did	not	show	PTN	to	be	highly	expressed	in	the	4T1	tumours.	Despite	this,	the	role	of	PTN	in	breast	cancer	resistance	to	sunitinib	warrants	further	investigation.	Mechanistic	target	of	rapamycin	(mTOR),	a	pro-angiogenic	protein	kinase,	whose	phosphorylation	is	known	to	be	inhibited	by	sunitinib	(297),	is	also	up-regulated	in	the	non-responsive	cohort.	MTOR	is	known	to	enhance	pro-angiogenic	hypoxia	inducible	factor	(HIF)	signalling	(298)	and	therefore	may	also	be	playing	a	role	in	mediating	sunitinib	resistance.	This	result	suggests	that	sunitinib	treatment	of	breast	cancer	could	be	improved	by	co-treatment	with	mTOR	inhibitors,	temsirolimus	and	everolimus.			This	expression	data	suggests	that	despite	sunitinib	targeted	genes	being	inhibited	in	the	non-responsive	cohort,	angiogenesis	and	tumour	growth	was	maintained	by	the	up-regulation	of	alternative	pathways	to	angiogenesis.	This	rendered	the	tumour	innately	resistant	to	sunitinib	induced	angiogenic	blockade.				
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7.3.2	Acquired	resistance	Whereas	innately	resistant	tumours	appeared	to	display	a	distinct	angiogenic	expression	profile,	leading	to	insensitivity	to	sunitinib	treatment,	tumours	that	displayed	acquired	resistance	in	this	investigation,	instead	showed	initial	responsiveness,	characterised	by	the	inhibition	of	key	sunitinib	targeted	pathways,	followed	by	a	gradual	reversal	of	this	inhibition.	As	discussed	this	resulted	not	in	a	transition	to	the	alternate	angiogenic	profile	of	the	non-responsive	cohort,	but	rather	a	loss	of	sensitivity	in	the	targeted	pathways	to	sunitinib	blockade,	leading	to	constitutive	activation.	This	resulted	in	this	cohort	developing	an	expression	profile	progressively	more	similar	to	the	untreated	cohort.	This	finding	is	not	without	precedent,	Sakai	et	al.,	2013	(299)	generated	a	sunitinib	resistant	RCC	cell	line,	through	prolonged	treatment	with	sunitinib.	They	found	that	the	cells	acquired	resistance	via	the	constitutive	activation	of	target	signal	transduction	pathways.	It	is	plausible	that	this	phenomenon	is	due	to	mutations	in	the	target	pathways,	leaving	them	immune	to	sunitinib	inhibition.	This	offers	a	survival	benefit	to	the	cells	affected	and	is	propagated	throughout	the	tumour.	This	mechanism	of	acquired	resistance	has	been	observed	in	gastrointestinal	tumours	treated	with	sunitinib,	but	only	after	approximately	a	year	of	response	(300).	It	is	unlikely	however	that	9	days	is	sufficient	for	tumours	to	have	acquired	such	mutations.		The	loss	of	sunitinib	signalling	sensitivity	was	coupled	in	the	tumour	with	the	up-regulation	of	a	number	of	pro-angiogenic	genes.	RTqPCR,	IHC	and	IF	validation	of	this	profile,	identified	AQP1,	ANGPT2,	DARC,	MMRN2	and	VEGFR2,	to	be	significantly	up-
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regulated	at	1300	mm3,	in	the	responsive	cohort	alone	and	enhanced	AQP1	expression	to	be	a	distinct	marker	of	acquired	resistance	in	this	experiment.		
	
7.3.3	AQP1	in	acquired	resistance	to	sunitinib	AQP1	is	a	widely	expressed	cell	surface	water	channel,	important	for	water	transfer	in	the	kidney	(301),	but	with	a	key	function	in	many	cells	including	endothelium,	allowing	the	rapid	transit	of	water	across	the	plasma	membrane,	facilitating	the	increase	in	cellular	volume	critical	for	cell	proliferation	(302).	The	up-regulation	of	AQP1	has	been	reported	in	murine	kidney	tumours	after	acquired	resistance	to	sunitinib	therapy	(303)	as	well	as	in	instances	of	pathological	neovascularisation	accompanying	liver	cirrhosis	(304).	AQP1	has	also	been	reported	to	be	involved	in	fibroblast	growth	factor	FGF	induced	endothelial	invasion	(304).	This	could	potentially	implicate	AQP1	expression	as	a	surrogate	marker	of	enhanced	FGF	signalling,	in	resistant	tumour	vessels.	FGF	is	a	pro-angiogenic	growth	factor,	the	signalling	of	which	is	not	inhibited	by	sunitinib	therapy	and	has	been	implicated	in	antiangiogenic	resistance	(156).	If	FGF	signalling	were	active	in	the	resistant	tumours	it	would	suggest	that	the	initially	responsive	cohort	acquired	resistance	not	just	via	constitutive	activation	of	target	pathways,	but	also	via	the	up-regulation	of	alternative	angiogenic	pathways.	The	expression	of	AQP1	in	human	breast	tumours	receiving	sunitinib	therapy,	warrants	investigation	to	determine	whether	it	is	a	novel	marker	of	acquired	anti-angiogenic	resistance.		
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This	thesis	has	detailed	the	transcriptomic	analysis	of	the	tumour	vascular	expression	profile	of	colorectal	and	renal	cancers	and	colorectal	metastases	to	the	liver.	This	has	resulted	in	the	identification	of	two	potential	tumour	vascular	targets,	MCAM	and	GRIN2D,	and	three	potential,	tumour	type	specific,	prognostic	markers,	MCAM,	LAMA4	and	GRIN2D.	With	further	work,	these	markers	could	be	used	to	develop	both	ligand-targeted	therapies	and	diagnostic	tests.				In	addition	the	behaviour	of	breast	tumours	displaying	acquired	and	innate	resistance	to	the	anti-angiogenic	therapy,	sunitinib,	was	investigated	and	revealed	that	innately	resistant	tumours	display	enhanced	metastasis	when	treated	with	sunitinib,	highlighting	the	need	for	reliable	markers	of	resistance.	Transcriptomic	analysis	of	the	tumour	and	vascular	expression	profiles	in	these	cancers,	identified	a	number	of	potential	markers	of	resistance	including	PTN,	mTOR,	and	AQP1.	The	validation	of	these	markers	is	at	an	early	stage,	but	with	further	investigation	they	could	be	used	diagnostically	to	guide	therapy	selection	and	therapeutically	to	circumvent	resistance	to	sunitinib	in	breast	cancer.		Besides	these	key	findings	that	will	hopefully	contribute	to	cancer	treatment	and	prognostication	in	the	future,	other	results	contained	within	this	thesis	also	contribute	to	the	understanding	of	cancer	and	how	vascular-targeted	therapies	might	be	used.	The	tumour	vasculature	is	a	highly	promising	target	for	anti-cancer	therapy,	given	its	key	role	in	tumour	development.	It	is	also	a	difficult	target	however.	It	is	a	non-cancerous	component	of	the	tumour,	which	was	initially	seen	as	an	advantage,	suggesting	it	would	be	less	adaptive	than	the	tumour	cells	(8).	This	has	been	found	to	not	be	the	case	however.	These	“normal”	cells	are	distorted	structurally,	behaviourally	and	in	terms	of	
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their	expression	profile	by	the	extreme	environment,	of	hypoxia,	hypoglycaemia,	acidity	and	a	multitude	of	other	factors	encountered	in	the	tumour.	Analysis	of	the	pan-tumour	endothelial	expression	profile,	described	in	chapter	5,	demonstrates	this	effect	well.	A	spectrum	of	different	factors	are	thought	to	transcriptionally	regulate	the	genes	identified	in	this	analysis.	Cytokine	signalling	from	infiltrating	immune	cells	appears	to	be	responsible	for	the	up-regulation	of	many	of	the	identified	genes.		ANGPT2	has	been	shown	to	be	induced	by	tumour	necrosis	factor	alpha	(TNF-α)	(305);	ESM1	by	TNF-α	and	interleukin	1	beta	(IL1-β)	(306);	FSTL1	by	IL1-β	(307);	CCL20	by	TNF	and	interferon-gamma	(IFN-γ)	(308);	TGM2	by	IFN-γ	(309)	and	BGN,	SPARC	and	VIM	by	transforming	growth	factor	beta	(TGF-β)	(310-312).	In	addition	the	activation	of	hypoxia	inducible	factors	(HIFs)	have	been	shown	to	regulate	both	LOX	and	RGS5	expression	(313,314).	Interestingly	RGS5	itself	regulates	the	expression	of	the	thrombin	receptor	F2R	(also	known	as	PAR-1)	(315),	another	gene	consistently	up-regulated	within	the	analysis.	This	suggests	that	F2R	may	be	up-regulated	in	this	setting	as	a	downstream	result	of	hypoxia	induced	RGS5	activation.	Activation	by	tumour-derived	growth	factors	is	also	thought	to	be	a	key	regulator	of	tumour	endothelial	markers	(TEMs)	and	indeed	as	discussed	in	chapter	5,	MCAM	expression	is	regulated	by	VEGF.				It	is	not	only	the	intrinsic	tumour	environment	that	impacts	on	this	expression	profile,	but	also	the	changes	induced	by	therapeutic	intervention.	As	described	in	chapter	7,	the	vasculature	of	different	groups	of	breast	tumours,	challenged	by	sunitinib	angiogenic	blockade,	respond	in	quite	distinct	manners.	Some	are	inhibited,	but	acquire	resistance	through	a	loss	of	sensitivity	to	treatment	blockade	over	time.	This	is	possibly	induced	
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by	a	crisis	point	being	reached	within	the	tumour	where	it	can’t	develop	sufficient	vessels	to	grow,	one	or	a	group	of	endothelial	cells	adapt	to	the	therapy,	are	selectively	favoured	and	vascularise	the	tumour.	Some	other	tumours	do	not	respond	to	the	blockade	at	all,	have	intrinsically	developed	a	dependence	of	non-blockaded	pathways	to	growth	and	therefore	have	not	gone	through	any	crisis	or	selection	and	so	still	show	signs	of	sensitivity	to	sunitinib	blockade.		This	data	highlights	the	vasculature	as	an	extremely	heterogeneous	and	adaptive	compartment	of	the	tumour.	To	achieve	treatment	efficacy	considerable	work	is	required	to	find	the	optimal	indication	for	a	therapy.	As	was	shown	in	chapter	5,	MCAM	is	highly	expressed	in	the	vessels	of	clear	cell	RCC,	but	to	a	far	lesser	extent	in	other	renal	malignancies,	or	even	other	architectures	of	RCC.	GRIN2D	also	appears	to	be	expressed	to	the	greatest	extent	in	colorectal	and	stomach	cancers,	but	even	then	only	in	40%	of	cases.	Only	62%	of	breast	tumours	examined	in	chapter	6	responded	to	sunitinib	therapy	and	response	has	been	reported	to	be	even	lower	in	the	clinic	(276,278).	These	findings	all	suggest	that	research	should	be	focused	on	developing	new	therapies,	optimal	in	different	indications,	but	also	marrying	these	and	existing	therapies	with	diagnostic	tests	that	can	reliably	predict	response.			The	investigation	of	the	survival	impact	of	TEMs	identified	in	this	thesis,	illustrated	another	interesting	aspect	of	tumour	vessel	behavior.	Namely	the	existence	of	TEMs	predictive	of	more	or	less	aggressive	tumours.	High	expression	of	MCAM	and	LAMA4	on	ccRCC	tumour	vessels	is	very	strongly	predictive	of	poor	survival,	more	advanced	and	aggressive	tumours	and	enhanced	metastasis.	On	the	other	hand	GRIN2D	
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expression	on	the	vessels	CRC	was	associated	with	enhanced	survival.	This	dichotomy	can	be	explained	by	the	differing	functions	of	the	TEMs	involved,	as	discussed	in	chapters	4	and	5.	Briefly,	MCAM	is	an	adhesion	molecule	known	to	promote	endothelial	cell	motility	and	tumour	vessel	invasion	(251),	but	also	reported	to	be	expressed	on	some	tumour	cells,	therefore	its	expression	on	vessels	could	promote	extravasation,	leading	to	enhanced	metastasis.	LAMA4,	besides	potentially	operating	synergistically	with	MCAM,	has	also	been	reported	to	promote	tumour	cell	invasion	via	the	interaction	with	various	integrins.	GRIN2D,	on	the	other	hand,	is	a	dedicated	ion	channel	and	glutamate	receptor,	which	as	reported	in	this	thesis,	is	involved	in	functional	vessel	formation	in	vitro.	Its	expression	could	therefore	be	a	marker	of	more	functional	vessel	formation,	enhancing	tumour	perfusion	and	chemotherapy	infiltration,	as	reported	for	ROBO4-Slit2	signalling	(231).			CLEC14a,	a	tumour	vessel	associated	adhesion	molecule,	reported	to	mediate	endothelial	cell	attachment	to	the	extracellular	matrix	via	multimerin-2	in	a	manner	akin	to	MCAM	and	LAMA4	(316),	is	reported	to	enhance	survival	in	non-small-cell	lung	cancer	(230),	for	an	as	yet	undetermined	reason.	This	suggests	that	it	will	be	no	simple	matter	to	dissect	pro-	and	anti-survival	TEMs	into	groups.	The	impact	of	a	TEM	on	survival	is	an	important	determination	to	make	however,	from	a	therapeutic	point	of	view,	as	well	as	prognostic.	Tumour	vascular	targeting	has	the	potential	to	achieve	rapid	tumour	regression,	however,	given	the	adaptive	and	heterogeneous	nature	of	the	tumour	vasculature,	this	may	result	in	the	selection	and	revascularisation	of	the	tumour	with	vessels	not	expressing	the	target.	In	the	case	of	an	anti-survival	target,	this	could	result	in	a	down-staged	tumour	optimised	for	further	treatment,	a	hope	for	
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MCAM	targeted	therapies.	If	targeting	a	pro-survival	marker	however,	the	treatment	could	result	in	a	tumour	with	decreased	perfusion,	or	other	factors	not	conducive	to	survival,	depending	on	the	nature	of	the	target,	which	could	reduce	the	therapeutic’s	operational	synergy	with	other	anti-cancer	treatments.	Given	that	cancer	vessel	targeted	agents	cannot	themselves	destroy	the	tumour,	the	productive	combination	of	these	therapeutics	with	cancer-cell-targeted	agents	is	critical	for	success	[reviewed	in	(1)].			This	thesis	describes	the	identification	of	vascular	markers	of	potential	use	in	cancer	treatment,	prognostication	and	prediction	of	therapy	resistance,	but	there	is	much	work	still	to	do	to	realise	the	optimal	utility	of	these	findings.														
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Supplementary	section	to	7.2.2	“The	impact	of	sunitinib	treatment	on	tumour	
and	endothelial	gene	expression.”			Comparative	analysis	of	the	microarray	data	(generated	as	described	in	section	7.2.1),	facilitated	the	in	silico	investigation	of	changes	in	signalling	of	key	sunitinib	targeted	pathways,	(VEGFR-1&2,	PDGFR-α&β	and	FLT3,	Appendix	figures	A,	B	and	C	respectively).	The	Qiagen	Ingenuity	pathway	prediction	software	was	used	to	generate	a	predicted	expression	change	profile	within	each	of	the	pathways,	upon	the	inhibition	of	VEGFR-1&2,	PDGFR-α&β	and	FLT3	(the	supposed	effect	of	sunitinib	activity),	(Appendix	figures	A,	B	and	C	(i)).	This	was	then	compared	with	the	observed	gene	expression	changes	between	arrays.	This	investigation	identified	genes	>2	fold	changed	and	with	a	Benjamini	and	Hochberg	1995	(317)	adjusted	P-value	<	0.05,	in	the	following	comparison	matrices;	bulk	tissue	and	endothelium	from	the	responsive	versus	untreated,	non-responsive	versus	untreated	and	responsive	versus	non-responsive	cohorts	at	1300	mm3	(Appendix	figures	A,	B	and	C	(ii)).	The	2	vs.	2	comparison	matrices	generated	from	the	day	9	and	600	mm3	responsive	and	untreated	cohorts,	were	also	included	in	this	pathway	analysis,	however,	due	to	their	reduced	n-numbers	they	are	suboptimal	for	this	setting	(due	to	inferior	p-values),	therefore	the	selection	threshold	was	set	to	>2	fold	gene	expression	change	and	unadjusted	p-value	<0.05.			This	analysis	revealed	that	at	day	9	signalling	of	each	of	the	pathways	in	the	responsive	cohort	broadly	resembled	that	predicted	from	sunitinib	treatment,	suggesting	that	at	this	stage	the	tumours	were	sensitive	to	sunitinib	(Appendix	figures	A,	B	and	C	(ii:1)).	
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Sunitinib	inhibition	of	each	of	the	pathways	was	lost	however,	in	the	responsive	versus	untreated	cohort	at	the	600	and	1300	mm3	size	points	(Appendix	figures	A,	B	and	C	(ii:2&3)),	suggesting	that	by	this	point	the	tumour	had	become	resistant	to	sunitinib	therapy.	This	data	supports	the	pattern	of	tumour	sensitivity	reported	for	the	responsive	group	in	chapter	6.	The	non-responsive	cohort	on	the	other	hand,	when	its	expression	profile	was	compared	to	that	of	the	untreated	group,	displayed	sensitivity	to	sunitinib	treatment	at	1300	mm3,	in	either	the	bulk,	or	endothelial	fractions,	or	both.	Additionally	when	comparing	the	two	treated	cohorts,	the	responsive	group	consistently	showed	greater	activation	of	each	pathway	than	the	non-responsive	group	at	1300	mm3	(Appendix	figures	A,	B	and	C	(ii:4-8)).			This	data	broadly	agrees	with	the	pattern	of	response	reported	in	section	7.2.2	adding	a	supplementary	level	of	detail	as	regards	the	effect	of	sunitinib	treatment	on	the	expression	of	genes	downstream	of	the	drug’s	target	receptors.	It	should	be	noted	that	changes	to	gene	expression	don’t	necessarily	translate	to	changes	in	the	activity	of	the	gene	product.	For	genuine	activity	analysis	the	phosphorylation	state	of	downstream	target	would	have	to	be	assessed	(eg.	by	western	blot	analysis).	However,	the	analysis	detailed	in	this	supplementary	section	does	provide	some	insight	into	the	effect	of	sunitinib	treatment	and	resistance	on	downstream	players	in	targeted	signalling	pathways,	guiding	future	analysis	of	this	area,	via	RNA	and	protein	based	assays.		
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Appendix	figures	A,	B	and	C:	Tumour	and	vascular	signalling	is	differentially	affected	by	sunitinib	therapy	in	different	cohorts	and	timepoints.	Injenuity	software	pathway	predictions	of	signalling	in	the	A,	VEGFR-1&2,	B,	PDGFR-α&β	and	C,	FLT-3	pathways.	(i)	Predicted	effect	of	sunitinib	therapy	on	the	signalling	pathway.	Activity	of	the	target	receptors	were	reduced	in	silico	(in	line	with	predicted	sunitinib	activity)	(green)	and	downstream	genes	predicted	to	be	upregulated	(red),	downregulated	(blue),	or	where	there	is	conflicting	data	(yellow),	by	this	intervention	are	shown.	Greater	intensity	of	colour	denotes	a	greater	predicted	fold	change	in	expression.	(ii)	Effects	on	the	signalling	pathways	in	different	cohorts,	timepoints	and	comparison	matrices,	formulated	from	microarray	data	of	genes	>2	fold	changed	and	with	a	Benjamini	&	Hochberg,	1995	(317)	adjusted	P-value	<	0.05.	Genes	upregulated	(red)	and	downregulated	(green)	in	these	analyses	are	shown.	Greater	intensity	of	colour	denotes	a	greater	fold	change	in	expression.		The	functional	linkage	of	genes	in	the	pathways	to	one	another	is	illustrated.	Arrows	between	genes	denote	one	gene	enhancing	the	activity	of	the	other.	Flat	ended	lines	between	genes	denote	one	gene	inhibiting	the	activity	of	the	other.	Lines	with	no	ending	denote	a	connection	between	two	genes	where	the	effect	of	this	connection	on	gene	activity	is	not	conclusively	known.											
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Responsive	vs.	untreated	day	9	bulk	
VEGF	signalling	pathway	
Appendix	ﬁgure	A(ii:1)	
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Responsive	vs.	untreated	600	mm3	bulk	
VEGF	signalling	pathway	
Appendix	ﬁgure	A(ii:2)	
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Responsive	vs.	untreated	1300	mm3	bulk	
VEGF	signalling	pathway	
Appendix	ﬁgure	A(ii:3)	
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Non-responsive	vs.	untreated	1300	mm3	bulk	
VEGF	signalling	pathway	
Appendix	ﬁgure	A(ii:4)	
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Responsive	vs.	Non-responsive	1300	mm3	bulk	
VEGF	signalling	pathway	
Appendix	ﬁgure	A(ii:5)	
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Responsive	vs.	untreated	1300	mm3	EC	
VEGF	signalling	pathway	
Appendix	ﬁgure	A(ii:6)	
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Non-responsive	vs.	untreated	1300	mm3		EC	
VEGF	signalling	pathway	
Appendix	ﬁgure	A(ii:7)	
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Responsive	vs.	Non-responsive	1300	mm3	EC	
VEGF	signalling	pathway	
Appendix	ﬁgure	A(ii:8)	
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PDGF	signalling	pathway	
Appendix	ﬁgure	B(i)		
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PDGF	signalling	pathway	
Appendix	ﬁgure	B(ii:1)		
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PDGF	signalling	pathway	
Appendix	ﬁgure	B(ii:2)		
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PDGF	signalling	pathway	
Appendix	ﬁgure	B(ii:3)		
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PDGF	signalling	pathway	
Appendix	ﬁgure	B(ii:4)		
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PDGF	signalling	pathway	
Appendix	ﬁgure	B(ii:5)		
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PDGF	signalling	pathway	
Appendix	ﬁgure	B(ii:6)		
Responsive	vs.	untreated	1300	mm3	EC	
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PDGF	signalling	pathway	
Appendix	ﬁgure	B(ii:7)		
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PDGF	signalling	pathway	
Appendix	ﬁgure	B(ii:8)		
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FLT3	signalling	pathway	
Appendix	ﬁgure	C(i)		
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FLT3	signalling	pathway	
Appendix	ﬁgure	C(ii:1)		
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FLT3	signalling	pathway	
Appendix	ﬁgure	C(ii:2)		
Responsive	vs.	untreated	600	mm3	bulk	
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FLT3	signalling	pathway	
Appendix	ﬁgure	C(ii:3)		
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FLT3	signalling	pathway	
Appendix	ﬁgure	C(ii:4)		
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FLT3	signalling	pathway	
Appendix	ﬁgure	C(ii:5)		
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FLT3	signalling	pathway	
Appendix	ﬁgure	C(ii:6)		
Responsive	vs.	untreated	1300	mm3	EC	
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FLT3	signalling	pathway	
Appendix	ﬁgure	C(ii:7)		
Non-responsive	vs.	untreated	1300	mm3		EC	
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FLT3	signalling	pathway	
Appendix	ﬁgure	C(ii:8)		
Responsive	vs.	Non-responsive	1300	mm3	EC	
Upregulated	
Enhanced	
Inhibited	
Aﬀected	
Downregulated	
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